US20050010275A1 - Implantable medical devices - Google Patents

Implantable medical devices Download PDF

Info

Publication number
US20050010275A1
US20050010275A1 US10/683,314 US68331403A US2005010275A1 US 20050010275 A1 US20050010275 A1 US 20050010275A1 US 68331403 A US68331403 A US 68331403A US 2005010275 A1 US2005010275 A1 US 2005010275A1
Authority
US
United States
Prior art keywords
stent
polymer
lumen
temperature
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/683,314
Inventor
Ronald Sahatjian
Francisca Tan
Patrick Mather
Changdeng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Boston Scientific Scimed Inc
Original Assignee
University of Connecticut
Scimed Life Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/683,314 priority Critical patent/US20050010275A1/en
Application filed by University of Connecticut, Scimed Life Systems Inc filed Critical University of Connecticut
Priority to US10/958,435 priority patent/US7794494B2/en
Publication of US20050010275A1 publication Critical patent/US20050010275A1/en
Priority to US11/111,509 priority patent/US7976936B2/en
Assigned to SCIMED LIFE SYSTEMS, INC. reassignment SCIMED LIFE SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAHATJIAN, RONALD A., TAN, FRANCISCA, LIU, CHANGDENG, MATHER, PATRICK T.
Assigned to CONNECTICUT, UNIVERSITY OF reassignment CONNECTICUT, UNIVERSITY OF ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CAMPO, CHERYL J., LIU, CHANGDENG, MATHER, PATRICK T.
Assigned to CHANGDENG LIU, PATRICK T. MATHER reassignment CHANGDENG LIU ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOCKWOOD, KURT
Assigned to LIU, CHANGDENG, MATHER, PATRICK T. reassignment LIU, CHANGDENG RE-RECORD TO CORRECT THE NAME OF THE ASSIGNOR, PREVIOUSLY RECORDED ON REEL 016518 FRAME 0722. Assignors: SCIMED LIFE SYSTEMS, INC.
Priority to US12/880,483 priority patent/US20140135889A9/en
Priority to US12/940,388 priority patent/US8784465B2/en
Priority to US13/053,461 priority patent/US20110172753A1/en
Priority to US13/493,532 priority patent/US9115245B2/en
Priority to US15/185,851 priority patent/US20160296677A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958Inflatable balloons for placing stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002Implant devices for drainage of body fluids from one part of the body to another
    • A61M27/008Implant devices for drainage of body fluids from one part of the body to another pre-shaped, for use in the urethral or ureteral tract
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30Low-molecular-weight compounds
    • C08G18/38Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3893Low-molecular-weight compounds having heteroatoms other than oxygen containing silicon
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/48Polyethers
    • C08G18/4833Polyethers containing oxyethylene units
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40High-molecular-weight compounds
    • C08G18/61Polysiloxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00Polymeric products of isocyanates or isothiocyanates
    • C08G18/06Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/71Monoisocyanates or monoisothiocyanates
    • C08G18/718Monoisocyanates or monoisothiocyanates containing silicon
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/02Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
    • C08G61/04Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
    • C08G61/06Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds
    • C08G61/08Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/336Polymers modified by chemical after-treatment with organic compounds containing silicon
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/005Processes for mixing polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L65/00Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02Polyalkylene oxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/848Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
    • A61F2002/8483Barbs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008Fixation appliances for connecting prostheses to the body
    • A61F2220/0016Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0037Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in height or in length
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00Compositions for preparing biodegradable polymers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00Polymer mixtures characterised by other features
    • C08L2205/05Polymer mixtures characterised by other features containing polymer components which can react with one another

Definitions

  • the body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis.
  • An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprosthesis include stents and covered stents, sometimes called “stent-grafts”.
  • An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • Prostate enlargement also known as benign prostate hyperplasia or benign prostate hypertrophy
  • benign prostate hyperplasia is a common affliction among older men.
  • the condition involves swelling of the prostate.
  • the prostate surrounds the urethra, or urinary tract, and enlargement of the prostate may restrict passage of urine from the bladder towards the urethra.
  • Benign prostate hyperplasia is uncomfortable because it makes urination difficult or impossible.
  • the condition is also dangerous because it can lead to infection of the bladder and kidneys.
  • Prostate enlargement can be treated with surgery known as resection. Resection can be accomplished by cutting away a large portion of the prostate gland. Prostate enlargement can also be treated with heat treatment, cold treatment, or ablation.
  • a restricted urethra can be treated with a prostatic stent to support the urethra and keep it open despite pressure from the enlarged prostate.
  • a prostatic stent may be implanted permanently or as an interim solution.
  • the invention relates to implantable medical devices, for example, a stent including a polymer.
  • the invention features a medical device.
  • the medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis.
  • the stent is an apertured tubular member formed of a polymer and is assembled about the balloon.
  • the stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon.
  • the polymer does not flow substantially during expansion and substantial stress relaxation or creep does not occur so that the geometry of the stent is maintained.
  • a tubular endoprosthesis including a polymer body is provided and delivered into a body lumen.
  • the endoprosthesis is expanded in the body lumen under conditions of expanding pressure and temperature so that the wall thickness of the polymer body is substantially maintained.
  • a polymer tube is formed to a first, large diameter.
  • An aperture pattern is cut into the tube wall.
  • the polymer is crosslinked or crystallized.
  • the polymer tube is deformed to a second, small diameter.
  • the polymer tube is expanded in a body lumen to a diameter larger than the second diameter by application of pressure and heat.
  • a polymer tube is formed to a first, small diameter.
  • An aperture pattern is provided in the tube wall.
  • the polymer is crystallized or crosslinked.
  • the tube is expanded in a body lumen by application of pressure and heat.
  • an implantable medical apparatus in another aspect, includes an element operable for movement within the body by mechanical force applied to the element.
  • the element includes a polymer having a melt or glass transition temperature in the range above body temperature to about 50° C. or 60° C. and exhibiting a plateau in a plot of storage modulus as a function of temperature at melt or glass transition.
  • the element is a stent.
  • the stent may be generally a tubular body that includes an apertured wall.
  • the stent may be operable for expansion from a first, smaller diameter to a second larger diameter for implantation in a lumen.
  • the thickness of the stent wall varies by about 1% or less between the first and second diameter.
  • the invention features a medical device including a polymer having a melt or glass transition temperature above body temperature and exhibiting an approximate plateau in a plot of storage modulus as a function of temperature at melt or glass transition.
  • the melt or glass transition temperature may be, for example, above about 37° C.
  • the medical device may undergo a triggerable event at about the plateau.
  • the triggerable event may be, for example, a change in the flexibility, a change in the porosity, a change in the coefficient of friction or a change in the surface roughness.
  • the medical device may be, for example, a stent that has a portion that has a collapsed position that can be reverted to an expanded position by a trigger subsequent to insertion into the body.
  • the polymer body includes apertures.
  • the polymer body has a ratio of aperture open area to wall area of about 0.5 or more or 0.7 or more.
  • the endoprosthesis is expanded by simultaneously applying an expanding pressure and heat to the endoprosthesis.
  • the polymer body is heated above the melt or glass transition temperature of polymer in the polymer body.
  • the polymer body is elastomeric at the melt or glass transition temperature.
  • the polymer is elastomeric at body temperature.
  • the polymer is crystalline.
  • the polymer is crosslinked.
  • the polymer is radiation crosslinked.
  • the melt or glass transition temperature is about 40 to 50° C.
  • the melt or glass transition temperature has a transition range of about 5° C. or less.
  • the polymer exhibits a plateau in the melt or glass transition range in a plot of storage modulus as a function of temperature.
  • the polymer body includes a drug, radiopaque agent or magnetic heating agent.
  • the polymer is a shape memory polymer, e.g. capable of remembering a smaller diameter configuration after expansion.
  • the polymer is, for example, polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene, trans-isoprene, blends of polycaprolactone and n-butylacrylate and blends thereof.
  • An expansion pressure of about 1 atm or more is applied.
  • the endoprosthesis is delivered on a catheter.
  • the endoprosthesis is delivered to a site of occlusion and the site is simultaneously dilated while expanding the endoprosthesis.
  • the endoprosthesis is delivered to a site of lumen curvature and the endoprosthesis is expanded at the site.
  • the endoprosthesis is delivered to a vascular lumen.
  • the endoprosthesis is delivered adjacent (into) the prostate.
  • a heat applicator applies heat to the stent during inflation of the balloon to expand the balloon to the expanded diameter.
  • the polymer has a melt or glass transition temperature in the range of about 40 to 50° C. and a modulus at the melt or glass transition temperature sufficient to maintain the stent geometry or under application of pressure and/or heat. The polymer exhibits a plateau in the storage modulus in the range of melt or glass transition temperatures.
  • the stent has a wall thickness of about 0.005 to 5 mm.
  • the stent has an initial unexpanded inner diameter in the range of about 1 mm to 5 mm.
  • the stent has an expanded inner diameter of about 1 mm to 20 mm.
  • the stent may be expandable to about 100% or 400% or more of the initial inner diameter.
  • An example of a coronary stent has an initial inner diameter of about 2 mm, and expanded inner diameter of about 4 mm and the wall thickness is about 0.005 mm to 0.1 mm.
  • the stent can be in the form of a tube including aperture areas provided in the tube.
  • the aperture are in the shape of elongate slots, e.g., when the stent is in the small diameter condition.
  • the apertures have a dimension of about 1 mm or less in the small diameter condition.
  • the apertures are in the shape of diamond-like openings, e.g. when the stent is in an expanded condition.
  • the stent can be a wire-form formed of one or more filaments configured to generally define a tube.
  • Embodiments may include one or more of the following advantages.
  • a balloon expandable stent made of a polymer can be provided that maintains the integrity of the stent geometry on expansion and heating. Maintenance of stent geometry is desirable since geometry affects, for example, the resistance to compression in the body and a predictable geometry is important to avoid irregular surfaces, kinking, or extensions of material into the body lumen which can interfere with the flow of body fluid.
  • the polymers can be elastomers that have melting or glass transitions at temperatures safe for use in the body and exhibit elastomeric properties at both the melted or glass transition stage and the solid or crystalline phase.
  • the stent body exhibits high resistance to inward compressive forces when the polymer is in the solid or crystalline phase.
  • the elastomeric nature of the polymer in the melted or glass state enhances the ability to maintain geometry as the stent is expanded. For example, the polymer exhibits minimal flow during expansion and the thickness of the stent remains substantially constant. Elastomeric properties in the crystalline or solid state enhance the ability to conform to torturous curvature in narrow body lumens. High compression resistance allows the stent to maintain the body lumen open and resist occluding forces such as elastic recoil or the growth of thrombus from the vessel wall.
  • the invention features a polymeric stent having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
  • the stent may be in the form, for example, of a coiled elongated element (for example, a strand, a tape or a flattened tube).
  • the stent may be further heated to a second temperature that is higher than the first temperature and removed as a substantially uncoiled element.
  • the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent.
  • the medicament is compounded into the plastic or is a coating on the plastic.
  • the portion is at an end of the stent and the portion is flared or stepped. In other implementations, the portion includes less than 50% of the length of the stent.
  • the invention features a polymeric stent in the form of a coiled elongated element, and having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
  • the modulus of the element lowers sufficiently that the stent can be removed from the cavity or lumen as a substantially uncoiled element.
  • the invention features a method of treating a non-vascular cavity or lumen.
  • the method includes inserting a polymeric stent having a portion in a collapsed position that can be reverted, by heating, to an expanded position. Following insertion, the stent is heated sufficiently to revert the portion in the collapsed position to the expanded position.
  • the method may further include heating the stent having the portion in the expanded position sufficiently to soften the stent, and removing the softened stent from the cavity or lumen.
  • the stent may be, for example, a coiled elongated element (for example, a rod, a tape or flattened tube) and the heating of the stent prior to removal allows the stent to be removed in a substantially uncoiled state.
  • This method provides ease of removal, for example, for removing prostatic stents that have been inserted on an interim basis.
  • the heating may be performed, for example, on a delivery tube.
  • the portion of the stent is at the end of the stent and may be flared when in the expanded position. In other embodiments, for example, the portion of the stent is not at an end of the stent.
  • the invention features a polymeric stent including metal particles.
  • a portion of the stent has a collapsed position that can be reverted to an expanded position by heating.
  • the heating may be performed using inductive heating to revert the portion in the collapsed position to the expanded position.
  • the invention features a stent having an exterior surface that includes a plurality of protruding elements that extend outwardly from the surface.
  • the protruding elements may be useful in helping the stent retain its position, for example, after insertion into the prostatic urethra.
  • the protruding elements are formed of monofilament.
  • the monofilament may include a plurality of constrictions along its length.
  • the stent is a polymeric stent and the stent has a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
  • FIGS. 1A and 1B are side views of a portion of a stent in a small diameter and expanded condition, respectively.
  • FIGS. 1C and 1D are cross-sectional views of a portion of a stent in a small diameter and expanded condition, respectively.
  • FIGS. 2A-2C illustrate delivery of a stent into a body lumen.
  • FIG. 3 is a plot of storage modulus as a function of temperature.
  • FIG. 3A is a plot of storage modulus as a function of temperature for samples of PCO with varying degrees of crosslinking.
  • FIG. 3B is a WAXS 20 plot for samples of PCO with varying degrees of crosslinking.
  • FIG. 4 illustrates manufacture and use of a stent.
  • FIG. 5 illustrates manufacture and use of a stent.
  • FIG. 6 is a perspective view of a stent with an end in an expanded position.
  • FIG. 7 is a side view of the stent shown in FIG. 6 .
  • FIG. 8 is a side view of the stent shown in FIG. 6 with the end in a collapsed position.
  • FIG. 8A is a graph of heat flow as a function of temperature for several POSS polyurethanes.
  • FIG. 8B is a graph of storage modulus as a function of temperature for several POSS polyurethanes.
  • FIG. 9 is a perspective view of a wrapping fixture.
  • FIG. 10 is a cross-sectional view of a restricted prostatic urethra.
  • FIG. 11 is a cross-sectional view illustrating delivery of a stent to the prostatic urethra.
  • FIG. 12 is a cross-sectional view of a prostatic stent deployed in the urethra.
  • FIG. 13 is a side view of an alternative delivery system.
  • FIG. 13A-13B are side views of an alternative delivery system.
  • FIG. 14 is a cross-sectional view illustrating removal of a prostatic stent.
  • FIG. 15 is a graph of storage modulus (E′) VS temperature for PCO.
  • FIG. 16 is a graph of storage modulus (E′) VS temperature for PVAc/PVDF/PMMA blends.
  • FIG. 17 is a side view of an alternative stent with two ends portions in expanded positions.
  • FIG. 18 is the stent shown in FIG. 17 with ends in collapsed positions.
  • FIG. 19 is a side view of an alternative stent with three portions in expanded positions.
  • FIG. 20 is a side view of an alternative stent made with a flattened tube.
  • FIG. 21 is a cross-sectional view of the stent shown in FIG. 20 , taken along 21 - 21 .
  • FIG. 22 is a side view of an alternative stent made with a tape.
  • FIG. 23 is a perspective view of a stent with a plurality of protruding elements, the end of the stent is in an expanded position.
  • FIG. 24 is a side view of the stent shown in FIG. 23 .
  • FIG. 25 is a side view of the stent shown in FIG. 23 with the end in a collapsed position.
  • FIG. 26 is a perspective view of an alternative stent with a plurality of protruding elements, the end of the stent in an expanded position.
  • FIG. 27 is a side view of the stent shown in FIG. 26 .
  • FIG. 28 is a side view of the stent shown in FIG. 26 with an end in a collapsed position.
  • FIG. 32 Tensile storage modulus versus temperature for a range of PLA/PVAc blends whose composition is indicated in the plot.
  • a stent 10 includes a polymer body 12 generally defining a tube.
  • the stent includes open areas 14 .
  • the open areas are relatively small and defined as slots cut through the wall of the stent.
  • the slots are widened to diamond-like shapes.
  • the expansion mechanism of the stent utilizes a deformation (arrows) of the wall material about the open areas. As illustrated, the expansion results in a generally regular, symmetric, geometric pattern that resists and distributes inward compression of the stent by forces imposed by the lumen wall.
  • the polymer does not substantially flow or thin out on expansion, so that a reliable expansion geometry and wall thickness can be achieved.
  • Other stent constructions are suitable.
  • filament-form stents in which filaments of polymer material are arranged to define a generally tubular structure can be used. Open areas are defined between the filaments.
  • An example of a stent design including helical filaments is provided in Wallsten, U.S. Pat. No. 4,655,771. Suitable aperture wall designs are also described in Palmaz U.S. Pat. No. 4,733,665.
  • Another suitable arrangement is exemplified by the Express stent, commercially available from Boston Scientific, Natick, Mass.
  • the stent is delivered utilizing a catheter 24 , which includes a catheter body 25 that carries a balloon 26 at its distal end.
  • the catheter includes an inflation apparatus 28 such as a syringe or pump apparatus which can be used to inject and circulate inflation fluid into the catheter, where it is directed by a lumen to the interior of the balloon so that the balloon can be inflated.
  • the inflation apparatus can include a heating apparatus 30 , to heat the inflation fluid directed to the balloon.
  • the catheter is delivered into a vessel 20 to the site of an obstruction 31 typically utilizing a guidewire 32 .
  • the guidewire 32 extends through a lumen within the body 25 of the catheter.
  • the stent 10 is positioned over the inflatable balloon 26 .
  • the balloon is initially in a small diameter deflated condition.
  • the stent is in a small diameter condition over the balloon.
  • the balloon is inflated by actuating the inflation apparatus 28 .
  • the inflation fluid is heated to heat the polymer body of the stent 10 .
  • the stent is expanded into contact with the body lumen.
  • the stent can be expanded simultaneously with the widening of the obstructed region.
  • the temperature of the inflation fluid is typically decreased to reverse the softening of the stent body 10 .
  • the temperature of the stent has been reduced in this manner, it remains implanted in the vessel to resist vessel recoil and reduce restenosis after the balloon is deflated and the catheter is removed from the body.
  • Suitable polymers include those that maintain stent geometry under expansion conditions, allowing for intricate stent geometries such as apertured tubes having high open area to wall ratios.
  • the stent can be expanded without fracture or substantial irreversible stress relaxation or creep.
  • the stent is heated to or above the melt or glass transition temperature during expansion.
  • the polymer is in a softened state. In this state, the polymer can be predictably deformed, typically about aperture regions during expansion.
  • the soft condition permits proper apposition of the stent to the lumen wall without kinking and without damage due to excessive stiffness, which could straighten the lumen from its native curvature and lead to dissections or other trauma.
  • the polymer After the stent is fully expanded and cooled, the polymer substantially sets in the proper apposition, e.g. about a native curvature. Excessive recoil of the stent to a linear configuration is avoided, reducing trauma about the vessel. At the same time, the polymer can have some elastomeric properties in the cooled, hardened state so that the stent can flex with natural vessel motion. After cooling, the stent exhibits sufficient resistance to inward radial force to reduce restenosis due to, e.g., lumen wall recoil. The polymer has sufficient strength so that the stent wall can be kept relatively thin while resisting restenosis from lumen wall forces.
  • Suitable polymers include elastomers that are crosslinked and/or crystalline.
  • the crosslink and/or crystalline nature is sufficient to resist excessive creep or stress relaxation when the polymer is heated and expanded.
  • the polymer can be crosslinked so that it exhibits the desired elastomeric properties but not crosslinked to the degree that it becomes excessively brittle. Too little crosslinking does not establish sufficient resistance to flow during heating and expansion to maintain stent geometry.
  • crosslinking can be adjusted to adjust the melt or glass transition temperature and transition temperature range. A narrow melt transition range is desirable, e.g. 5° C. or 10° C. or less.
  • Crosslinking can be achieved by application of radiation such as e-beam, UV, gamma, x-ray radiation or by heat-activated chemical crosslinking techniques.
  • Chemical crosslinking agents include peroxides, such as benzoyl peroxide or dicumyl peroxide (DCP), and azo compounds, such as 2,2′-azobis(2,4-dimethyl valeronitrile) or 2,2′-azobis[N-(2-propenyl)-2-methylpropionamide].
  • Radiation techniques provide the advantage that the polymer typically does not have to be substantially heated to achieve crosslinking.
  • An intricate aperture pattern provided in a stent precursor tube can be maintained and heat-induced flow of pre-crosslinked polymer can be avoided.
  • gamma radiation an exposure of about 50-300, e.g. 250 kilograys typically provides sufficient crosslinking. Melting and crystallization temperatures are measured using a differential scanning calorimetry.
  • the polymer can have elastomeric properties in the melted or softened state. Elastomeric properties at melt or glass transition can be investigated by measuring the modulus of elasticity or storage modulus as a function of temperature and determining the elastomeric nature of the material in the desired expansion temperature range. Referring to FIG. 3 , a plot of storage modulus as a function of temperature is provided. Storage modulus decreases as the material is heated. At the melt or glass transition, a plateau “P” is typically consistent with an elastomeric nature. At much higher temperatures, the modulus drops off more quickly, indicating a material which could flow under pressure. To determine storage modulus, a dynamic mechanical analyzer (Perkin Elmer) can be used.
  • Perkin Elmer Perkin Elmer
  • Dynamic mechanical analysis was carried out in tensile mode at an operating frequency of 1 Hz, a static force of 10 mN, and oscillation amplitude of 5 ⁇ m (approximately 0.1% strain) and an automatic tension setting of 125%. Temperature ramps were conducted at 4° C./minute over the range ⁇ 100° C. to 100° C.
  • the storage modulus of neat PCO begins to decrease sharply to about 2 MPa at the completion of melting at 71° C. As found with DSC, this transition temperature is observed mechanically to decrease with increasing degree of crosslinking. For temperatures greater than T m , the modulus of neat PCO, trace (i), continues to decrease to a point where the material flows like a viscous liquid, not showing a persistent rubbery plateau ( FIG. 3 ). This feature hampers the applicability of neat PCO for use as a shape memory polymer due to an inability to be deformed as a rubber above T m without rapid stress relaxation.
  • cured PCO which contains just 1% peroxide, represented by trace (ii), will allow significant shape memory effects owing to its persistent rubbery plateau above 72° C. As the amount of peroxide increases, the rubbery plateau modulus increases, allowing for enhanced mechanical energy storage, but the transition temperature and the steepness of the transition decrease.
  • trace (v) in FIG. 3A the thermomechanical response that is observed is inconducive to shape memory effects as the fixing (crystallization) temperature is lower than room temperature so that shape fixing would require subambient cooling and the temporary shape would be expected to drift via partial melting. In addition, the melting transition is too broad for dramatic strain recovery to be expected.
  • Suitable polymers include elastomers that are typically crosslinked and/or crystalline and exhibit melt or glass transitions at temperatures that are above body temperature and safe for use in the body, e.g. at about 40 to 50° C. Suitable polymers can have an elastic modulus of about 60,000 or 70,000 psi or more at 25° C. (ASTM D638M). Such polymers may have a variety of room temperature moduli, from rigid glassy materials having storage moduli of several GPa to compliant rubbers with moduli as low as tens of MPa. Moreover, the moduli may tuned over the range 0.5 ⁇ E ⁇ 10 MPa, as dictated by the end application.
  • Suitable polymers include polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene (particularly, crosslinked polyethylene), trans-isoprene, block copolymers of polyethylene terephthalate (PET) and blends of polycaprolactone and n-butylacrylate.
  • PCO polycyclooctene
  • PMMA polymethylmethacrylate
  • a suitable PVAc/PVDF tube is formed by compounding 60-80 parts (by weight) PVAc (B-100, mw 500,000, ChemPoint, Cleveland, Ohio) with 40 to 20 parts PVDF (Grade 1010, Solvay Fluoropolymers, Houston, Tex.).
  • the PVAc/PVDF is a crystalline material that can be utilized with or without crosslinking.
  • the polymer body can be made of mixtures of polymers or multiple polymer layers.
  • the polymer forming the stent body can be compounded to include a drug, which elutes from the polymer, or radiopaque material.
  • the structural polymer body can be coated with other polymers to carry drug or control drug delivery from the structural polymer.
  • the polymer body can also exhibit shape memory properties. This feature of the polymer can be used in combination with the expansion properties discussed above.
  • the polymer can be configured to remember an enlarged or reduced diameter configuration.
  • the stent can be delivered into the body, and expanded by a combination of heat and radial pressure as described above. After a time, the stent can be retrieved by reheating the stent.
  • the heating causes the stent to revert its small diameter condition.
  • the remembered stent diameter is less than the vessel diameter and the stent can be more easily removed from the vessel.
  • Such an application might be useful, for example, for a stent delivered into the prostate where removal and replacement is desirable.
  • a polymer tube 40 is constructed by extrusion or molding a suitable polymer to an initial diameter di which in the same or greater than the target lumen diameter.
  • the strands can be formed by extrusion, followed by arranging the strands into a tube, e.g. by weaving or knitting.
  • the tube wall is then cut to provide a pattern of open areas in a desirable geometric pattern, e.g. by laser cutting.
  • the polymer can be recrystallized or crosslinked, if necessary.
  • the tube is heated typically near or above the melt or glass transition and mechanically deformed to a small diameter, suitable for delivery.
  • the tube is cooled, e.g. to room temperature.
  • the tube is assembled onto a catheter, delivered into the body, and expanded by application of heat, to the melt or glass transition, while inflating the balloon as discussed above. (If the polymer has shape memory properties, the polymer tends to expand upon heating to a larger, remembered diameter.
  • a polymer tube 50 is constructed to an initial diameter di, smaller than the vessel diameter.
  • the tube wall is cut to provide an open area in a desirable pattern so that when the stent is expanded, a compression-resistant geometry will result.
  • the polymer is recrystallized or crosslinked, if necessary.
  • the tube is assembled in a catheter, delivered into the body, and expanded by heating to the melt or glass transition temperature while inflating the balloon to provide an outward radial expansion, as discussed above. If the polymer has shape memory properties, the stent can be subsequently re-heated so it reverts back to its remembered small diameter configuration and removed from the body.
  • the stent can have an expanded inner diameter of about 2 to about 20 mm.
  • the initial inner diameter can be in the range of about 1 to about 3 mm.
  • the wall thickness is in the range of about 0.005 mm to 20 mm.
  • the wall thickness variation between delivery and expanded states is within about 10%, 5% or 1% or less.
  • the ratio of the open area to the wall area in the expanded state is about 0.5 to 0.7 or more.
  • the tube wall area is the area of the tube defined by polymer.
  • the open area is the open area defined by the apertures.
  • a particular stent for coronary use has an initial diameter of about 2 mm, an expanded diameter of about 4 mm, and a wall thickness of about 0.005 mm to 0.1 mm.
  • the stent can be used for various applications including coronary, neuro, carotid, peripheral vasculature, ureteral, and prostate lumens. The stent is particularly useful where the lumen path is highly curved or irregular.
  • the catheter can be, e.g. an angioplasty balloon catheter with a relatively non-distendable inflating balloon suitable for expansion of occluded regions of a vascular lumen.
  • the balloon may include a polymer such as PET, which has a burst pressure of about 1.5 to 5 atm or more.
  • the stent can be heated by heating the balloon inflation fluid.
  • the balloon inflation fluid can be heated by e.g., heating the fluid delivery device outside the body using e.g., resistive heating tape.
  • the catheter can carry a heating device.
  • a resistive heater or RF heater can be provided in the interior of the balloon.
  • a heated balloon catheter is described in Abele et al. U.S. Pat. No. 5,496,311 and U.S.
  • Vessel heating as described in the '311 can be used in combination with stent delivery as discussed herein.
  • the stent can be heated directly.
  • the polymer can be compounded to include a material, such as magnetic particles, which are susceptible to heating by magnetic effects, such as hysteresis effects.
  • a magnetic field can be imposed on the stent body by a source on a catheter or outside the body. Particles are available as the Smartbond System from Triton Systems, Inc., Chelmsford, Mass. Heating by magnetic effects is discussed in U.S. Pat. No. 6,056,844.
  • the stent can also be heated during delivery without applying expansion force to soften the stent, improving its flexibility and thus improving delivery to a treatment site through a tortuous vessel path.
  • a polycyclooctene polymer (Vistenemer 8012 pellets, mw 90,000, Degussa, NJ) is melt processed in an extruder to produce a tube having dimensions of about 0.118 inch O.D. and 0.070 inch I.D. (wall thickness about 0.024 inch). The tube is cut to a length of about 4 cm. The tube is subject to UV excimer laser ablation cutting to provide an aperture pattern of rectangular slots having a width of about 0.2 mm and a length of about 8 mm. Beam energy and pulse rate are selected to avoid substantial heating or melting of the polymer.
  • the polymer can be compounded with about 10% TiO 2 (T8141, Dupont) to enhance absorption of laser radiation.
  • a suitable pattern is consistent with the Express stent (commercially available from Boston Scientific, Natick, Mass.). (Alternatively, a pattern as described in Palmaz U.S. Pat. No. 4,733,665 can be used.)
  • the tube is heated to a temperature below its melt point, e.g., to about 39 to 40° C. in a water bath and expanded by balloon catheter to a diameter of about 5 mm and positioned on a mandrel (PTFE tube) to maintain the expanded shape and diameter.
  • the tube is then cooled to room temperature.
  • the polymer is then crosslinked by e-beam radiation at 250 K Grays (Steris Isomedics Services, Northborough, Mass.). Crosslinking fixes the stent in the condition.
  • the crosslinked PCO has an elastic (Youngs) modulus of about 74945 psi at about 25° C. (ASTM D638M)).
  • the stent is heated to the polymer melt temperature, about 45° C. and collapsed over a deflated balloon (diameter of about 2 mm) with a 4 mm inflated maximum diameter and 2 cm length.
  • a suitable balloon catheter is a 75 cm Meditech UltraThin Catheter, available from Boston Scientific, Natick, Mass.).
  • the balloon and stent are immersed in a water bath of about 42 to 45° C. and water the same temperature is used to inflate the balloon.
  • the stent is expanded to about 4 mm diameter (ID) at an inflation pressure of about 1 to 1.5 atm (measured at the delivery syringe). After expansion, the heating is discontinued and the balloon and inflation fluid allowed to cool to body temperature (while the balloon remains inflated). Alternatively, a cooled contrast fluid can be circulated to the balloon.
  • ID mm diameter
  • a cooled contrast fluid can be circulated to the balloon.
  • the stent exhibits no visible reduction in wall thickness or irregular flow of polymer into the stent open areas.
  • the stent in the heated, expanded state, the stent can be bent around a mandrel of about 0.75 cm radius without kinking. After the stent is cooled, it maintains the curved form.
  • stent 100 includes a coiled rod 120 composed of a polymer.
  • Stent 100 includes an elongated portion 140 having a general diameter d 1 and an end portion 160 having a maximum diameter d 2 .
  • General diameter dl for example, may be between about 3 mm and about 25 mm, more preferably between about 6 mm and about 14 mm, and maximum diameter d 2 , for example, may be between about 7 mm and about 30 mm, more preferably between about 10 mm and about 17 mm.
  • the stent When stent 100 is designed, for example, for insertion into a urethra, the stent may have an overall length, for example, of between about 3 mm and about 15 mm, preferably between about 6 mm and 10 mm, and end portion 160 may have a length, for example, of from about 3 mm to about 15 mm, preferably from about 5 mm to about 10 mm. End portion 160 is in a flared position. Referring to FIG. 8 , stent 100 is shown with end portion 160 in a collapsed position that can be reverted with heating to the expanded position shown in FIGS. 6 and 7 .
  • the portion of the stent in the collapsed position that can be reverted to the expanded position is, for example, greater than 5%, 10%, or even 25% of the overall length L of the stent, and less than 80% or 65% of the overall length L of the stent.
  • the of the overall length L of the stent may be between 10% and 65% of the overall length L of the stent.
  • the polymers preferably are cross-linked and/or crystalline elastomers that have melt or glass transition temperatures that are above body temperature, for example, greater than 45° C. or 55° C.
  • the degree of cross-linking can be used to adjust, for example, the melt or glass transition temperature, and range, of the polymer.
  • the polymer preferably has a relatively narrow, for example, less that 5° C. or 10° C., melt or glass transition temperature range.
  • the polymer preferably has elastomer properties in its melted or softened state.
  • Preferred polymers have an elastic modulus, for example, of about 60,000 psi or 70,000 psi or more at 25° C. (ASTM D638).
  • polymers include polynorbornene and copolymers of polynorbornene, blends of polynorbornene with KRATON® (thermoplastic elastomer) and polyethylene, styrenic block copolymer elastomers (e.g., styrene-butadiene), polymethylmethacrylate (PMMA), polyethylene, polyurethane, polyisoprene, polycaprolactone and copolymers of polycaprolactone, polylactic acid (PLA) and copolymers of polylactic acid, polyglycolic acid (PGA) and copolymers of polyglycolic acid, copolymers of PLA and PGA, polyenes, nylons, polycyclooctene (PCO), polyvinyl acetate (PVAc), polyvinylidene fluoride (PVDF), blends of polyvinyl acetate/polyvinylidine fluoride (PVAc/PVDF), blends of polyvin
  • the polymers above are also useful for the stents of FIGS. 1, 4 and 5 .
  • Particular polyurethanes are made by reacting (A) a polyol, (B) a chain extender dihydroxyl-terminated POSS and (C) a diisocyanate, where POSS stands for a polyhedral oligomeric silsesquioxane diol.
  • the polyol (A) can be polyethylene glycol (PEG), polycaprolactone (PCL), polycyclooctene (PCO), trans-1,4 butadiene, transisoprene, polynorbornene diol and polymethacrylate copolymer
  • the chain extender(B) can be TMP cyclopentyldiol-POSS, TMP cyclohexyldiol-POSS, TMP isobutyldiol-POSS, transcyclohexanediolcyclohexane-POSS, or transcyclohexanediolisobutyl-POSS
  • the diisocyanate (C) can be selected from a large number of diisocyanates and is preferably 4,4′ diphenyl methylene diisocyanate (MDI).
  • diisocyanates (C) that are suitable for use in the synthesis of hybrid polyurethane SMPs include: toluene-2,4-diisocyanate (TDI), toluene-2,6diisocyanate, hexamethylene-1,6-diisocyanate (HDI), 4 , 4 ′diphenylmethane diisocyanate (MDI), isophorone diisocyanate (IPDI), and hydrogenate 4,4′-diphenylmethane diisocyanate (H12MDI).
  • TDI toluene-2,4-diisocyanate
  • HDI hexamethylene-1,6-diisocyanate
  • MDI isophorone diisocyanate
  • H12MDI hydrogenate 4,4′-diphenylmethane diisocyanate
  • FIG. 8A A graph of heat flow as a function of temperature for several POSS polyurethanes is shown in FIG. 8A and a graph of storage modulus as a function of temperature for several POSS polyurethanes is shown in FIG. 8B .
  • This scheme shows an example of synthesis of TPU using polyethylene glycol as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate in toluene.
  • This scheme shows an example of synthesis of TPU using polycaprolactone diol as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate.
  • This scheme shows an example of synthesis of TPU using polyocyclooctene as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate.
  • any of the polymers mentioned above may be filled with, for example, nanoparticles of clay and silica to, for example, increase the modulus of the plastic.
  • Dispersing agents and/or compatibilizing agents may be used, for example, to improve the blending of polymers and the blending of polymers with fillers.
  • Dispersing agents and/or compatibilizing agents include, for example, ACRAWAX® (ethylene bis-stearamide), polyurethanes and ELVALOY® (acrylic-functionalized polyethylene).
  • the polymers can be cross-linked by application of radiation such as e-beam, UV, gamma, x-ray radiation or by heat-activated chemical crosslinking techniques. Radiation techniques provide the advantage that the polymer typically does not have to be substantially heated to achieve crosslinking. For e-beam radiation, an exposure of about 200-300, e.g. 250 kilograys, typically provides sufficient crosslinking.
  • wrapping fixture 200 can be used for making coiled stent 100 .
  • Wrapping fixture 200 includes a base 220 for support, a mandrel 240 with a flared end 260 , slits 280 for fixing the plastic rod 120 , an aperture 290 for fixing the plastic rod 120 on the non-flared end and a fixing screw 299 for releasably fixing mandrel 240 to wrapping fixture 200 .
  • Stent 100 is manufactured from plastic rod 120 made by a variety of methods known in the art (e.g., extrusion, coextrusion, injection molding, casting, compression molding). If casting is used, the polymers may have tunable critical temperatures and rubber modulus have been synthesized using a thermosetting random copolymer formed from two vinyl monomers that yield controlled T g and casting-type processing. Such copolymers were crosslinked with a difunctional vinyl monomer (crosslinker), the concentration of crosslinker controlling the rubber modulus and thus the work potential during recovery.
  • Rod 120 may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more. Plastic rod 120 and wrapping fixture 200 are heated to the softening temperature of the polymer, making the plastic rod 120 malleable.
  • the rod 120 is inserted into aperture 290 that is machined through mandrel 240 to fix the rod at the starting end.
  • the rod 120 is tightly wrapped around mandrel 240 , including flared end 260 .
  • plastic rod 120 is pushed into slits 280 .
  • the overall length of the stent 100 may be, for example, about 2 mm to about 150 mm or more. The overall length required depends upon the application.
  • the plastic rod 120 now fixed in place on the mandrel 240 , is heated to above the softening point of the material and maintained at that temperature long enough to anneal the rod and fix the shape. Typically, the time required to fix the shape is from about 0.25 hr to 10 hr or more.
  • stent 100 is removed from mandrel 240 .
  • the flared end of the coil is tapered down and collapsed so that the diameter along the entire length of the stent is approximately d 1 . Collapsing the flared end 160 of stent 100 allows for ease of insertion, for example, into a restricted prostatic urethra.
  • a 56:24:20 mixture of PVAc/PVDF/PMMA is dry bended and loaded into the hopper of an extruder.
  • the PVAc is grade B-100
  • the PVDF is Solvay SOLEF® 1010
  • the PMMA is Atofina PLEXIGLAS® V045.
  • the mixture is melt processed to produce 1.27 mm (0.05 inch) monofilament.
  • the rod is made into a coil by winding it around wrapping fixture 200 .
  • the fixture and the rod are immersed into a 50° C. water bath. At this temperature, the rod becomes malleable enough to wind easily around the mandrel and secured in place to prohibit the uncoiling of the helical shape.
  • the mandrel is removed from the fixture with the stent locked in place and placed into an oven at 110° C. for one hour to anneal the stent.
  • This annealing process locks the permanent shape of the coil.
  • the mandrel and coil are cooled to room temperature, and the stent is removed from the mandrel.
  • the stent had on overall length of approximately 73 mm and a flared end portion length of approximately 7 mm.
  • the diameter d 1 of the body is approximately 6 mm and the maximum diameter d 2 of the flare on the open end is approximately 11 mm.
  • the flared end of the coil is tapered down with brief heating to 50° C. and manipulation, followed by cooling, so that the diameter is approximately 6 mm along the entire length of the stent.
  • a 70:30 mixture of PVAc/PVDF is dry bended and loaded into the hopper of an extruder.
  • the mixture is melt processed to produce 1.27 mm (0.05 inch) monofilament.
  • the rod is made into a coil by winding it around wrapping fixture 200 .
  • the fixture and the rod are immersed into a 50° C. water bath. At this temperature, the rod becomes malleable enough to wind easily around the mandrel and secured in place to prohibit the uncoiling of the helical shape.
  • the mandrel is removed from the fixture with the stent locked in place and placed into an oven at 110° C. for one hour to anneal the stent. This annealing process locks the permanent shape of the coil.
  • the mandrel and coil are cooled to room temperature, and the stent is removed from the mandrel.
  • the stent had on overall length of approximately 73 mm and a flared end portion length of approximately 7 mm.
  • the diameter d 1 of the body is approximately 6 mm and the maximum diameter d 2 of the flare on the open end is approximately 11 mm.
  • the flared end of the coil is tapered down with brief heating to 50° C. and manipulation, followed by cooling, so that the diameter is approximately 6 mm along the entire length of the stent.
  • stent 100 may be, for example, inserted into restricted urethra 300 on delivery tube 320 .
  • end portion 160 is in a collapsed position.
  • warm water e.g., 45° C.-55° C.
  • Heating reverts the collapsed end 160 to a flared, expanded position ( FIG. 12 ).
  • the flared, expanded position allows stent 100 to remain fixed in position, for example, in the prostatic urethra.
  • delivery tube 320 is a long cylindrical tube into which a ureteral scope 380 is inserted.
  • Delivery tube 320 has a distal end 330 over which stent 100 is placed.
  • Delivery 320 is fitted with a side port 350 including a stopcock 370 through which saline can be flushed for irrigation.
  • Delivery tube 320 with stent 100 in place is delivered into, for example, the prostatic urethra with the aid of a ureteral scope.
  • hot saline is flushed through port 350 to revert the collapsed end 160 to a flared, expanded position ( FIG. 12 ).
  • the flared, expanded end allows stent 100 to remain fixed in position, for example, in or adjacent the prostatic urethra or external sphincter between the prostate and the bladder to prevent migration.
  • the direction of the flare can, of course, be oriented in other directions.
  • the scope and delivery tube 320 are withdrawn, leaving stent 100 in place.
  • an alternative delivery system is illustrated that includes a tube 320 with a screw on tip 331 onto which a stent 100 is placed after collapsing the end portion 160 .
  • the assembly is inserted into, for example, the prostatic urethra.
  • Stent 100 may be, for example, inserted into restricted urethra 300 on balloon catheter (not shown). During insertion, end portion 160 is in a collapsed position. After insertion, warn water is flushed through the guide wire lumen of the balloon catheter to flood the area and to heat the stent. Heating of the stent by the water reverts the collapsed end 160 to a flared, expanded position The flared, expanded position allows stent 100 to remain fixed in position, for example, in the prostatic urethra. If there is an obstruction in the lumen into which the stent is deployed the stricture can be dilated using the balloon to help the stent open fully and maintain a uniform diameter inside the vessel.
  • coiled stent 100 with an end 160 in the expanded position can be removed with the aid of a catheter equipped with a grasping device 360 and a ureteral scope 380 for visualizing stent 100 in, for example, the prostatic urethra.
  • a catheter equipped with a grasping device 360 and a ureteral scope 380 for visualizing stent 100 in, for example, the prostatic urethra.
  • end 400 of stent 100 has been visualized with ureteral scope 380
  • the stent is grasped with grasping device 360 .
  • ureteral scope 380 is removed from the catheter and is replaced with a heating device (not shown), e.g. a catheter. Heating stent 100 above the softening point of the polymer, e.g., from about 45° C. to about 55° C. for polycyclooctene (PCO), and pulling the end 400 of stent 100 through the orifice 420 allows the stent to be removed in
  • FIG. 11 shows heating of stent 100 with a warm liquid on a delivery tube
  • heating may be accomplished with the use of IR, RF or inductive heating.
  • stent 10 into other body lumens or cavities.
  • other body lumens or cavities include the biliary duct, cystic duct, a ureter, a bulbar urethra or a hepatic duct.
  • the modulus of polycyclooctene (PCO) that can, for example, be the polymer of stent 100 is shown as a function of temperature. Below approximately ⁇ 65° C. (T g , region A), PCO exists a rigid, glassy polymer. Above T g , but below T m , PCO exists as a flexible elastomer (region B). Above T m , PCO exists as a relatively low modulus elastomer. Above T m , for example, stent 100 composed of PCO can be removed from a lumen or cavity of the body, the prostatic urethra, for example, in a substantially uncoiled state.
  • PCO polycyclooctene
  • the modulus of a ternary blend of PVAc/PVDF/PMMA that can, for example, be the polymer of stent 100 is shown as a function of temperature. Adding PMMA offers the advantage, for example, of increasing the modulus of the blend.
  • Stent 100 reverts from its collapsed position to its expanded position upon re-heating above T m (region C) because the modulus of the material lowers sufficiently to release the residual stress that was “frozen” into stent 100 during the rapid cooling.
  • FIGS. 17-28 show other examples of stents.
  • coiled stent 500 has two end portions 520 and 540 in expanded positions. End portions 520 and 540 can be collapsed ( FIG. 18 ) for ease of insertion into a body cavity or lumen, and reverted with heat to expanded positions.
  • coiled stent 600 has two end portions 620 and 660 and a central portion 640 in expanded positions. All three portions may be collapsed (not shown), and then reverted to expanded positions.
  • coiled stent 700 made from a flattened tube 710 has an end portion 720 in an expanded position.
  • the flattened tube can, for example, add strength to the stent.
  • the tube can have a major diameter, for example, of between about 1.0 mm to about 3.0 mm, more preferably between about 1.5 mm to about 2.25 mm, and major inner diameter, for example, of between about 0.5 mm to about 2.5 mm, more preferably between about 1.25 mm and about 1.75 mm.
  • End portion 720 may be collapsed (not shown) and then reverted to an expanded position.
  • flattened tube 710 has an interior 740 that may be filled with, for example, a medicament.
  • the medicament may be triclosan or salicylic acid. Release of medicament from flattened tube 710 , for example, may reduce the risk of infection. Interior 740 may also be filled with, for example, paclitaxel or mitoxantrone. Release of the these medicaments from interior 740 may be, for example, useful for treating prostate cancer and reducing prostatic hyperplasia.
  • coiled stent 800 made from tape 810 has an end portion 820 that may be collapsed and then reverted to an expanded position.
  • Tape 810 may have a thickness from about 0.5 mm to about 2.0 mm, more preferably from about 0.75 mm to about 1.25 mm, and a width, for example, of from bout 1.0 mm to about 3.0 mm, more preferably from about 1.75 mm to about 3.00 mm.
  • an aperture 840 is provided so that a trailing string (not shown) can be included for ease of removal with the grasping device shown in FIG. 14 .
  • coiled stent 900 is made from plastic rod and has an end portion 920 that may be collapsed and then reverted to an expanded position.
  • Stent 900 includes a plurality of protruding elements 940 that are integral with and extend outwardly from the plastic rod from which the stent is made.
  • coiled stent 1000 is made from plastic rod, for example, oriented monofilament, and has an end portion 1020 that may be collapsed and then reverted to an expanded position.
  • Stent 1000 includes a plurality of protruding elements 1060 that extend outwardly from the plastic rod from which the stent is made. The friction provided by protruding elements 940 , 1060 can help to hold stent 900 , 1000 in place within, for example, the prostatic urethra.
  • Protruding elements 940 are made, for example, by cutting into the plastic rod with, for example, a sharp edged instrument, for example, a knife, so as penetrate a depth into the plastic rod.
  • the depth of penetration P is adjusted to provide acceptable frictional properties, while minimizing the impact on the mechanical properties of the plastic rod.
  • the maximum depth of penetration into the plastic rod, measured inwardly from the outer surface of the plastic rod is, for example, from about 1 to about 50% of the average thickness of the plastic rod.
  • the mechanical properties of the plastic rod may be reduced and if the depth of penetration is too low, the resulting protruding elements may be too small to provide the appropriate frictional properties when expanded in a body cavity or lumen, for example, the prostatic urethra.
  • Other cutting means are possible, for example, water knife and laser cutting means, to reduce the impact of the cutting on the mechanical properties of the plastic rod.
  • the shape of the plastic rod from which the stent is made may be of other forms than that shown above. For example, it may be in the form of, for example, a coiled elongated flattened tube and the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent.
  • stent 900 is manufactured from plastic rod made by a variety of methods known in the art (e.g., extrusion and coextrusion).
  • the plastic rod may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more.
  • the protruding elements are put onto the plastic rod before wrapping the mandrel shown and discussed above. After wrapping the mandrel, the plastic rod and wrapping fixture 200 are heated to the softening temperature of the polymer, making the plastic rod malleable.
  • the protrusions are annealed in the “up” position, that is, with the protruding elements extending outwardly by “prying up” the protruding elements that results from cutting.
  • Prying up the protruding elements may be achieved by, for example, running a surface across the protruding elements in a direction opposite the cut direction. Annealing is continued to fix the shape. After cooling, the stent is removed from mandrel. Before packaging, the flared end of the coil is tapered down along with protruding elements and collapsed so that the diameter along the entire length of the stent is approximately d 1 . Collapsing the flared end and protruding elements allows for ease of insertion, for example, into a restricted prostatic urethra. In some implementations, the flared end and the main body are collapsed to have a diameter less than d 1 .
  • the end portion Upon heating, the end portion reverts to its expanded position and the protruding elements revert to their up positions. If a medicament is placed in the cavities 960 from which the protruding elements 940 are carved, it may be released upon expansion of the stent.
  • Stent 1000 with protruding elements 1060 is made by, for example, wrapping a thicker plastic rod with a thinner plastic rod, for example, a monofilament, that includes a plurality of constrictions, for example, knots along its length.
  • the elevation E above an outer surface of the thicker plastic rod is adjusted to provide acceptable frictional properties.
  • the maximum elevation above an outer surface of the thicker plastic rod is, for example, from about 1 to about 50% of the average thickness of thicker plastic rod.
  • the shape of the rods from which the stent is made may be of other forms than that shown above.
  • it may be in the form of, for example, a coiled elongated flattened tube and the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent.
  • stent 1000 is manufactured from plastic rod made by a variety of methods known in the art (e.g., extrusion and coextrusion).
  • the thicker plastic rod may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more.
  • the thinner plastic rod from which the protruding elements are fashioned may have a diameter of, for example, from about 0.2 mm to about 20 mm.
  • the constrictions, for example, knots are placed on the thinner plastic rod and the thinner plastic rod is wrapped around the outer surface of the thicker plastic rod. The ends of the thinner plastic rod are heat staked to hold the thinner plastic rod onto the outer surface of the thicker plastic rod.
  • the assembly of the thinner and thicker plastic rod is wrapped around the mandrel shown and discussed above.
  • the plastic rods and wrapping fixture 200 are heated to the softening temperature of the polymer of the thicker plastic rod, making the plastic rod malleable. Annealing is continued to fix the shape.
  • the stent is removed from mandrel.
  • the flared end of the coil is tapered down so that the diameter along the entire length of the stent is approximately d 1 . Collapsing the flared end and protruding elements allows for ease of insertion, for example, into a restricted prostatic urethra.
  • the thinner plastic rod may contain a medicament that is released upon expansion, for example, in the prostatic urethra.
  • the thinner plastic rod is made of a degradable material and the degradable material is filled with a medicament.
  • the entire stent for example, the stents of FIGS. 4, 5 , 20 , 23 and 26 , may have an expanded position.
  • only a portion or portions of the stent may be composed of the polymer.
  • the remainder of the stent may be, for example, composed of a non-polymeric material (e.g., a metal or metal alloy, e.g., Ni/Ti alloy).
  • the stent may be composed of multiple layers of materials, for example, by co-extruding the layers when making an elongated element.
  • the stent may be a multiple segment stent.
  • the polymer in any of the above stents may be a blend of polymers, for example, miscible blends of a semicrystalline polymers with an amorphous polymer.
  • miscible blends of a semicrystalline polymers with an amorphous polymer.
  • a single glass transition results, without broadening.
  • the equilibrium crystallinity which controls the plateau modulus between T g and T m where shape fixing is performed
  • blend composition i.e., relative levels of each component.
  • Polymers blends with a relatively high modulus in the fixed state at room temperature, having a tunable and sharp transition, the permanent shape of which can be remolded repeatedly above certain melting temperatures are prepared by the blending of crystalline polymers (C′) with amorphous polymers (A′), such that they are a single miscible phase in the molten state (allowing processing to stress-free native states) but crystalline to a limited and tailored extent and which further vitrify on cooling to room temperature.
  • the recovery of the polymer blend may be fast, for example, within seconds.
  • PVDF poly(vinylidene fluoride)
  • PVA polylactide
  • PEG poly(ethylene glycol)
  • PEG polyethylene
  • PVC polyethylene-co-vinyl acetate
  • PVDC poly(vinylidene chloride)
  • PVDC copolymers of poly vinylidene chloride
  • PVDC polyvinylidene chlor
  • PVAc poly(vinyl acetate)
  • PMA poly methyl acrylate
  • PEA poly ethyl acrylate
  • aPMMA atactic poly methyl methacrylate
  • iPMMA isotactic poly methyl methacrylate
  • sPMMA syndiotactic poly methyl methacrylate
  • PVAc poly(vinyl acetate)
  • PLA semicrystalline polylactide
  • PVDF poly(vinylidene fluoride)
  • the polymers show complete miscibility at all blending ratios with a single glass transition temperature, while crystallization (exclusive of PVAc) is partially maintained.
  • the T g 's of the blends are employed as the critical temperature for triggering the shape recovery while the crystalline phases serve as physical crosslinking sites for elastic deformation above T g , but below T m .
  • the preferred blends are formed from poly vinyl acetate(PVAC) and poly(lactic acid) (PLA) or poly(vinylidene fluoride) (PVDF).
  • PVAC poly vinyl acetate
  • PLA poly(lactic acid)
  • PVDF poly(vinylidene fluoride)
  • examples of other suitable blends include the pair PVDF/PMMA and ternary blends of PVDF/PMMA/PVAc.
  • the PMMA and the combination of PMMA/PVAc serve the same role as PVAc in the blends as have been previously described.
  • An advantage of adding PMMA is that the critical temperature can be increased arbitrarily to about 80° C. and the room temperature modulus can also be increased.
  • the PVDF may be substituted by poly(vinylidene chloride) (PVDC), by copolymers of poly(vinylidene chloride/ply(vinyl chloride), or by any “C” polymer vide supra.
  • PVAc poly(vinyl chloride) with poly(butyl acrylate) or poly (butyl methacrylate)
  • PVC/PBA poly(butyl methacrylate)
  • PVAc simultaneously lowers the crystallinity of PVDF while increasing T g .
  • PVC may serve the same role as PVDF, but it already has a low degree of crystallinity, but a relatively high T g ( ⁇ 80° C.).
  • the second component (PBA) serves only the role of decreasing T g .
  • PBA smal molecule plasticizers, most notably dioctylphthalate (DOP), but is preferred to use a biocompatible polymeric plasticizer for intended implantable applications.
  • DOP dioctylphthalate
  • the range of PBA compositions is 10-40%, with 20% being the most advantageous, yielding a T g ⁇ 40° C.
  • the crystallization behavior of semicrystalline PLA was investigated via DSC.
  • the PLA samples were first heat pressed at 180° C. for 10 minutes and then quenched to room temperature with water cooling.
  • the storage modulus of the polymer blends was also measured using DMTA, first investigating the effects of annealing on the storage modulus. Below their glass transition temperatures, T g , both samples exhibit similar high storage moduli (3 GPa), as well as similar softening points. When heated above T g , the storage modulus of thermally quenched samples decreases sharply to about 2 MPa; however, further increasing the temperature induces a modulus increase attributed to recrystallization of the samples at higher temperatures. This also proved that the sample is not in an equilibrium state and that its mechanical properties in the rubbery region depend on thermal history. To reach equilibrium, the sample was annealed at 110° C. for 1 hour as previously described for DSC analyses.
  • the storage modulus above T g shifts to about 200 MPa until melting, the increase being due to an increase of the degree of crystallinity on annealing to tune the rubbery modulus at equilibrium state,.
  • PLA was blended in different proportions to PVAc and annealed as above. Storage moduli for such blends were measured and the results are plotted in FIG. 32 . It can be seen that, below T g , all of the samples show similar large moduli while above T g the moduli decrease to a plateau whose magnitude depends on crystallinity and thus PLA content. This trend is in accordance with that of DSC and XRD, and can be explained by the fact that the increase of storage moduli came from the physical crosslinking formed by crystals and the filler effect of the high modulus crystalline phase.
  • the storage moduli of the blends which give the rigidity of the materials, were also measured.
  • the results are similar to those of the PLA/PVAc blends, the PVDF/PVAc blends being very rigid below the critical temperatures (T g ), and featuring a sharp modulus changes at the Tg to a plateau modulus ranging from several MPa to tens of MPa, depending on the degree of crystallinity of the blends.
  • These plateau moduli can be tuned by adjusting the degree of crystallinity of the blend, that is, adjust the blend composition.
  • Bioabsorbable polymers include, for example, polyurethanes and polyurethane copolymers such as those described above with the general formula (directly below), where X/Y is, for example, 1 to 20, n is, for example, 2 to 1000, and the total degree of polymerization m is, for example, 2 to 100
  • X/Y is, for example, 1 to 20
  • n is, for example, 2 to 1000
  • m is, for example, 2 to 100
  • suitable monomers include caprolactone, ethyleneglycol, ethylene oxide, lactic acid, and glycolic acid.
  • the copolymers from these monomers can hydrolyze and cleave the polymer linkage.
  • an implantable medical stent may be delivered into the body using a catheter.
  • the stent can be delivered in a small diameter form and then expanded at a treatment site by triggering a shape change (for example, by heat application) caused by the shape memory properties of the polymer.
  • the stent can also be expanded by a mechanical expander such as an inflatable balloon of the type used on an angioplasty catheter.
  • the stent is sized (e.g., an expanded inner diameter of about 2 mm to about 20 mm) and configured for use in the vascular system, particularly the coronary arteries, and implanted after or simultaneously with an angioplasty procedure to maintain an open lumen and reduce restenosis.
  • Vascular stents are described in U.S. Provisional Application No. 60/418,023, which is hereby incorporated in full by reference.
  • a stent for coronary use can have an initial diameter of about 2 mm, an expanded diameter of about 4 mm, and a wall thickness of about 0.005 mm to 0.1 mm.
  • Other exemplary applications include neuro, carotid, peripheral, and vasculature lumens.
  • the vascular stent can be bioabsorbable or non-bioabsorbable.
  • a stent e.g., a bioabsorbable or a non-bioabsorbable stent, is constructed for use in nonvascular lumens, such as the esophagus, ureteral, biliary, or prostate.
  • the stent is conductive to allow an electrical current to pass through the stent, for example, to deliver electricity to an area of the body or to trigger, for example, a physical change in the stent, for example, a change in the diameter of the stent.
  • the stent for example, of FIGS. 4, 23 and 26 , is made porous by, for example, adding a chemical foaming agent to the polymer from which the stent is made during the production the plastic strand.
  • the stent is porous and includes a medicament.
  • the initial porosity of the stent can be reduced, for example, by the application of heat and pressure before deployment in the body. Upon deployment of the stent in the body, the porosity is increased by a triggering event, for example, the application of heat to the stent at the desired site of treatment.

Abstract

A medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is, for example, an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit from provisional application 60/418,023, filed Oct. 11, 2002; 60/488,323, filed Jul. 18, 2003; 60/419,506, filed Oct. 18, 2002; 60/466,401, filed Apr. 29, 2003; and 60/488,590, filed Jul. 18, 2003, all hereby incorporated by reference in their entirety.
  • TECHNICAL FIELD This invention relates to implantable medical devices and methods of delivering the same. BACKGROUND
  • The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprosthesis include stents and covered stents, sometimes called “stent-grafts”.
  • An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
  • Prostate enlargement, also known as benign prostate hyperplasia or benign prostate hypertrophy, is a common affliction among older men. The condition involves swelling of the prostate. The prostate surrounds the urethra, or urinary tract, and enlargement of the prostate may restrict passage of urine from the bladder towards the urethra. Benign prostate hyperplasia is uncomfortable because it makes urination difficult or impossible. The condition is also dangerous because it can lead to infection of the bladder and kidneys.
  • Prostate enlargement can be treated with surgery known as resection. Resection can be accomplished by cutting away a large portion of the prostate gland. Prostate enlargement can also be treated with heat treatment, cold treatment, or ablation.
  • Sometimes a restricted urethra can be treated with a prostatic stent to support the urethra and keep it open despite pressure from the enlarged prostate. A prostatic stent may be implanted permanently or as an interim solution.
  • SUMMARY
  • The invention relates to implantable medical devices, for example, a stent including a polymer.
  • In one aspect, the invention features a medical device. The medical device includes a balloon catheter having an expandable member, e.g., an inflatable balloon, at its distal end and a stent or other endoprosthesis. The stent is an apertured tubular member formed of a polymer and is assembled about the balloon. The stent has an initial diameter for delivery into the body and can be expanded to a larger diameter by inflating the balloon. The polymer does not flow substantially during expansion and substantial stress relaxation or creep does not occur so that the geometry of the stent is maintained.
  • In another aspect, a tubular endoprosthesis including a polymer body is provided and delivered into a body lumen. The endoprosthesis is expanded in the body lumen under conditions of expanding pressure and temperature so that the wall thickness of the polymer body is substantially maintained.
  • In another aspect, a polymer tube is formed to a first, large diameter. An aperture pattern is cut into the tube wall. The polymer is crosslinked or crystallized. The polymer tube is deformed to a second, small diameter. The polymer tube is expanded in a body lumen to a diameter larger than the second diameter by application of pressure and heat.
  • In another aspect, a polymer tube is formed to a first, small diameter. An aperture pattern is provided in the tube wall. The polymer is crystallized or crosslinked. The tube is expanded in a body lumen by application of pressure and heat.
  • In another aspect, an implantable medical apparatus includes an element operable for movement within the body by mechanical force applied to the element. The element includes a polymer having a melt or glass transition temperature in the range above body temperature to about 50° C. or 60° C. and exhibiting a plateau in a plot of storage modulus as a function of temperature at melt or glass transition. In embodiments, the element is a stent. The stent may be generally a tubular body that includes an apertured wall. The stent may be operable for expansion from a first, smaller diameter to a second larger diameter for implantation in a lumen. The thickness of the stent wall varies by about 1% or less between the first and second diameter.
  • In another aspect, the invention features a medical device including a polymer having a melt or glass transition temperature above body temperature and exhibiting an approximate plateau in a plot of storage modulus as a function of temperature at melt or glass transition. The melt or glass transition temperature may be, for example, above about 37° C. The medical device may undergo a triggerable event at about the plateau. The triggerable event may be, for example, a change in the flexibility, a change in the porosity, a change in the coefficient of friction or a change in the surface roughness. The medical device may be, for example, a stent that has a portion that has a collapsed position that can be reverted to an expanded position by a trigger subsequent to insertion into the body.
  • Aspects may include one or more of the following features. The polymer body includes apertures. The polymer body has a ratio of aperture open area to wall area of about 0.5 or more or 0.7 or more. The endoprosthesis is expanded by simultaneously applying an expanding pressure and heat to the endoprosthesis. The polymer body is heated above the melt or glass transition temperature of polymer in the polymer body. The polymer body is elastomeric at the melt or glass transition temperature. The polymer is elastomeric at body temperature. The polymer is crystalline. The polymer is crosslinked. The polymer is radiation crosslinked. The melt or glass transition temperature is about 40 to 50° C. The melt or glass transition temperature has a transition range of about 5° C. or less. The polymer exhibits a plateau in the melt or glass transition range in a plot of storage modulus as a function of temperature. The polymer body includes a drug, radiopaque agent or magnetic heating agent. The polymer is a shape memory polymer, e.g. capable of remembering a smaller diameter configuration after expansion. The polymer is, for example, polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene, trans-isoprene, blends of polycaprolactone and n-butylacrylate and blends thereof. An expansion pressure of about 1 atm or more is applied. The endoprosthesis is delivered on a catheter. The endoprosthesis is delivered to a site of occlusion and the site is simultaneously dilated while expanding the endoprosthesis. The endoprosthesis is delivered to a site of lumen curvature and the endoprosthesis is expanded at the site. The endoprosthesis is delivered to a vascular lumen. The endoprosthesis is delivered adjacent (into) the prostate.
  • Aspects may include one or more of the following. A heat applicator applies heat to the stent during inflation of the balloon to expand the balloon to the expanded diameter. The polymer has a melt or glass transition temperature in the range of about 40 to 50° C. and a modulus at the melt or glass transition temperature sufficient to maintain the stent geometry or under application of pressure and/or heat. The polymer exhibits a plateau in the storage modulus in the range of melt or glass transition temperatures. The stent has a wall thickness of about 0.005 to 5 mm. The stent has an initial unexpanded inner diameter in the range of about 1 mm to 5 mm. The stent has an expanded inner diameter of about 1 mm to 20 mm. The stent may be expandable to about 100% or 400% or more of the initial inner diameter. An example of a coronary stent has an initial inner diameter of about 2 mm, and expanded inner diameter of about 4 mm and the wall thickness is about 0.005 mm to 0.1 mm. The stent can be in the form of a tube including aperture areas provided in the tube. The aperture are in the shape of elongate slots, e.g., when the stent is in the small diameter condition. The apertures have a dimension of about 1 mm or less in the small diameter condition. The apertures are in the shape of diamond-like openings, e.g. when the stent is in an expanded condition. The stent can be a wire-form formed of one or more filaments configured to generally define a tube.
  • Embodiments may include one or more of the following advantages. A balloon expandable stent made of a polymer can be provided that maintains the integrity of the stent geometry on expansion and heating. Maintenance of stent geometry is desirable since geometry affects, for example, the resistance to compression in the body and a predictable geometry is important to avoid irregular surfaces, kinking, or extensions of material into the body lumen which can interfere with the flow of body fluid. The polymers can be elastomers that have melting or glass transitions at temperatures safe for use in the body and exhibit elastomeric properties at both the melted or glass transition stage and the solid or crystalline phase. The stent body exhibits high resistance to inward compressive forces when the polymer is in the solid or crystalline phase. The elastomeric nature of the polymer in the melted or glass state enhances the ability to maintain geometry as the stent is expanded. For example, the polymer exhibits minimal flow during expansion and the thickness of the stent remains substantially constant. Elastomeric properties in the crystalline or solid state enhance the ability to conform to torturous curvature in narrow body lumens. High compression resistance allows the stent to maintain the body lumen open and resist occluding forces such as elastic recoil or the growth of thrombus from the vessel wall.
  • In another aspect, the invention features a polymeric stent having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen. The stent may be in the form, for example, of a coiled elongated element (for example, a strand, a tape or a flattened tube). The stent may be further heated to a second temperature that is higher than the first temperature and removed as a substantially uncoiled element. When the stent is in the form, for example, of a coiled elongated flattened tube, the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent. In some implementations, the medicament is compounded into the plastic or is a coating on the plastic. In some implementations, the portion is at an end of the stent and the portion is flared or stepped. In other implementations, the portion includes less than 50% of the length of the stent.
  • In another aspect, the invention features a polymeric stent in the form of a coiled elongated element, and having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen. When the stent is heated to a second temperature higher than the first temperature, the modulus of the element lowers sufficiently that the stent can be removed from the cavity or lumen as a substantially uncoiled element.
  • In yet another aspect, the invention features a method of treating a non-vascular cavity or lumen. The method includes inserting a polymeric stent having a portion in a collapsed position that can be reverted, by heating, to an expanded position. Following insertion, the stent is heated sufficiently to revert the portion in the collapsed position to the expanded position. The method may further include heating the stent having the portion in the expanded position sufficiently to soften the stent, and removing the softened stent from the cavity or lumen.
  • The stent may be, for example, a coiled elongated element (for example, a rod, a tape or flattened tube) and the heating of the stent prior to removal allows the stent to be removed in a substantially uncoiled state. This method provides ease of removal, for example, for removing prostatic stents that have been inserted on an interim basis. The heating may be performed, for example, on a delivery tube.
  • In some embodiments, the portion of the stent is at the end of the stent and may be flared when in the expanded position. In other embodiments, for example, the portion of the stent is not at an end of the stent.
  • In still another aspect, the invention features a polymeric stent including metal particles. A portion of the stent has a collapsed position that can be reverted to an expanded position by heating. The heating may be performed using inductive heating to revert the portion in the collapsed position to the expanded position.
  • In another aspect, the invention features a stent having an exterior surface that includes a plurality of protruding elements that extend outwardly from the surface. The protruding elements may be useful in helping the stent retain its position, for example, after insertion into the prostatic urethra.
  • In some embodiments, the protruding elements are formed of monofilament. The monofilament may include a plurality of constrictions along its length.
  • In some implementations, the stent is a polymeric stent and the stent has a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
  • The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, and advantages of the invention will be apparent from the description and drawings and from the claims.
  • DESCRIPTION OF DRAWINGS
  • FIGS. 1A and 1B are side views of a portion of a stent in a small diameter and expanded condition, respectively.
  • FIGS. 1C and 1D are cross-sectional views of a portion of a stent in a small diameter and expanded condition, respectively.
  • FIGS. 2A-2C illustrate delivery of a stent into a body lumen.
  • FIG. 3 is a plot of storage modulus as a function of temperature.
  • FIG. 3A is a plot of storage modulus as a function of temperature for samples of PCO with varying degrees of crosslinking.
  • FIG. 3B is a WAXS 20 plot for samples of PCO with varying degrees of crosslinking.
  • FIG. 4 illustrates manufacture and use of a stent.
  • FIG. 5 illustrates manufacture and use of a stent.
  • FIG. 6 is a perspective view of a stent with an end in an expanded position.
  • FIG. 7 is a side view of the stent shown in FIG. 6.
  • FIG. 8 is a side view of the stent shown in FIG. 6 with the end in a collapsed position.
  • FIG. 8A is a graph of heat flow as a function of temperature for several POSS polyurethanes.
  • FIG. 8B is a graph of storage modulus as a function of temperature for several POSS polyurethanes.
  • FIG. 9 is a perspective view of a wrapping fixture.
  • FIG. 10 is a cross-sectional view of a restricted prostatic urethra.
  • FIG. 11 is a cross-sectional view illustrating delivery of a stent to the prostatic urethra.
  • FIG. 12 is a cross-sectional view of a prostatic stent deployed in the urethra.
  • FIG. 13 is a side view of an alternative delivery system.
  • FIG. 13A-13B are side views of an alternative delivery system.
  • FIG. 14 is a cross-sectional view illustrating removal of a prostatic stent.
  • FIG. 15 is a graph of storage modulus (E′) VS temperature for PCO.
  • FIG. 16 is a graph of storage modulus (E′) VS temperature for PVAc/PVDF/PMMA blends.
  • FIG. 17 is a side view of an alternative stent with two ends portions in expanded positions.
  • FIG. 18 is the stent shown in FIG. 17 with ends in collapsed positions.
  • FIG. 19 is a side view of an alternative stent with three portions in expanded positions.
  • FIG. 20 is a side view of an alternative stent made with a flattened tube.
  • FIG. 21 is a cross-sectional view of the stent shown in FIG. 20, taken along 21-21.
  • FIG. 22 is a side view of an alternative stent made with a tape.
  • FIG. 23 is a perspective view of a stent with a plurality of protruding elements, the end of the stent is in an expanded position.
  • FIG. 24 is a side view of the stent shown in FIG. 23.
  • FIG. 25 is a side view of the stent shown in FIG. 23 with the end in a collapsed position.
  • FIG. 26 is a perspective view of an alternative stent with a plurality of protruding elements, the end of the stent in an expanded position.
  • FIG. 27 is a side view of the stent shown in FIG. 26.
  • FIG. 28 is a side view of the stent shown in FIG. 26 with an end in a collapsed position.
  • FIG. 29 DSC traces of PLA (top) quenched from T=180° C. or (bottom) annealed at T=110° C. for 1 hr.
  • FIG. 30 DSC traces for PLA/PVAc blends following annealing for 1 hour at T=110° C. A heating rate of 10° C./min was employed. PLA wt-% is indicated with each trace.
  • FIG. 31 Glass transition temperatures measured following quenching of the PLA/PVAc blends (solid points). Solid line is best fit to the Fox equation, 1/Tg=wa/Tg a+wb/Tg b.
  • FIG. 32 Tensile storage modulus versus temperature for a range of PLA/PVAc blends whose composition is indicated in the plot.
  • DETAILED DESCRIPTION
  • Referring to FIGS. 1A and 1B, a stent 10 includes a polymer body 12 generally defining a tube. The stent includes open areas 14. Referring particularly to FIG. 1A, in a small diameter condition, such as for delivery to a treatment site in the body, the open areas are relatively small and defined as slots cut through the wall of the stent. Referring particularly to FIG. 1B, in the expanded condition, the slots are widened to diamond-like shapes. The expansion mechanism of the stent utilizes a deformation (arrows) of the wall material about the open areas. As illustrated, the expansion results in a generally regular, symmetric, geometric pattern that resists and distributes inward compression of the stent by forces imposed by the lumen wall. Referring as well to FIGS. 1B and 1D, the wall thickness T of the stent does not substantially change upon expansion from the small diameter collapsed (TC) condition to the expanded condition (TE)(TC=TE). The polymer does not substantially flow or thin out on expansion, so that a reliable expansion geometry and wall thickness can be achieved. Other stent constructions are suitable. For example, filament-form stents in which filaments of polymer material are arranged to define a generally tubular structure can be used. Open areas are defined between the filaments. An example of a stent design including helical filaments is provided in Wallsten, U.S. Pat. No. 4,655,771. Suitable aperture wall designs are also described in Palmaz U.S. Pat. No. 4,733,665. Another suitable arrangement is exemplified by the Express stent, commercially available from Boston Scientific, Natick, Mass.
  • Referring to FIGS. 2A-2C, the delivery of a stent into the body is illustrated. The stent is delivered utilizing a catheter 24, which includes a catheter body 25 that carries a balloon 26 at its distal end. At the proximal end, the catheter includes an inflation apparatus 28 such as a syringe or pump apparatus which can be used to inject and circulate inflation fluid into the catheter, where it is directed by a lumen to the interior of the balloon so that the balloon can be inflated. In addition, the inflation apparatus can include a heating apparatus 30, to heat the inflation fluid directed to the balloon. The catheter is delivered into a vessel 20 to the site of an obstruction 31 typically utilizing a guidewire 32. The guidewire 32 extends through a lumen within the body 25 of the catheter.
  • Referring particularly to FIGS. 2A and 2B, the stent 10 is positioned over the inflatable balloon 26. Referring particularly to FIG. 2A for delivery into the body, the balloon is initially in a small diameter deflated condition. The stent is in a small diameter condition over the balloon. Referring particularly to FIG. 2B, when the treatment site is reached, the balloon is inflated by actuating the inflation apparatus 28. The inflation fluid is heated to heat the polymer body of the stent 10. By providing outward radial force while heating the stent, the stent is expanded into contact with the body lumen. The stent can be expanded simultaneously with the widening of the obstructed region. After expansion to the desired diameter, the temperature of the inflation fluid is typically decreased to reverse the softening of the stent body 10. Referring particularly to FIG. 2C, after the temperature of the stent has been reduced in this manner, it remains implanted in the vessel to resist vessel recoil and reduce restenosis after the balloon is deflated and the catheter is removed from the body.
  • Suitable polymers include those that maintain stent geometry under expansion conditions, allowing for intricate stent geometries such as apertured tubes having high open area to wall ratios. At temperatures above body temperature and under conditions of radial expanding pressure, the stent can be expanded without fracture or substantial irreversible stress relaxation or creep. Typically, the stent is heated to or above the melt or glass transition temperature during expansion. In this condition, the polymer is in a softened state. In this state, the polymer can be predictably deformed, typically about aperture regions during expansion. In addition, the soft condition permits proper apposition of the stent to the lumen wall without kinking and without damage due to excessive stiffness, which could straighten the lumen from its native curvature and lead to dissections or other trauma. After the stent is fully expanded and cooled, the polymer substantially sets in the proper apposition, e.g. about a native curvature. Excessive recoil of the stent to a linear configuration is avoided, reducing trauma about the vessel. At the same time, the polymer can have some elastomeric properties in the cooled, hardened state so that the stent can flex with natural vessel motion. After cooling, the stent exhibits sufficient resistance to inward radial force to reduce restenosis due to, e.g., lumen wall recoil. The polymer has sufficient strength so that the stent wall can be kept relatively thin while resisting restenosis from lumen wall forces.
  • Suitable polymers include elastomers that are crosslinked and/or crystalline. The crosslink and/or crystalline nature is sufficient to resist excessive creep or stress relaxation when the polymer is heated and expanded. The polymer can be crosslinked so that it exhibits the desired elastomeric properties but not crosslinked to the degree that it becomes excessively brittle. Too little crosslinking does not establish sufficient resistance to flow during heating and expansion to maintain stent geometry. In addition, crosslinking can be adjusted to adjust the melt or glass transition temperature and transition temperature range. A narrow melt transition range is desirable, e.g. 5° C. or 10° C. or less. Crosslinking can be achieved by application of radiation such as e-beam, UV, gamma, x-ray radiation or by heat-activated chemical crosslinking techniques. Chemical crosslinking agents include peroxides, such as benzoyl peroxide or dicumyl peroxide (DCP), and azo compounds, such as 2,2′-azobis(2,4-dimethyl valeronitrile) or 2,2′-azobis[N-(2-propenyl)-2-methylpropionamide]. Radiation techniques provide the advantage that the polymer typically does not have to be substantially heated to achieve crosslinking. An intricate aperture pattern provided in a stent precursor tube can be maintained and heat-induced flow of pre-crosslinked polymer can be avoided. For gamma radiation, an exposure of about 50-300, e.g. 250 kilograys typically provides sufficient crosslinking. Melting and crystallization temperatures are measured using a differential scanning calorimetry.
  • The polymer can have elastomeric properties in the melted or softened state. Elastomeric properties at melt or glass transition can be investigated by measuring the modulus of elasticity or storage modulus as a function of temperature and determining the elastomeric nature of the material in the desired expansion temperature range. Referring to FIG. 3, a plot of storage modulus as a function of temperature is provided. Storage modulus decreases as the material is heated. At the melt or glass transition, a plateau “P” is typically consistent with an elastomeric nature. At much higher temperatures, the modulus drops off more quickly, indicating a material which could flow under pressure. To determine storage modulus, a dynamic mechanical analyzer (Perkin Elmer) can be used. Dynamic mechanical analysis was carried out in tensile mode at an operating frequency of 1 Hz, a static force of 10 mN, and oscillation amplitude of 5 μm (approximately 0.1% strain) and an automatic tension setting of 125%. Temperature ramps were conducted at 4° C./minute over the range −100° C. to 100° C.
  • Chemically crosslinking PCO also has a direct impact on the thermomechanical properties, e.g. modulus versus temperature, through the establishment of a permanent network and indirectly through morphological transitions. Revealing such effects by the use of DMA, FIG. 3A shows plots of the tensile storage modulus (E′) versus temperature for cured PCOs prepared with varying amounts of DCP. All of the PCO samples are characterized by a solid-like storage modulus (about 1.7 GPa) for temperatures below T=−70° C. with this modulus value being invariant to the crosslinking density. For temperatures above T=−70° C., the apparent onset of Tg in the PCO samples, E′ begins to decrease gradually to a level that is dependent on crosslink density, but spanning 0.05 to 0.5 GPa. The decrease in the modulus with crosslinking in this temperature region can be understood from the results of the DSC and wide angle x-ray scattering (WAXS), FIG. 3B, that showed crosslinking reduces the degree of crystallinity of PCO. It is to be expected that the crystalline phase will function as both the fixing mechanism for shape memory and a means of controlling room temperature modulus over a full order of magnitude. For temperatures nearing T=62° C., close to the melting temperature measured by DSC, the storage modulus of neat PCO begins to decrease sharply to about 2 MPa at the completion of melting at 71° C. As found with DSC, this transition temperature is observed mechanically to decrease with increasing degree of crosslinking. For temperatures greater than Tm, the modulus of neat PCO, trace (i), continues to decrease to a point where the material flows like a viscous liquid, not showing a persistent rubbery plateau (FIG. 3). This feature hampers the applicability of neat PCO for use as a shape memory polymer due to an inability to be deformed as a rubber above Tm without rapid stress relaxation. On the other hand, cured PCO, which contains just 1% peroxide, represented by trace (ii), will allow significant shape memory effects owing to its persistent rubbery plateau above 72° C. As the amount of peroxide increases, the rubbery plateau modulus increases, allowing for enhanced mechanical energy storage, but the transition temperature and the steepness of the transition decrease. In the case of PCO with 10% DCP, shown as trace (v) in FIG. 3A, the thermomechanical response that is observed is inconducive to shape memory effects as the fixing (crystallization) temperature is lower than room temperature so that shape fixing would require subambient cooling and the temporary shape would be expected to drift via partial melting. In addition, the melting transition is too broad for dramatic strain recovery to be expected.
  • Suitable polymers include elastomers that are typically crosslinked and/or crystalline and exhibit melt or glass transitions at temperatures that are above body temperature and safe for use in the body, e.g. at about 40 to 50° C. Suitable polymers can have an elastic modulus of about 60,000 or 70,000 psi or more at 25° C. (ASTM D638M). Such polymers may have a variety of room temperature moduli, from rigid glassy materials having storage moduli of several GPa to compliant rubbers with moduli as low as tens of MPa. Moreover, the moduli may tuned over the range 0.5<E<10 MPa, as dictated by the end application. Suitable polymers include polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene (particularly, crosslinked polyethylene), trans-isoprene, block copolymers of polyethylene terephthalate (PET) and blends of polycaprolactone and n-butylacrylate. A suitable PVAc/PVDF tube is formed by compounding 60-80 parts (by weight) PVAc (B-100, mw 500,000, ChemPoint, Cleveland, Ohio) with 40 to 20 parts PVDF (Grade 1010, Solvay Fluoropolymers, Houston, Tex.). The PVAc/PVDF is a crystalline material that can be utilized with or without crosslinking.
  • The polymer body can be made of mixtures of polymers or multiple polymer layers. The polymer forming the stent body can be compounded to include a drug, which elutes from the polymer, or radiopaque material. The structural polymer body can be coated with other polymers to carry drug or control drug delivery from the structural polymer. The polymer body can also exhibit shape memory properties. This feature of the polymer can be used in combination with the expansion properties discussed above. For example, the polymer can be configured to remember an enlarged or reduced diameter configuration. For example, the stent can be delivered into the body, and expanded by a combination of heat and radial pressure as described above. After a time, the stent can be retrieved by reheating the stent. In this case, the heating causes the stent to revert its small diameter condition. The remembered stent diameter is less than the vessel diameter and the stent can be more easily removed from the vessel. Such an application might be useful, for example, for a stent delivered into the prostate where removal and replacement is desirable.
  • Refer to FIGS. 4 and 5, manufacture and use of the stent is illustrated. Referring particularly to FIG. 4, in a first step, a polymer tube 40 is constructed by extrusion or molding a suitable polymer to an initial diameter di which in the same or greater than the target lumen diameter. (For stents made of polymer strands, the strands can be formed by extrusion, followed by arranging the strands into a tube, e.g. by weaving or knitting.) The tube wall is then cut to provide a pattern of open areas in a desirable geometric pattern, e.g. by laser cutting. The polymer can be recrystallized or crosslinked, if necessary. Next, the tube is heated typically near or above the melt or glass transition and mechanically deformed to a small diameter, suitable for delivery. The tube is cooled, e.g. to room temperature. The tube is assembled onto a catheter, delivered into the body, and expanded by application of heat, to the melt or glass transition, while inflating the balloon as discussed above. (If the polymer has shape memory properties, the polymer tends to expand upon heating to a larger, remembered diameter.
  • Referring particularly to FIG. 5, a polymer tube 50 is constructed to an initial diameter di, smaller than the vessel diameter. The tube wall is cut to provide an open area in a desirable pattern so that when the stent is expanded, a compression-resistant geometry will result. The polymer is recrystallized or crosslinked, if necessary. The tube is assembled in a catheter, delivered into the body, and expanded by heating to the melt or glass transition temperature while inflating the balloon to provide an outward radial expansion, as discussed above. If the polymer has shape memory properties, the stent can be subsequently re-heated so it reverts back to its remembered small diameter configuration and removed from the body.
  • In particular embodiments, the stent can have an expanded inner diameter of about 2 to about 20 mm. The initial inner diameter can be in the range of about 1 to about 3 mm. The wall thickness is in the range of about 0.005 mm to 20 mm. The wall thickness variation between delivery and expanded states is within about 10%, 5% or 1% or less. The ratio of the open area to the wall area in the expanded state is about 0.5 to 0.7 or more. (The tube wall area is the area of the tube defined by polymer. The open area is the open area defined by the apertures.) A particular stent for coronary use has an initial diameter of about 2 mm, an expanded diameter of about 4 mm, and a wall thickness of about 0.005 mm to 0.1 mm. The stent can be used for various applications including coronary, neuro, carotid, peripheral vasculature, ureteral, and prostate lumens. The stent is particularly useful where the lumen path is highly curved or irregular.
  • The catheter can be, e.g. an angioplasty balloon catheter with a relatively non-distendable inflating balloon suitable for expansion of occluded regions of a vascular lumen. The balloon may include a polymer such as PET, which has a burst pressure of about 1.5 to 5 atm or more. The stent can be heated by heating the balloon inflation fluid. The balloon inflation fluid can be heated by e.g., heating the fluid delivery device outside the body using e.g., resistive heating tape. Alternatively, the catheter can carry a heating device. For example, a resistive heater or RF heater can be provided in the interior of the balloon. A heated balloon catheter is described in Abele et al. U.S. Pat. No. 5,496,311 and U.S. Pat. No. 4,955,377. Vessel heating as described in the '311 can be used in combination with stent delivery as discussed herein. Alternatively, the stent can be heated directly. For example, the polymer can be compounded to include a material, such as magnetic particles, which are susceptible to heating by magnetic effects, such as hysteresis effects. A magnetic field can be imposed on the stent body by a source on a catheter or outside the body. Particles are available as the Smartbond System from Triton Systems, Inc., Chelmsford, Mass. Heating by magnetic effects is discussed in U.S. Pat. No. 6,056,844. The stent can also be heated during delivery without applying expansion force to soften the stent, improving its flexibility and thus improving delivery to a treatment site through a tortuous vessel path.
  • EXAMPLE
  • A polycyclooctene polymer (Vistenemer 8012 pellets, mw 90,000, Degussa, NJ) is melt processed in an extruder to produce a tube having dimensions of about 0.118 inch O.D. and 0.070 inch I.D. (wall thickness about 0.024 inch). The tube is cut to a length of about 4 cm. The tube is subject to UV excimer laser ablation cutting to provide an aperture pattern of rectangular slots having a width of about 0.2 mm and a length of about 8 mm. Beam energy and pulse rate are selected to avoid substantial heating or melting of the polymer. The polymer can be compounded with about 10% TiO2 (T8141, Dupont) to enhance absorption of laser radiation. A suitable pattern is consistent with the Express stent (commercially available from Boston Scientific, Natick, Mass.). (Alternatively, a pattern as described in Palmaz U.S. Pat. No. 4,733,665 can be used.) The tube is heated to a temperature below its melt point, e.g., to about 39 to 40° C. in a water bath and expanded by balloon catheter to a diameter of about 5 mm and positioned on a mandrel (PTFE tube) to maintain the expanded shape and diameter. The tube is then cooled to room temperature. The polymer is then crosslinked by e-beam radiation at 250 K Grays (Steris Isomedics Services, Northborough, Mass.). Crosslinking fixes the stent in the condition. (The crosslinked PCO has an elastic (Youngs) modulus of about 74945 psi at about 25° C. (ASTM D638M)). The stent is heated to the polymer melt temperature, about 45° C. and collapsed over a deflated balloon (diameter of about 2 mm) with a 4 mm inflated maximum diameter and 2 cm length. (A suitable balloon catheter is a 75 cm Meditech UltraThin Catheter, available from Boston Scientific, Natick, Mass.). The balloon and stent are immersed in a water bath of about 42 to 45° C. and water the same temperature is used to inflate the balloon. The stent is expanded to about 4 mm diameter (ID) at an inflation pressure of about 1 to 1.5 atm (measured at the delivery syringe). After expansion, the heating is discontinued and the balloon and inflation fluid allowed to cool to body temperature (while the balloon remains inflated). Alternatively, a cooled contrast fluid can be circulated to the balloon. The stent exhibits no visible reduction in wall thickness or irregular flow of polymer into the stent open areas. In addition, in the heated, expanded state, the stent can be bent around a mandrel of about 0.75 cm radius without kinking. After the stent is cooled, it maintains the curved form.
  • Referring to FIGS. 6-8, stent 100 includes a coiled rod 120 composed of a polymer. Stent 100 includes an elongated portion 140 having a general diameter d1 and an end portion 160 having a maximum diameter d2. General diameter dl, for example, may be between about 3 mm and about 25 mm, more preferably between about 6 mm and about 14 mm, and maximum diameter d2, for example, may be between about 7 mm and about 30 mm, more preferably between about 10 mm and about 17 mm. When stent 100 is designed, for example, for insertion into a urethra, the stent may have an overall length, for example, of between about 3 mm and about 15 mm, preferably between about 6 mm and 10 mm, and end portion 160 may have a length, for example, of from about 3 mm to about 15 mm, preferably from about 5 mm to about 10 mm. End portion 160 is in a flared position. Referring to FIG. 8, stent 100 is shown with end portion 160 in a collapsed position that can be reverted with heating to the expanded position shown in FIGS. 6 and 7.
  • Generally, the portion of the stent in the collapsed position that can be reverted to the expanded position is, for example, greater than 5%, 10%, or even 25% of the overall length L of the stent, and less than 80% or 65% of the overall length L of the stent. For example, the of the overall length L of the stent may be between 10% and 65% of the overall length L of the stent.
  • The polymers preferably are cross-linked and/or crystalline elastomers that have melt or glass transition temperatures that are above body temperature, for example, greater than 45° C. or 55° C. The degree of cross-linking can be used to adjust, for example, the melt or glass transition temperature, and range, of the polymer. The polymer preferably has a relatively narrow, for example, less that 5° C. or 10° C., melt or glass transition temperature range.
  • The polymer preferably has elastomer properties in its melted or softened state. Preferred polymers have an elastic modulus, for example, of about 60,000 psi or 70,000 psi or more at 25° C. (ASTM D638).
  • Examples of polymers include polynorbornene and copolymers of polynorbornene, blends of polynorbornene with KRATON® (thermoplastic elastomer) and polyethylene, styrenic block copolymer elastomers (e.g., styrene-butadiene), polymethylmethacrylate (PMMA), polyethylene, polyurethane, polyisoprene, polycaprolactone and copolymers of polycaprolactone, polylactic acid (PLA) and copolymers of polylactic acid, polyglycolic acid (PGA) and copolymers of polyglycolic acid, copolymers of PLA and PGA, polyenes, nylons, polycyclooctene (PCO), polyvinyl acetate (PVAc), polyvinylidene fluoride (PVDF), blends of polyvinyl acetate/polyvinylidine fluoride (PVAc/PVDF), blends of polymethylmethacrylate/polyvinyl acetate/polyvinylidine fluoride (PVAc/PVDF/PMMA) and polyvinylchloride (PVC).
  • In some embodiments, the polymers above are also useful for the stents of FIGS. 1, 4 and 5.
  • Particular polyurethanes are made by reacting (A) a polyol, (B) a chain extender dihydroxyl-terminated POSS and (C) a diisocyanate, where POSS stands for a polyhedral oligomeric silsesquioxane diol. The polyol (A) can be polyethylene glycol (PEG), polycaprolactone (PCL), polycyclooctene (PCO), trans-1,4 butadiene, transisoprene, polynorbornene diol and polymethacrylate copolymer, the chain extender(B) can be TMP cyclopentyldiol-POSS, TMP cyclohexyldiol-POSS, TMP isobutyldiol-POSS, transcyclohexanediolcyclohexane-POSS, or transcyclohexanediolisobutyl-POSS and the diisocyanate (C) can be selected from a large number of diisocyanates and is preferably 4,4′ diphenyl methylene diisocyanate (MDI). Other diisocyanates (C) that are suitable for use in the synthesis of hybrid polyurethane SMPs include: toluene-2,4-diisocyanate (TDI), toluene-2,6diisocyanate, hexamethylene-1,6-diisocyanate (HDI), 4,4′diphenylmethane diisocyanate (MDI), isophorone diisocyanate (IPDI), and hydrogenate 4,4′-diphenylmethane diisocyanate (H12MDI).
  • The particular polyurethanes described directly above may be prepared the non-limiting schemes illustrated below. A graph of heat flow as a function of temperature for several POSS polyurethanes is shown in FIG. 8A and a graph of storage modulus as a function of temperature for several POSS polyurethanes is shown in FIG. 8B.
    Figure US20050010275A1-20050113-C00001
  • This scheme shows an example of synthesis of TPU using polyethylene glycol as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate in toluene.
    Figure US20050010275A1-20050113-C00002
  • This scheme shows an example of synthesis of TPU using polycaprolactone diol as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate.
    Figure US20050010275A1-20050113-C00003
  • This scheme shows an example of synthesis of TPU using polyocyclooctene as polyol, TMP Isobutyldiol-POSS as chain extender to react with 4,4′ diphenyl methylene diisocyanate.
  • Any of the polymers mentioned above may be filled with, for example, nanoparticles of clay and silica to, for example, increase the modulus of the plastic. Dispersing agents and/or compatibilizing agents may be used, for example, to improve the blending of polymers and the blending of polymers with fillers. Dispersing agents and/or compatibilizing agents include, for example, ACRAWAX® (ethylene bis-stearamide), polyurethanes and ELVALOY® (acrylic-functionalized polyethylene). The polymers can be cross-linked by application of radiation such as e-beam, UV, gamma, x-ray radiation or by heat-activated chemical crosslinking techniques. Radiation techniques provide the advantage that the polymer typically does not have to be substantially heated to achieve crosslinking. For e-beam radiation, an exposure of about 200-300, e.g. 250 kilograys, typically provides sufficient crosslinking.
  • Referring to FIG. 9, wrapping fixture 200 can be used for making coiled stent 100. Wrapping fixture 200 includes a base 220 for support, a mandrel 240 with a flared end 260, slits 280 for fixing the plastic rod 120, an aperture 290 for fixing the plastic rod 120 on the non-flared end and a fixing screw 299 for releasably fixing mandrel 240 to wrapping fixture 200.
  • Stent 100 is manufactured from plastic rod 120 made by a variety of methods known in the art (e.g., extrusion, coextrusion, injection molding, casting, compression molding). If casting is used, the polymers may have tunable critical temperatures and rubber modulus have been synthesized using a thermosetting random copolymer formed from two vinyl monomers that yield controlled Tg and casting-type processing. Such copolymers were crosslinked with a difunctional vinyl monomer (crosslinker), the concentration of crosslinker controlling the rubber modulus and thus the work potential during recovery. Rod 120 may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more. Plastic rod 120 and wrapping fixture 200 are heated to the softening temperature of the polymer, making the plastic rod 120 malleable. The rod 120 is inserted into aperture 290 that is machined through mandrel 240 to fix the rod at the starting end. The rod 120 is tightly wrapped around mandrel 240, including flared end 260. To fix plastic rod 120 in place, plastic rod 120 is pushed into slits 280. The overall length of the stent 100 may be, for example, about 2 mm to about 150 mm or more. The overall length required depends upon the application. The plastic rod 120, now fixed in place on the mandrel 240, is heated to above the softening point of the material and maintained at that temperature long enough to anneal the rod and fix the shape. Typically, the time required to fix the shape is from about 0.25 hr to 10 hr or more. After cooling, stent 100 is removed from mandrel 240. Before packaging, the flared end of the coil is tapered down and collapsed so that the diameter along the entire length of the stent is approximately d1. Collapsing the flared end 160 of stent 100 allows for ease of insertion, for example, into a restricted prostatic urethra.
  • Example 1
  • A 56:24:20 mixture of PVAc/PVDF/PMMA is dry bended and loaded into the hopper of an extruder. The PVAc is grade B-100, the PVDF is Solvay SOLEF® 1010 and the PMMA is Atofina PLEXIGLAS® V045. The mixture is melt processed to produce 1.27 mm (0.05 inch) monofilament. The rod is made into a coil by winding it around wrapping fixture 200. The fixture and the rod are immersed into a 50° C. water bath. At this temperature, the rod becomes malleable enough to wind easily around the mandrel and secured in place to prohibit the uncoiling of the helical shape. The mandrel is removed from the fixture with the stent locked in place and placed into an oven at 110° C. for one hour to anneal the stent. This annealing process locks the permanent shape of the coil. The mandrel and coil are cooled to room temperature, and the stent is removed from the mandrel. The stent had on overall length of approximately 73 mm and a flared end portion length of approximately 7 mm. The diameter d1 of the body is approximately 6 mm and the maximum diameter d2 of the flare on the open end is approximately 11 mm. Before packaging, the flared end of the coil is tapered down with brief heating to 50° C. and manipulation, followed by cooling, so that the diameter is approximately 6 mm along the entire length of the stent.
  • Example 2
  • A 70:30 mixture of PVAc/PVDF is dry bended and loaded into the hopper of an extruder. The mixture is melt processed to produce 1.27 mm (0.05 inch) monofilament. The rod is made into a coil by winding it around wrapping fixture 200. The fixture and the rod are immersed into a 50° C. water bath. At this temperature, the rod becomes malleable enough to wind easily around the mandrel and secured in place to prohibit the uncoiling of the helical shape. The mandrel is removed from the fixture with the stent locked in place and placed into an oven at 110° C. for one hour to anneal the stent. This annealing process locks the permanent shape of the coil. The mandrel and coil are cooled to room temperature, and the stent is removed from the mandrel. The stent had on overall length of approximately 73 mm and a flared end portion length of approximately 7 mm. The diameter d1 of the body is approximately 6 mm and the maximum diameter d2 of the flare on the open end is approximately 11 mm. Before packaging, the flared end of the coil is tapered down with brief heating to 50° C. and manipulation, followed by cooling, so that the diameter is approximately 6 mm along the entire length of the stent.
  • Referring to FIG. 10-12, stent 100 may be, for example, inserted into restricted urethra 300 on delivery tube 320. During insertion, end portion 160 is in a collapsed position. After insertion, warm water (e.g., 45° C.-55° C.) is flushed through delivery tube 320 that is in thermal contact with stent 100. Heating reverts the collapsed end 160 to a flared, expanded position (FIG. 12). The flared, expanded position allows stent 100 to remain fixed in position, for example, in the prostatic urethra.
  • Referring to FIG. 13 for a little more detail, delivery tube 320 is a long cylindrical tube into which a ureteral scope 380 is inserted. Delivery tube 320 has a distal end 330 over which stent 100 is placed. Delivery 320 is fitted with a side port 350 including a stopcock 370 through which saline can be flushed for irrigation. Delivery tube 320 with stent 100 in place is delivered into, for example, the prostatic urethra with the aid of a ureteral scope. Once stent 100 is in place, hot saline is flushed through port 350 to revert the collapsed end 160 to a flared, expanded position (FIG. 12). The flared, expanded end allows stent 100 to remain fixed in position, for example, in or adjacent the prostatic urethra or external sphincter between the prostate and the bladder to prevent migration. The direction of the flare can, of course, be oriented in other directions. The scope and delivery tube 320 are withdrawn, leaving stent 100 in place.
  • Referring to FIGS. 13-13A, an alternative delivery system is illustrated that includes a tube 320 with a screw on tip 331 onto which a stent 100 is placed after collapsing the end portion 160. The assembly is inserted into, for example, the prostatic urethra.
  • Other delivery methods are within the claims. Stent 100 may be, for example, inserted into restricted urethra 300 on balloon catheter (not shown). During insertion, end portion 160 is in a collapsed position. After insertion, warn water is flushed through the guide wire lumen of the balloon catheter to flood the area and to heat the stent. Heating of the stent by the water reverts the collapsed end 160 to a flared, expanded position The flared, expanded position allows stent 100 to remain fixed in position, for example, in the prostatic urethra. If there is an obstruction in the lumen into which the stent is deployed the stricture can be dilated using the balloon to help the stent open fully and maintain a uniform diameter inside the vessel.
  • Referring to FIG. 14, coiled stent 100 with an end 160 in the expanded position can be removed with the aid of a catheter equipped with a grasping device 360 and a ureteral scope 380 for visualizing stent 100 in, for example, the prostatic urethra. Once end 400 of stent 100 has been visualized with ureteral scope 380, the stent is grasped with grasping device 360. Next, ureteral scope 380 is removed from the catheter and is replaced with a heating device (not shown), e.g. a catheter. Heating stent 100 above the softening point of the polymer, e.g., from about 45° C. to about 55° C. for polycyclooctene (PCO), and pulling the end 400 of stent 100 through the orifice 420 allows the stent to be removed in a substantially uncoiled state.
  • Although FIG. 11 shows heating of stent 100 with a warm liquid on a delivery tube, other heating methods are possible. For example, heating may be accomplished with the use of IR, RF or inductive heating.
  • Although insertion into a prostatic urethra has been used as an example, insertion of stent 10 into other body lumens or cavities is possible. For example, other body lumens or cavities include the biliary duct, cystic duct, a ureter, a bulbar urethra or a hepatic duct.
  • Referring to FIG. 15, the modulus of polycyclooctene (PCO) that can, for example, be the polymer of stent 100 is shown as a function of temperature. Below approximately −65° C. (Tg, region A), PCO exists a rigid, glassy polymer. Above Tg, but below Tm, PCO exists as a flexible elastomer (region B). Above Tm, PCO exists as a relatively low modulus elastomer. Above Tm, for example, stent 100 composed of PCO can be removed from a lumen or cavity of the body, the prostatic urethra, for example, in a substantially uncoiled state.
  • Referring to FIG. 16, the modulus of a ternary blend of PVAc/PVDF/PMMA that can, for example, be the polymer of stent 100 is shown as a function of temperature. Adding PMMA offers the advantage, for example, of increasing the modulus of the blend.
  • Referring once again to FIG. 15 and to FIGS. 6-8, heating stent 100 in the expanded position briefly above Tm (region C) and then cooling rapidly below Tm (e.g., region B) “freezes” stress into stent 100. Stent 100 reverts from its collapsed position to its expanded position upon re-heating above Tm (region C) because the modulus of the material lowers sufficiently to release the residual stress that was “frozen” into stent 100 during the rapid cooling.
  • FIGS. 17-28 show other examples of stents.
  • Referring to FIGS. 17 and 18, coiled stent 500 has two end portions 520 and 540 in expanded positions. End portions 520 and 540 can be collapsed (FIG. 18) for ease of insertion into a body cavity or lumen, and reverted with heat to expanded positions.
  • Referring to FIG. 19, coiled stent 600 has two end portions 620 and 660 and a central portion 640 in expanded positions. All three portions may be collapsed (not shown), and then reverted to expanded positions.
  • Referring to FIGS. 20 and 21, coiled stent 700 made from a flattened tube 710 has an end portion 720 in an expanded position. The flattened tube can, for example, add strength to the stent. The tube can have a major diameter, for example, of between about 1.0 mm to about 3.0 mm, more preferably between about 1.5 mm to about 2.25 mm, and major inner diameter, for example, of between about 0.5 mm to about 2.5 mm, more preferably between about 1.25 mm and about 1.75 mm. End portion 720 may be collapsed (not shown) and then reverted to an expanded position. Referring to FIG. 21, flattened tube 710 has an interior 740 that may be filled with, for example, a medicament. The medicament, for example, may be triclosan or salicylic acid. Release of medicament from flattened tube 710, for example, may reduce the risk of infection. Interior 740 may also be filled with, for example, paclitaxel or mitoxantrone. Release of the these medicaments from interior 740 may be, for example, useful for treating prostate cancer and reducing prostatic hyperplasia.
  • Referring to FIG. 22, coiled stent 800 made from tape 810 has an end portion 820 that may be collapsed and then reverted to an expanded position. Tape 810, for example, may have a thickness from about 0.5 mm to about 2.0 mm, more preferably from about 0.75 mm to about 1.25 mm, and a width, for example, of from bout 1.0 mm to about 3.0 mm, more preferably from about 1.75 mm to about 3.00 mm. In this particular embodiment, an aperture 840 is provided so that a trailing string (not shown) can be included for ease of removal with the grasping device shown in FIG. 14.
  • Referring to FIGS. 23-25, coiled stent 900 is made from plastic rod and has an end portion 920 that may be collapsed and then reverted to an expanded position. Stent 900 includes a plurality of protruding elements 940 that are integral with and extend outwardly from the plastic rod from which the stent is made. Referring now to FIGS. 26-28, coiled stent 1000 is made from plastic rod, for example, oriented monofilament, and has an end portion 1020 that may be collapsed and then reverted to an expanded position. Stent 1000 includes a plurality of protruding elements 1060 that extend outwardly from the plastic rod from which the stent is made. The friction provided by protruding elements 940,1060 can help to hold stent 900,1000 in place within, for example, the prostatic urethra.
  • Protruding elements 940 are made, for example, by cutting into the plastic rod with, for example, a sharp edged instrument, for example, a knife, so as penetrate a depth into the plastic rod. The depth of penetration P is adjusted to provide acceptable frictional properties, while minimizing the impact on the mechanical properties of the plastic rod. In some implementations, the maximum depth of penetration into the plastic rod, measured inwardly from the outer surface of the plastic rod is, for example, from about 1 to about 50% of the average thickness of the plastic rod. If the depth penetration is too large, the mechanical properties of the plastic rod may be reduced and if the depth of penetration is too low, the resulting protruding elements may be too small to provide the appropriate frictional properties when expanded in a body cavity or lumen, for example, the prostatic urethra. Other cutting means are possible, for example, water knife and laser cutting means, to reduce the impact of the cutting on the mechanical properties of the plastic rod. The shape of the plastic rod from which the stent is made may be of other forms than that shown above. For example, it may be in the form of, for example, a coiled elongated flattened tube and the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent.
  • In some implementations, stent 900 is manufactured from plastic rod made by a variety of methods known in the art (e.g., extrusion and coextrusion). The plastic rod may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more. In a preferred method, the protruding elements are put onto the plastic rod before wrapping the mandrel shown and discussed above. After wrapping the mandrel, the plastic rod and wrapping fixture 200 are heated to the softening temperature of the polymer, making the plastic rod malleable. The protrusions are annealed in the “up” position, that is, with the protruding elements extending outwardly by “prying up” the protruding elements that results from cutting. Prying up the protruding elements may be achieved by, for example, running a surface across the protruding elements in a direction opposite the cut direction. Annealing is continued to fix the shape. After cooling, the stent is removed from mandrel. Before packaging, the flared end of the coil is tapered down along with protruding elements and collapsed so that the diameter along the entire length of the stent is approximately d1. Collapsing the flared end and protruding elements allows for ease of insertion, for example, into a restricted prostatic urethra. In some implementations, the flared end and the main body are collapsed to have a diameter less than d1. Upon heating, the end portion reverts to its expanded position and the protruding elements revert to their up positions. If a medicament is placed in the cavities 960 from which the protruding elements 940 are carved, it may be released upon expansion of the stent.
  • Stent 1000 with protruding elements 1060 is made by, for example, wrapping a thicker plastic rod with a thinner plastic rod, for example, a monofilament, that includes a plurality of constrictions, for example, knots along its length. The elevation E above an outer surface of the thicker plastic rod is adjusted to provide acceptable frictional properties. In some implementations, the maximum elevation above an outer surface of the thicker plastic rod is, for example, from about 1 to about 50% of the average thickness of thicker plastic rod. If the elevation E is too large, insertion of stent 1000 into, for example, a prostatic urethra may become difficult and if the maximum elevation above the protruding elements is too small, the protruding elements may not provide the appropriate frictional properties when expanded in a body cavity or lumen, for example, the prostatic urethra. The shape of the rods from which the stent is made may be of other forms than that shown above. For example, it may be in the form of, for example, a coiled elongated flattened tube and the flattened tube may include a central opening that includes a medicament that can be released by the inserted stent.
  • In some implementations, stent 1000 is manufactured from plastic rod made by a variety of methods known in the art (e.g., extrusion and coextrusion). The thicker plastic rod may have a diameter, for example, of about 0.25 mm to about 2.5 mm or more. The thinner plastic rod from which the protruding elements are fashioned may have a diameter of, for example, from about 0.2 mm to about 20 mm. In a preferred method, the constrictions, for example, knots, are placed on the thinner plastic rod and the thinner plastic rod is wrapped around the outer surface of the thicker plastic rod. The ends of the thinner plastic rod are heat staked to hold the thinner plastic rod onto the outer surface of the thicker plastic rod. Now, the assembly of the thinner and thicker plastic rod is wrapped around the mandrel shown and discussed above. After wrapping the mandrel, the plastic rods and wrapping fixture 200 are heated to the softening temperature of the polymer of the thicker plastic rod, making the plastic rod malleable. Annealing is continued to fix the shape. After cooling, the stent is removed from mandrel. Before packaging, the flared end of the coil is tapered down so that the diameter along the entire length of the stent is approximately d1. Collapsing the flared end and protruding elements allows for ease of insertion, for example, into a restricted prostatic urethra. In some implementations, the thinner plastic rod may contain a medicament that is released upon expansion, for example, in the prostatic urethra. In other implementations, the thinner plastic rod is made of a degradable material and the degradable material is filled with a medicament.
  • In some embodiments, the entire stent, for example, the stents of FIGS. 4, 5, 20, 23 and 26, may have an expanded position.
  • Other Embodiments
  • In some of the embodiments of any of the above stents, only a portion or portions of the stent (e.g., the portion(s) having an expanded position) may be composed of the polymer. The remainder of the stent may be, for example, composed of a non-polymeric material (e.g., a metal or metal alloy, e.g., Ni/Ti alloy). Moreover, the stent may be composed of multiple layers of materials, for example, by co-extruding the layers when making an elongated element. The stent may be a multiple segment stent.
  • The polymer in any of the above stents may be a blend of polymers, for example, miscible blends of a semicrystalline polymers with an amorphous polymer. For those blends that are miscible at the molecular level, a single glass transition results, without broadening. Additionally, in such miscible blends the equilibrium crystallinity (which controls the plateau modulus between Tg and Tm where shape fixing is performed) also changes dramatically and systematically with blend composition; i.e., relative levels of each component.
  • Polymers blends with a relatively high modulus in the fixed state at room temperature, having a tunable and sharp transition, the permanent shape of which can be remolded repeatedly above certain melting temperatures are prepared by the blending of crystalline polymers (C′) with amorphous polymers (A′), such that they are a single miscible phase in the molten state (allowing processing to stress-free native states) but crystalline to a limited and tailored extent and which further vitrify on cooling to room temperature. The recovery of the polymer blend may be fast, for example, within seconds. Examples for (C′) include poly(vinylidene fluoride) (PVDF) (Tg=−35° C., Tm=175° C.), polylactide (PLA) (Tg=56° C., Tm=165° C.), poly(hydroxy butyrate), poly(ethylene glycol) (PEG), polyethylene, polyethylene-co-vinyl acetate, poly(vinyl chloride) (PVC), and poly(vinylidene chloride) (PVDC) and copolymers of poly vinylidene chloride (PVDC)/poly vinyl chloride (PVC). Examples for (A′) include poly(vinyl acetate) (PVAc) (Tg=35° C.), poly methyl acrylate (PMA), poly ethyl acrylate (PEA), atactic poly methyl methacrylate (aPMMA), isotactic poly methyl methacrylate (iPMMA), syndiotactic poly methyl methacrylate (sPMMA), and other poly alkyl methacrylates.
  • In some preferred embodiments formed from two miscible polymer blends, the blend is prepared by mixing amorphous poly(vinyl acetate) (PVAc) (Tg=35° C.) with semicrystalline polylactide (PLA) (Tg=56° C., Tm=165° C.) or poly(vinylidene fluoride) (PVDF). The polymers show complete miscibility at all blending ratios with a single glass transition temperature, while crystallization (exclusive of PVAc) is partially maintained. The Tg's of the blends are employed as the critical temperature for triggering the shape recovery while the crystalline phases serve as physical crosslinking sites for elastic deformation above Tg, but below Tm.
  • The preferred blends are formed from poly vinyl acetate(PVAC) and poly(lactic acid) (PLA) or poly(vinylidene fluoride) (PVDF). However, examples of other suitable blends include the pair PVDF/PMMA and ternary blends of PVDF/PMMA/PVAc. The PMMA and the combination of PMMA/PVAc serve the same role as PVAc in the blends as have been previously described. An advantage of adding PMMA is that the critical temperature can be increased arbitrarily to about 80° C. and the room temperature modulus can also be increased. The PVDF may be substituted by poly(vinylidene chloride) (PVDC), by copolymers of poly(vinylidene chloride/ply(vinyl chloride), or by any “C” polymer vide supra.
  • It has further been found that blending poly(vinyl chloride) with poly(butyl acrylate) or poly (butyl methacrylate) (PVC/PBA) has certain advantages. In the PVDF/PVAc case, PVAc simultaneously lowers the crystallinity of PVDF while increasing Tg. PVC may serve the same role as PVDF, but it already has a low degree of crystallinity, but a relatively high Tg (˜80° C.). Thus in this embodiment, the second component (PBA) serves only the role of decreasing Tg. This can also be achieved with smal molecule plasticizers, most notably dioctylphthalate (DOP), but is preferred to use a biocompatible polymeric plasticizer for intended implantable applications. The range of PBA compositions is 10-40%, with 20% being the most advantageous, yielding a Tg˜40° C.
  • Melt blending of PLA/PVAc and PVDF/PVAc of varying blend ratios was performed in a 30 ml Brabender mixer. The mixer was equilibrated at T=180° C. for 5 minutes after which the mixer blade rotation was adjusted to 25 RPM and the premixed polymers pellets added to the chamber over the course of 1 minute. The polymers were mixed for 10 minute to ensure good dispersion. Nitrogen was purged through the chamber to mitigate potential oxidative degradation during mixing. After mixing, the blend was taken out of the chamber, cooled to room temperature, and then pressed between heated platens of a Carver press at 180° C. for 5 minutes under a load of 8 metric tons. A spacer was used to control the thickness of the film and rapid cooling to room temperature was carried out. The films thus formed were used for the subsequent thermal and mechanical characterization.
  • The TGA results demonstrated that both PLA and PVAc are stable for T<300° C. Above this temperature PLA degrades completely (no char yield), while the PVAc degrades to yield an intermediate char yield of 25 wt % for 375<T<425° C. but complete degradation above 450° C. Blend processing and thermal and dynamic mechanical analyses (DSC and DMA) were performed below 250° C., to completely avoid degradation.
  • The crystallization behavior of semicrystalline PLA was investigated via DSC. The PLA samples were first heat pressed at 180° C. for 10 minutes and then quenched to room temperature with water cooling. One sample was directly analyzed by DSC, while another was first annealed at 110° C. (=1/2(Tg+Tm)) for 1 hour to reach an equilibrium level of crystallinity. FIG. 29 shows a comparison of thermal behavior for these two samples. It was observed that quenching the PLA melt results in a low degree of crystallinity and virtually no recrystallization on heating, both indicating slow crystallization. Annealing at 110° C. for 1 hour results in significant crystallization evidenced by a large melting endotherm at T=155° C. The melting temperature did not shift dramatically due to annealing, but the endotherm shape did change. Complementary WAXD experiments yielded the same conclusions.
  • The crystallization behavior selected of polymer blends was also analyzed. All of the samples were heat pressed at 180° C. for 10 minutes and then annealed at 10° C. for 1 hour before thermal analysis, providing a standard condition for extensive crystallization. FIG. 30 summarizes the first DSC heating trace of the samples measured after annealing. The results indicate that PVAc itself is amorphous (though with large physical aging content) but that incorporation of PLA leads to crystallization in proportion to the PLA wt-%. Also, the peak endotherm positions (melting transitions) shift slightly to higher temperatures with increasing PLA content. Quenching these samples to T=20° C. and reheating to 200° C. again showed clearly that single Tg's are observed and that crystallization can be largely suppressed. Importantly for shape memory, the single glass transition events were not broadened in the blends relative to the pure components, suggesting that the amorphous phase was quite homogeneous for all of the blends. The observed Tg values are plotted in FIG. 31 along with the best fit with the Fox equation, showing slight positive deviation. This leads to a conclusion that strong interactions between the two polymers that reduces free volume of the polymer blends and hence, increased glass transition temperature relative to the Fox equation prediction has occurred.
  • In order to elucidate the effect of PVAc on the degree of crystallinity and the crystal structures, the crystalline diffraction patterns were observed via wide-angle x-ray diffraction. The results indicate that the PVAc phase has only an amorphous halo, thus being totally amorphous, while the PLA exhibits three very strong diffraction peaks at 2θ=22.3°, 25.0° and 28.6°, corresponding to d-spacings of 5.92, 5.29, and 4.64 A°, respectively. Upon addition of PVAc, all of the peak intensities were depressed, but the peak positions remained essentially unchanged. Consistent with the DSC results, the degree of crystallinity increases in proportion to PLA addition. From the peak width at half height, it was found that the crystalline lamellae size did not decrease, although the degree of crystallinity decreased, with increasing PVAc content. This means that the decrease in crystallinity and depression of the melting transitions are not due to a change of crystal size, but rather may be due to a thinning of the lamellae thickness or to a decrease of the crystal concentration.
  • The storage modulus of the polymer blends was also measured using DMTA, first investigating the effects of annealing on the storage modulus. Below their glass transition temperatures, Tg, both samples exhibit similar high storage moduli (3 GPa), as well as similar softening points. When heated above Tg, the storage modulus of thermally quenched samples decreases sharply to about 2 MPa; however, further increasing the temperature induces a modulus increase attributed to recrystallization of the samples at higher temperatures. This also proved that the sample is not in an equilibrium state and that its mechanical properties in the rubbery region depend on thermal history. To reach equilibrium, the sample was annealed at 110° C. for 1 hour as previously described for DSC analyses. The storage modulus above Tg shifts to about 200 MPa until melting, the increase being due to an increase of the degree of crystallinity on annealing to tune the rubbery modulus at equilibrium state,. PLA was blended in different proportions to PVAc and annealed as above. Storage moduli for such blends were measured and the results are plotted in FIG. 32. It can be seen that, below Tg, all of the samples show similar large moduli while above Tg the moduli decrease to a plateau whose magnitude depends on crystallinity and thus PLA content. This trend is in accordance with that of DSC and XRD, and can be explained by the fact that the increase of storage moduli came from the physical crosslinking formed by crystals and the filler effect of the high modulus crystalline phase.
  • Stress-free shape memory tests were carried out in hot water at 65° C., with an annealed sample composed of 30% PLA. The results show that the sample features quick and complete shape memory behavior: the sample recovers to the original shape (straight bar) within 10 seconds, with most of the recovery being accomplished within the first several seconds.
  • The same characterizations were carried out on the blends of PVDF and PVAc as above disclosed. The TGA and DSC results show that PVDF is also thermally stable up to 300° C., and the mixtures form only one glass transition, the values fall between the Tgs of the two homopolymers and changes with changing composition. At the same time, the melting points and the degrees of crystallinity were depressed with the incorporation of amorphous PVAc.
  • The storage moduli of the blends, which give the rigidity of the materials, were also measured. The results are similar to those of the PLA/PVAc blends, the PVDF/PVAc blends being very rigid below the critical temperatures (Tg), and featuring a sharp modulus changes at the Tg to a plateau modulus ranging from several MPa to tens of MPa, depending on the degree of crystallinity of the blends. These plateau moduli can be tuned by adjusting the degree of crystallinity of the blend, that is, adjust the blend composition.
  • The polymer in any of the above stents may be bioabsorbable or non-bioabsorbable. Bioabsorbable polymers include, for example, polyurethanes and polyurethane copolymers such as those described above with the general formula (directly below), where X/Y is, for example, 1 to 20, n is, for example, 2 to 1000, and the total degree of polymerization m is, for example, 2 to 100
    Figure US20050010275A1-20050113-C00004

    The bioabsorbability of the polymers is enhanced by copolymerization of polyurethane and POSS with suitable monomers. Examples of suitable monomers include caprolactone, ethyleneglycol, ethylene oxide, lactic acid, and glycolic acid. The copolymers from these monomers can hydrolyze and cleave the polymer linkage.
  • Other embodiments of stents can also be formed to include materials described above. In some embodiments, an implantable medical stent may be delivered into the body using a catheter. The stent can be delivered in a small diameter form and then expanded at a treatment site by triggering a shape change (for example, by heat application) caused by the shape memory properties of the polymer. The stent can also be expanded by a mechanical expander such as an inflatable balloon of the type used on an angioplasty catheter.
  • In some embodiments, the stent is sized (e.g., an expanded inner diameter of about 2 mm to about 20 mm) and configured for use in the vascular system, particularly the coronary arteries, and implanted after or simultaneously with an angioplasty procedure to maintain an open lumen and reduce restenosis. Vascular stents are described in U.S. Provisional Application No. 60/418,023, which is hereby incorporated in full by reference. For example, a stent for coronary use can have an initial diameter of about 2 mm, an expanded diameter of about 4 mm, and a wall thickness of about 0.005 mm to 0.1 mm. Other exemplary applications include neuro, carotid, peripheral, and vasculature lumens. The vascular stent can be bioabsorbable or non-bioabsorbable.
  • In other embodiments, a stent, e.g., a bioabsorbable or a non-bioabsorbable stent, is constructed for use in nonvascular lumens, such as the esophagus, ureteral, biliary, or prostate.
  • In other embodiments, the stent is conductive to allow an electrical current to pass through the stent, for example, to deliver electricity to an area of the body or to trigger, for example, a physical change in the stent, for example, a change in the diameter of the stent.
  • In still other embodiments, the stent, for example, of FIGS. 4, 23 and 26, is made porous by, for example, adding a chemical foaming agent to the polymer from which the stent is made during the production the plastic strand. In some implementations, the stent is porous and includes a medicament. The initial porosity of the stent can be reduced, for example, by the application of heat and pressure before deployment in the body. Upon deployment of the stent in the body, the porosity is increased by a triggering event, for example, the application of heat to the stent at the desired site of treatment.

Claims (105)

1. A product comprising a balloon catheter having an expandable member and a stent mounted on the expandable member, the stent comprising an apertured tubular member formed of a polymer, the stent having an initial diameter for delivery into a body lumen and which can be expanded to a second diameter in the lumen by expanding the expandable member, wherein during expansion the polymer does not substantially flow and substantial stress relaxation or creep does not occur so that the geometry of the tubular member is maintained.
2. The product of claim 1, wherein the polymer exhibits a plateau in its plot of storage modulus as a function of temperature.
3. The product of claim 1, wherein the polymer has a melt temperature from about 40° C. to about 50° C.
4. The product of claim 1, wherein the polymer has a melt temperature range of less than about 5° C.
5. The product of claim 1, wherein the polymer has a glass transition temperature from about 40° C. to about 50° C.
6. The product of claim 1, wherein the polymer has a glass transition temperature range of less than about 5° C.
7. The product of claim 1, wherein the polymer is elastomeric at room temperature.
8. The product of claim 1, wherein the polymer is bioabsorbable.
9. The product of claim 1, wherein the polymer is crosslinked.
10. The product of claim 9, wherein the polymer is radiation crosslinked.
11. The product of claim 9, wherein the polymer is chemically crosslinked.
12. The product of claim 1, wherein the polymer is a shape memory polymer.
13. The product of claim 1, wherein the polymer is selected from the group consisting of polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene, trans-isoprene, blends of polycaprolactone and n-butylacrylate, POSS polyurethane polymers and blends thereof.
14. The polymer of claim 1, wherein the wherein the polymer includes an additive selected from the group consisting of drugs, radiopaque agents and magnetic heating agents.
15. The product of claim 1, wherein the initial diameter is from about 1 mm to about 5 mm.
16. The product of claim 1, wherein the expanded diameter is from about 1 mm to about 20 mm.
17. The product of claim 1, wherein the expanded diameter is from about 100% to about 400% the initial diameter.
18. The product of claim 1, wherein the apertured tubular member is formed from a plurality of filaments, the plurality of filaments forming a tubular structure.
19. The product of claim 1, wherein the ratio of apertured open area to total area of the tubular member is greater than about 0.5.
20. The product of claim 1, wherein the apertures are diamond-like openings.
21. A product comprising a tubular endoprosthesis having a body formed of a polymer, the endoprosthesis being designed for delivery into a body lumen, wherein when the endoprosthesis is expanded in the lumen under conditions of expanding pressure and temperature, the wall thickness of the body is substantially maintained.
22. The product of claim 21, wherein a change in the wall thickness is less than about 1%.
23. The implantable medical device of claim 21, wherein the wall thickness is from about 0.005 mm to about 5 mm.
24. The product of claim 21, wherein the polymer is selected from the group consisting of polynorbornene, polycaprolactone, polyenes, nylons, polycyclooctene (PCO), blends of PCO and styrene-butadiene rubber, polyvinyl acetate/polyvinylidinefluoride (PVAc/PVDF), blends of PVAc/PVDF/polymethylmethacrylate (PMMA), polyurethanes, styrene-butadiene copolymers, polyethylene, trans-isoprene, blends of polycaprolactone and n-butylacrylate, POSS polyurethanes and blends thereof.
25. The product of claim 21, wherein the polymer has a melt temperature from about 40° C. to about 50° C.
26. The product of claim 21, wherein the polymer has a glass transition temperature from about 40° C. to about 60° C.
27. The product of claim 21, wherein the polymer is bioabsorbable.
28. The product of claim 21, wherein the polymer is crosslinked.
29. The product of claim 28, wherein the polymer is radiation crosslinked.
30. The product of claim 28, wherein the polymer is chemically crosslinked.
31. The product of claim 21, wherein the polymer is a shape memory polymer.
32. The product of claim 21, wherein the polymer exhibits a plateau in its plot of storage modulus as a function of temperature.
33. The polymer of claim 21, wherein the wherein the polymer includes an additive selected from the group consisting of drugs, radiopaque agents and magnetic heating agents.
34. A method of delivering a stent into a lumen using a catheter, the method comprising:
delivering an apertured stent formed of a polymer and mounted on an expandable member of a catheter into a lumen,
expanding the expandable member to also expand the stent within the lumen so that the polymer does not substantially flow and substantial stress relaxation or creep does not occur so that the geometry of the tubular member is maintained; and
unexpanding the expandable member.
35. The method of claim 34, wherein the expandable member is a balloon at the distal tip of a catheter.
36. The method of claim 34, wherein the polymer has a melt temperature from about 40° C. to about 60° C.
37. The method of claim 34, wherein the polymer has a glass transition temperature is from about 40° C. to about 60° C.
38. The method of claim 34, wherein the lumen is a vascular lumen.
39. The method of claim 34, wherein the lumen is a non-vascular lumen.
40. A method of delivering a tubular prosthesis formed of a polymer into a body lumen, comprising
delivering the tubular prosthesis into the lumen, and
expanding the endoprosthesis under conditions of expanding pressure and rising temperature, wherein during expansion the wall thickness of the prosthesis is substantially maintained.
41. A method of making an implantable medical device comprising:
forming a tube from a polymer, the tube having a first diameter and including a wall;
cutting an aperture pattern into the wall of the tube while the tube has the first diameter;
crosslinking the polymer while the tube has the first diameter; and
deforming the tube to a second diameter, the second diameter smaller than the first diameter.
42. A method of delivering an implantable medical device comprising:
providing a catheter having an expandable member at its distal end;
placing a device made by the method of claim 41 onto the expandable member;
delivering the device to a body lumen;
expanding the device under conditions of expanding pressure and temperature to cause expansion of the device to the larger diameter; and
cooling the stent so that the device remains in the expanded larger diameter in the body lumen; and
removing the catheter from the body, thereby leaving behind the device within the body.
43. A method of making an implantable medical device comprising:
forming a tube from a polymer, the tube having a first diameter and including a wall;
cutting an aperture pattern into the wall while the tube has the first diameter; and
crosslinking the polymer while the tube has the first diameter.
44. A method of delivering an implantable medical device comprising:
providing a catheter having an expandable member at its distal end;
placing a device made by the method of claim 43 onto the expandable member;
delivering the device to a body lumen;
expanding the device under conditions of expanding pressure and temperature to cause expansion of the device to the larger diameter; and
cooling the stent so that the device remains in the expanded larger diameter in the body lumen; and
removing the catheter from the body, thereby leaving behind the device within the body.
45. An implantable medical apparatus, comprising:
an element operable for movement within the body by mechanical force applied to the element, said element including a polymer having a melt or glass transition temperature in the range above body temperature to about 60° C. and exhibiting a plateau in a plot of storage modulus as a function of temperature at melt or glass transition.
46. The apparatus of claim 45, wherein the element is a stent.
47. The apparatus of claim 46, wherein the stent is a generally tubular body including an apertured wall.
48. The apparatus of claim 47, wherein the stent is operable for expansion from a first, smaller diameter to a second larger diameter for implantation in a lumen, wherein the thickness of the stent wall varies by about 1% or less between the first and second diameter.
49. The apparatus of claim 47, wherein the stent can be bent around a mandrel of about 0.75 cm radius without kinking.
50. A medical device comprising a polymer having a melt or glass transition temperature above body temperature and exhibiting an approximate plateau in a plot of storage modulus as a function of temperature at melt or glass transition.
51. The medical device of claim 50, wherein the melt or glass transition temperature is above about 37° C.
52. The medical device of claim 50, wherein the melt or glass transition temperature is above about 50° C.
53. The medical device of claim 50, wherein the melt or glass transition temperature is between about 37° C. and about 50° C.
54. The medical device of claim 50, wherein the element undergoes a triggerable event at about the plateau.
55. The medical device of claim 54, wherein the triggerable event is a change in the flexibility.
56. The medical device of claim 54, wherein the triggerable event is a change in the porosity.
57. The medical device of claim 54, wherein the triggerable event is a change in the coefficient of friction.
58. The medical device of claim 54, wherein the triggerable event is a change in the surface roughness.
59. The medical device of claim 54, wherein the medical device is a stent and has a portion that has a collapsed position that can be reverted to an expanded position by a trigger subsequent to insertion into the body.
60. A polymeric stent having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
61. The stent of claim 60, wherein the stent is in the form of a coiled elongated element.
62. The stent of claim 61, wherein when the stent is heated to a second temperature higher than the first temperature, the modulus of the element lowers sufficiently that the stent can be removed from a cavity or lumen as a substantially uncoiled element.
63. The stent of claim 60, wherein the portion is at an end of the stent.
64. The stent of claim 63, wherein the portion of the stent is flared.
65. The stent of claim 60, wherein at least two portions of the stent have a collapsed position that can be reverted to an expanded position following insertion into a cavity or lumen.
66. The stent of claim 61, wherein the elongated element comprises a strand.
67. The stent of claim 61, wherein the elongated element comprises a tape.
68. The stent of claim 61, wherein the elongated element comprises a flattened tube.
69. The stent of claim 68, wherein the flattened tube has a generally central opening that includes a medicament that can be released by the inserted stent.
70. The stent of claim 60, wherein the first temperature is greater than about 37° C.
71. The stent of claim 62, wherein the second temperature is greater than about 37° C.
72. The stent of claim 60, wherein the stent comprises a polymer selected from a group consisting of polynorbornene and copolymers of polynorbornene, polyethylene, styrenic block copolymer elastomers, polymethylmethacrylate, polyurethane, polyisoprene, polycaprolactone and copolymers of polycaprolactone, polylactic acid (PLA) and copolymers of polylactic acid, polyglycolic acid and copolymers of polyglycolic acid, copolymers of PLA and PGA, polyenes, nylons, polycyclooctene, polyvinyl acetate, polyvinylidene fluoride polyvinylchloride (PVC) and blends thereof.
73. The stent of claim 60, wherein the stent has a length and the portion comprises less than 50% of the length of the stent.
74. A polymeric stent in the form of a coiled elongated element, and having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen, and wherein when the stent is heated to a second temperature higher than the first temperature, the modulus of the element lowers sufficiently that the stent can be removed from a cavity or lumen as a substantially uncoiled element.
75. A method of treating a non-vascular cavity or lumen in a mammal, the method comprising:
inserting, into the non-vascular lumen or cavity of the mammal, a polymeric stent having a portion in a collapsed position that can be reverted to an expanded position by heating following insertion; and
heating the inserted stent sufficiently to revert the portion in the collapsed position to the expanded position.
76. The method of claim 75, further comprising:
heating the stent having the portion in the expanded position sufficiently to soften the stent; and
removing the softened stent from the cavity or lumen.
77. The method of claim 75, wherein the portion is at an end of the stent.
78. The method of claim 77, wherein the portion of the stent is flared.
79. The method of claim 75, wherein at least two portions of the stent have a collapsed position that can be reverted to an expanded position following insertion, and wherein during the heating both portions revert to expanded positions.
80. The method of claim 75, wherein the stent is in the form of a coiled elongated element.
81. The method of claim 75, wherein the collapsed position that can be reverted to an expanded position following insertion is not an end of the stent.
82. The method of claim 80, further comprising:
heating the stent sufficiently to soften the stent; and
removing the softened stent from the cavity or lumen as a substantially uncoiled strand.
83. The method of claim 75, wherein the heating is performed with a liquid.
84. The method of claim 75, wherein the heating is performed so that the temperature is less than about 55° C.
85. The method of claim 75, wherein the heating is performed by a delivery tube including a warmed liquid.
86. The method of claim 75, wherein the delivery tube is a balloon catheter.
87. The method of claim 75, wherein the heating is performed using RF energy.
88. The method of claim 75, wherein the heating is performed using IR energy.
89. The method of claim 75, wherein the heating is performed using inductive heating.
90. The method of claim 89, wherein the stent further comprises metal particles.
91. The method of claim 75, wherein the lumen is a urethra.
92. The method of claim 75, wherein the lumen is a biliary duct.
93. The method of claim 75, wherein the lumen is a cystic duct.
94. The method of claim 75, wherein the lumen is in the gastrointestinal system.
95. The method of claim 75, wherein the lumen is in the pulmonary system.
96. The method of claim 75, wherein the lumen is in the hepatic system.
97. The method of claim 75, wherein the stent comprises a polymer selected from the group consisting of polynorbornene and copolymers of polynorbornene, polyethylene, styrenic block copolymer elastomers, polymethylmethacrylate, polyurethane, polyisoprene, polycaprolactone and copolymers of polycaprolactone, polylactic acid (PLA) and copolymers of polylactic acid, polyglycolic acid and copolymers of polyglycolic acid, copolymers of PLA and PGA, polyenes, nylons, polycyclooctene, polyvinyl acetate, polyvinylidene fluoride polyvinylchloride (PVC) and blends thereof.
98. A polymeric stent comprising metal particles, wherein a portion of the stent has a collapsed position that can be reverted to an expanded position by heating after insertion of the stent.
99. The stent of claim 98, wherein the stent can be heated by inductive heating to revert the portion in the collapsed position to the expanded position.
100. A stent having an exterior surface that includes a plurality of protruding elements that extend outwardly from the surface, the stent also having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen.
101. The stent of claim 100, wherein the protruding elements are formed of monofilament.
102. The stent of claim 101, wherein the monofilament includes a plurality of constrictions along its length.
103. The stent of claim 100, wherein the protruding elements are integral with and formed from the exterior surface.
104. A method of treating a cavity or lumen in a mammal, the method comprising:
inserting, into the lumen or cavity of the mammal, a polymeric stent having an exterior surface that includes a plurality of protruding elements that extend outwardly from the surface, the stent also having a portion that has a collapsed position that can be reverted to an expanded position by heating above a first temperature subsequent to insertion of the stent into a cavity or lumen; and
heating the inserted stent sufficiently to revert the portion in the collapsed position to the expanded position.
105. The method of claim 104, further comprising:
heating the stent sufficiently to soften the stent; and
removing the softened stent from the cavity or lumen as a substantially uncoiled strand.
US10/683,314 2002-10-11 2003-10-10 Implantable medical devices Abandoned US20050010275A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/683,314 US20050010275A1 (en) 2002-10-11 2003-10-10 Implantable medical devices
US10/958,435 US7794494B2 (en) 2002-10-11 2004-10-05 Implantable medical devices
US11/111,509 US7976936B2 (en) 2002-10-11 2005-04-21 Endoprostheses
US12/880,483 US20140135889A9 (en) 2002-10-11 2010-09-13 Implantable medical devices
US12/940,388 US8784465B2 (en) 2002-10-11 2010-11-05 Implantable medical devices
US13/053,461 US20110172753A1 (en) 2003-07-18 2011-03-22 Endoprostheses
US13/493,532 US9115245B2 (en) 2002-10-11 2012-06-11 Implantable medical devices
US15/185,851 US20160296677A1 (en) 2003-07-18 2016-06-17 Endoprostheses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41802302P 2002-10-11 2002-10-11
US41950602P 2002-10-18 2002-10-18
US46640103P 2003-04-29 2003-04-29
US48832303P 2003-07-18 2003-07-18
US48859003P 2003-07-18 2003-07-18
US10/683,314 US20050010275A1 (en) 2002-10-11 2003-10-10 Implantable medical devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/958,435 Continuation-In-Part US7794494B2 (en) 2002-10-11 2004-10-05 Implantable medical devices

Publications (1)

Publication Number Publication Date
US20050010275A1 true US20050010275A1 (en) 2005-01-13

Family

ID=32097153

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/683,167 Expired - Fee Related US7091297B2 (en) 2002-10-11 2003-10-10 Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US10/683,314 Abandoned US20050010275A1 (en) 2002-10-11 2003-10-10 Implantable medical devices

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/683,167 Expired - Fee Related US7091297B2 (en) 2002-10-11 2003-10-10 Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments

Country Status (8)

Country Link
US (2) US7091297B2 (en)
EP (5) EP2260882B1 (en)
JP (2) JP4960631B2 (en)
AT (1) ATE499396T1 (en)
AU (4) AU2003277332B2 (en)
CA (2) CA2501617C (en)
DE (1) DE60336158D1 (en)
WO (2) WO2004033515A2 (en)

Cited By (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US20040122174A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Blends of amorphous and semicrystalline polymers having shape memory properties
US20050021131A1 (en) * 2003-06-16 2005-01-27 Subramanian Venkatraman Polymeric stent and method of manufacture
US20050197687A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US20050197689A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US20050197690A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US20050216074A1 (en) * 2002-10-11 2005-09-29 Sahatjian Ronald A Implantable medical devices
US20050222677A1 (en) * 1995-06-07 2005-10-06 Bates Brian L Coated implantable medical device
US20050245719A1 (en) * 2002-10-11 2005-11-03 Mather Patrick T Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20050251249A1 (en) * 2002-10-11 2005-11-10 Sahatjian Ronald A Endoprostheses
US20060129232A1 (en) * 2004-12-10 2006-06-15 Dicarlo Paul Implantable medical devices, and methods of delivering the same
US20060142838A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for loading and deploying same
US20060142842A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for making same
US20060142845A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for making same
US20060171981A1 (en) * 2005-02-01 2006-08-03 Richard Robert E Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
US20060259051A1 (en) * 2005-04-08 2006-11-16 Alveolus, Inc. Duodenum stent and associated method
US20060259113A1 (en) * 2005-04-26 2006-11-16 Alveolus, Inc. Esophageal stent and associated method
US20060259131A1 (en) * 2005-05-16 2006-11-16 Masoud Molaei Medical devices including metallic films and methods for making same
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070038176A1 (en) * 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions
US20070093618A1 (en) * 2003-10-10 2007-04-26 Tammy Cheng Urethane compositions containing carbinol-functional silicone resins
US20070135751A1 (en) * 2005-12-09 2007-06-14 Dicarlo Paul D Medical devices
US20070150047A1 (en) * 1995-06-07 2007-06-28 Med Institute, Inc. Implantable medical device with bioabsorbable coating
US20070156231A1 (en) * 2006-01-05 2007-07-05 Jan Weber Bioerodible endoprostheses and methods of making the same
US20070178129A1 (en) * 2006-02-01 2007-08-02 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070191923A1 (en) * 2006-02-16 2007-08-16 Jan Weber Medical balloons and methods of making the same
US20070191931A1 (en) * 2006-02-16 2007-08-16 Jan Weber Bioerodible endoprostheses and methods of making the same
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070224244A1 (en) * 2006-03-22 2007-09-27 Jan Weber Corrosion resistant coatings for biodegradable metallic implants
US20070224116A1 (en) * 2006-03-27 2007-09-27 Chandru Chandrasekaran Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
US20070271763A1 (en) * 2006-05-25 2007-11-29 Bin Huang Method of crimping a polymeric stent
US20080004691A1 (en) * 2006-06-29 2008-01-03 Boston Scientific Scimed, Inc. Medical devices with selective coating
US20080009939A1 (en) * 2006-05-26 2008-01-10 Gueriguian Vincent J Bioabsorbable stent with radiopaque coating
US20080039921A1 (en) * 2004-06-30 2008-02-14 Wallsten Medical S.A. Balloon Catheter
US20080051759A1 (en) * 2006-08-24 2008-02-28 Boston Scientific Scimed, Inc. Polycarbonate polyurethane venous access devices
US20080058919A1 (en) * 2006-08-01 2008-03-06 Kramer-Brown Pamela A Composite polymeric and metallic stent with radiopacity
US20080071351A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
US20080071353A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis containing magnetic induction particles
US20080071352A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US20080082162A1 (en) * 2006-09-15 2008-04-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20080086195A1 (en) * 2006-10-05 2008-04-10 Boston Scientific Scimed, Inc. Polymer-Free Coatings For Medical Devices Formed By Plasma Electrolytic Deposition
US20080086201A1 (en) * 2006-09-15 2008-04-10 Boston Scientific Scimed, Inc. Magnetized bioerodible endoprosthesis
US20080097302A1 (en) * 2006-09-20 2008-04-24 Boston Scientific Scimed, Inc. Medical balloons with modified surfaces
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US20080097620A1 (en) * 2006-05-26 2008-04-24 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US20080097577A1 (en) * 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
US20080109072A1 (en) * 2006-09-15 2008-05-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20080131479A1 (en) * 2006-08-02 2008-06-05 Jan Weber Endoprosthesis with three-dimensional disintegration control
US20080132988A1 (en) * 2006-12-01 2008-06-05 Scimed Life Systems, Inc. Balloon geometry for delivery and deployment of shape memory polymer stent with flares
US20080147166A1 (en) * 1995-06-07 2008-06-19 Bates Brian L Coated implantable medical device
US20080145398A1 (en) * 1995-06-07 2008-06-19 Bates Brian L Coated implantable medical device
US20080161906A1 (en) * 2006-12-28 2008-07-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20080161900A1 (en) * 2006-06-20 2008-07-03 Boston Scientific Scimed, Inc. Medical devices including composites
WO2008086369A1 (en) * 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US20080199646A1 (en) * 2007-02-15 2008-08-21 Medtronic Vascular, Inc. Inline Particle Deposition Extrusion
US20080215138A1 (en) * 1995-06-07 2008-09-04 Bates Brian L Coated implantable medical device
US20080233164A1 (en) * 2004-01-20 2008-09-25 Ucl Biomedical Plc Polymer for Use in Conduits, Medical Devices and Biomedical Surface Modification
US20080294246A1 (en) * 2007-05-23 2008-11-27 Boston Scientific Scimed, Inc. Endoprosthesis with Select Ceramic Morphology
US20080303194A1 (en) * 2007-06-08 2008-12-11 Sabic Innovative Plastics Ip B.V. Mold apparatus for forming polymer and method
US20080319540A1 (en) * 2007-06-13 2008-12-25 Boston Scientific Scimed, Inc. Anti-migration features and geometry for a shape memory polymer stent
US20090012481A1 (en) * 1998-02-24 2009-01-08 Davey Christopher T High Flow Rate Dialysis Catheters and Related Methods
US20090018639A1 (en) * 2007-07-11 2009-01-15 Boston Scientific Scimed, Inc. Endoprosthesis coating
US20090029077A1 (en) * 2007-07-27 2009-01-29 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US20090026650A1 (en) * 2006-01-06 2009-01-29 Vipul Bhupendra Dave Method of forming a bioabsorbable drug delivery devices
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20090076588A1 (en) * 2007-09-13 2009-03-19 Jan Weber Endoprosthesis
US20090118822A1 (en) * 2007-11-02 2009-05-07 Holman Thomas J Stent with embedded material
US20090118809A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Endoprosthesis with porous reservoir and non-polymer diffusion layer
US20090118813A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Nano-patterned implant surfaces
US20090115104A1 (en) * 2007-10-26 2009-05-07 Sabic Innovative Plastics Ip B.V. System and Method for Forming Polymer
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US20090143855A1 (en) * 2007-11-29 2009-06-04 Boston Scientific Scimed, Inc. Medical Device Including Drug-Loaded Fibers
US20090143713A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor
US20090187141A1 (en) * 2007-10-19 2009-07-23 Raymond Lareau Recirculation minimizing catheter
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US20090281613A1 (en) * 2008-05-09 2009-11-12 Boston Scientific Scimed, Inc. Endoprostheses
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US20090306765A1 (en) * 2008-06-10 2009-12-10 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US20100008970A1 (en) * 2007-12-14 2010-01-14 Boston Scientific Scimed, Inc. Drug-Eluting Endoprosthesis
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US20100030326A1 (en) * 2008-07-30 2010-02-04 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US20100049296A1 (en) * 2008-08-22 2010-02-25 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20100087910A1 (en) * 2008-10-03 2010-04-08 Jan Weber Medical implant
US20100137977A1 (en) * 2007-08-03 2010-06-03 Boston Scientific Scimed, Inc. Coating for Medical Device Having Increased Surface Area
US20100137978A1 (en) * 2008-12-03 2010-06-03 Boston Scientific Scimed, Inc. Medical Implants Including Iridium Oxide
US20100204778A1 (en) * 2004-04-02 2010-08-12 Arterial Remodelling Technologies, Inc. Polymer-based stent assembly
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US20100222873A1 (en) * 2009-03-02 2010-09-02 Boston Scientific Scimed, Inc. Self-Buffering Medical Implants
US20100228341A1 (en) * 2009-03-04 2010-09-09 Boston Scientific Scimed, Inc. Endoprostheses
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US20100233238A1 (en) * 2006-03-24 2010-09-16 Boston Scientific Scimed, Inc. Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100249903A1 (en) * 2006-11-10 2010-09-30 C. R. Bard, Inc. Stent
US20100256546A1 (en) * 2009-04-03 2010-10-07 Davis Scott A Polycarbonate Polyurethane Venous Access Devices Having Enhanced Strength
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US20100262225A1 (en) * 2007-12-12 2010-10-14 Peter Schneider Device and method for tacking plaque to a blood vessel wall
US20100272882A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Endoprosthese
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US20100274352A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scrimed, Inc. Endoprosthesis with Selective Drug Coatings
US20100280612A1 (en) * 2004-12-09 2010-11-04 Boston Scientific Scimed, Inc. Medical Devices Having Vapor Deposited Nanoporous Coatings For Controlled Therapeutic Agent Delivery
US20100286763A1 (en) * 1998-04-11 2010-11-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US20100318183A1 (en) * 2005-02-28 2010-12-16 Keraenen Olli System For Improving The Function Of A Heart Valve
US20110022158A1 (en) * 2009-07-22 2011-01-27 Boston Scientific Scimed, Inc. Bioerodible Medical Implants
US20110054381A1 (en) * 2009-05-29 2011-03-03 Jacques Van Dam Biliary shunts, delivery systems, and methods of using the same
US20110071500A1 (en) * 2009-09-21 2011-03-24 Navilyst Medical, Inc. Branched catheter tip
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7951185B1 (en) * 2006-01-06 2011-05-31 Advanced Cardiovascular Systems, Inc. Delivery of a stent at an elevated temperature
US20110152992A1 (en) * 2007-12-12 2011-06-23 Peter Schneider Device and method for tacking plaque to blood vessel wall using wire mesh annular band
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US20110169197A1 (en) * 2006-06-28 2011-07-14 Bin Huang Fabricating Polymer Stents with Injection Molding
US20110172642A1 (en) * 2010-01-11 2011-07-14 Navilyst Medical Occlusion Resistant Catheter
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US20110230954A1 (en) * 2009-06-11 2011-09-22 Peter Schneider Stent device having focal elevating elements for minimal surface area contact with lumen walls
US20110238151A1 (en) * 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US20120003410A1 (en) * 2010-04-15 2012-01-05 Tatarka Paul D Partially crystalline cycloolefin elastomer medical tubing
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20130006141A1 (en) * 2011-06-29 2013-01-03 Cook Medical Technologies Llc Expandable Device for Full Thickness Biopsy
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
US20130085563A1 (en) * 2011-10-03 2013-04-04 Abbott Cardiovascular Systems Inc. Rubber toughened bioresorbable polymer peripheral scaffolds
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8992592B2 (en) 2004-12-29 2015-03-31 Boston Scientific Scimed, Inc. Medical devices including metallic films
US9050435B2 (en) 2011-03-22 2015-06-09 Angiodynamics, Inc. High flow catheters
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US9375327B2 (en) 2007-12-12 2016-06-28 Intact Vascular, Inc. Endovascular implant
US20160244570A1 (en) * 2015-02-24 2016-08-25 Albert-Ludwigs-Universität Freiburg Phase segregated block copolymers with tunable properties
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US20170079764A1 (en) * 2012-05-10 2017-03-23 Hoon Bum Lee Filler for removing wrinkles
US9603730B2 (en) 2007-12-12 2017-03-28 Intact Vascular, Inc. Endoluminal device and method
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US9707339B2 (en) 2012-03-28 2017-07-18 Angiodynamics, Inc. High flow rate dual reservoir port system
US9713704B2 (en) 2012-03-29 2017-07-25 Bradley D. Chartrand Port reservoir cleaning system and method
US9730818B2 (en) 2007-12-12 2017-08-15 Intact Vascular, Inc. Endoluminal device and method
US9908143B2 (en) 2008-06-20 2018-03-06 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US9913649B2 (en) 2014-05-28 2018-03-13 Boston Scientific Scimed, Inc. Catheter with radiofrequency cutting tip and heated balloon
US20180126129A1 (en) * 2014-07-21 2018-05-10 Stentorium Ltd Implantable Stent
US9980806B2 (en) 2008-10-22 2018-05-29 Boston Scientific Scimed, Inc. Shape memory tubular stent with grooves
US20180160216A1 (en) * 2016-12-06 2018-06-07 Bose Corporation Earpieces employing viscoelastic materials
US10022250B2 (en) 2007-12-12 2018-07-17 Intact Vascular, Inc. Deployment device for placement of multiple intraluminal surgical staples
US20180249987A1 (en) * 2013-11-20 2018-09-06 Covidien Lp Devices, systems, and methods for navigating a biopsy tool to a target location and obtaining a tissue sample using the same
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10166127B2 (en) 2007-12-12 2019-01-01 Intact Vascular, Inc. Endoluminal device and method
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
US10172729B2 (en) 2015-10-12 2019-01-08 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
CN109265972A (en) * 2018-09-07 2019-01-25 浙江华峰热塑性聚氨酯有限公司 The Matte thermoplastic polyurethane elastomer and preparation method thereof of easy processing high-modulus
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US10195029B2 (en) 2005-09-07 2019-02-05 Medtentia Internatinal Ltd Oy Device and method for improving the function of a heart valve
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10245167B2 (en) 2015-01-29 2019-04-02 Intact Vascular, Inc. Delivery device and method of delivery
US10271973B2 (en) 2011-06-03 2019-04-30 Intact Vascular, Inc. Endovascular implant
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10427329B2 (en) 2014-06-27 2019-10-01 Sabic Global Technologies B.V. Induction heated mold apparatus with multimaterial core and method of using the same
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
CN110960734A (en) * 2019-10-30 2020-04-07 上海七木医疗器械有限公司 Preparation method of degradable spiral stent
US10646359B2 (en) 2008-06-20 2020-05-12 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US10729881B2 (en) 2011-03-22 2020-08-04 Angiodynamics, Inc. High flow catheters
US10743857B2 (en) * 2018-07-26 2020-08-18 Endobetes, Inc. Lumen reinforcement and anchoring system
US10849770B2 (en) 2006-05-17 2020-12-01 C. R. Bard, Inc. Bend-capable tubular prosthesis
US10898356B2 (en) 2015-01-29 2021-01-26 Intact Vascular, Inc. Delivery device and method of delivery
US10993824B2 (en) 2016-01-01 2021-05-04 Intact Vascular, Inc. Delivery device and method of delivery
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US11096774B2 (en) 2016-12-09 2021-08-24 Zenflow, Inc. Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US11491038B2 (en) 2018-07-26 2022-11-08 Endobetes Inc. Lumen reinforcement and anchoring system
US11497888B2 (en) * 2015-05-29 2022-11-15 Biosensors International Group, Ltd. Bi-lumenal tube catheter support system
US11660218B2 (en) 2017-07-26 2023-05-30 Intact Vascular, Inc. Delivery device and method of delivery
US11890213B2 (en) 2019-11-19 2024-02-06 Zenflow, Inc. Systems, devices, and methods for the accurate deployment and imaging of an implant in the prostatic urethra
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US11931484B2 (en) 2021-01-15 2024-03-19 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194919A1 (en) * 1999-08-04 2006-08-31 Lichtenhan Joseph D Porosity control with polyhedral oligomeric silsesquioxanes
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
JP2005503865A (en) 2001-09-28 2005-02-10 ボストン サイエンティフィック リミテッド Medical device comprising nanomaterial and treatment method using the same
EP2260882B1 (en) 2002-10-11 2020-03-04 Boston Scientific Limited Implantable medical devices
DE10331787A1 (en) * 2003-07-11 2005-02-17 Degussa Ag NCO-containing compounds with covalently bonded polyhedral oligomeric silicon-oxygen cluster units
JP4805148B2 (en) * 2003-07-18 2011-11-02 ボストン サイエンティフィック リミテッド Medical instruments
US7377939B2 (en) * 2003-11-19 2008-05-27 Synecor, Llc Highly convertible endolumenal prostheses and methods of manufacture
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
CA2593471A1 (en) * 2004-12-10 2006-07-06 University Of Connecticut Shape memory polymer orthodontic appliances, and methods of making and using the same
EP1846470A1 (en) * 2005-01-13 2007-10-24 Mnemoscience GmbH Polymer material showing a sharp dependency of tensile strength in relation to two external stimuli
JP2008531769A (en) 2005-02-23 2008-08-14 ズィマー・テクノロジー・インコーポレーテッド Blend hydrogel and method for producing the same
JP2008538718A (en) * 2005-04-22 2008-11-06 ハイブリッド・プラスティックス・インコーポレイテッド Biomimetic material containing polyhedral oligomeric silsesquioxane
EP1907202B1 (en) 2005-07-01 2016-01-20 Carolyn M. Dry Multiple function, self-repairing composites with special adhesives
US8302634B2 (en) 2005-10-11 2012-11-06 National Oilwell Varco Denmark I/S Method of producing a flexible pipe and a flexible pipe
DE102005056532A1 (en) 2005-11-28 2007-05-31 Mnemoscience Gmbh Method for removal of tubular tissue supports e.g. stents from human or animal hollow organs, involves heating of tissue support to temperature below transition temperature, till softening
CN101321509A (en) * 2005-12-02 2008-12-10 Pnn医疗公司 A stent
AU2006321809A1 (en) * 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
JP4723992B2 (en) * 2005-12-12 2011-07-13 積水化学工業株式会社 Resin composition, insulating substrate, molded article, and electronic device
US8017107B2 (en) 2005-12-22 2011-09-13 Zimmer, Inc. Perfluorocyclobutane crosslinked hydrogels
DE102006012169B4 (en) * 2006-03-14 2007-12-13 Gkss-Forschungszentrum Geesthacht Gmbh Shape memory polymer with polyester and polyether segments, process for its preparation and shape programming and use
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
KR100792414B1 (en) 2006-07-20 2008-01-08 금호석유화학 주식회사 Nanocomposite of high 1,4-cis polybutadiene rubber and its manufacturing method
WO2008051254A1 (en) * 2006-10-27 2008-05-02 The Regents Of The University Of Colorado A polymer formulation a method of determining a polymer formulation and a method of determining a polymer fabrication
US8574308B2 (en) * 2007-03-13 2013-11-05 Smith & Nephew, Inc. Systems and methods for installing and removing an expandable polymer
US20100294996A1 (en) * 2007-03-23 2010-11-25 Holger Redtel Material for the formation of structures having a support function
US8765112B2 (en) * 2007-04-19 2014-07-01 University Of Massachusetts Thermal responsive polymer siloxanes, compositions, and method and applications related thereto
WO2008148385A1 (en) * 2007-06-06 2008-12-11 Pnn Medical A/S A stent
US20090035350A1 (en) 2007-08-03 2009-02-05 John Stankus Polymers for implantable devices exhibiting shape-memory effects
US7731988B2 (en) 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
DE102008004574A1 (en) * 2008-01-09 2009-07-16 Aesculap Ag Surgical suture with anchoring elements
DE102008016123A1 (en) 2008-03-20 2009-09-24 Gt Elektrotechnische Produkte Gmbh Shape memory polymers and process for their preparation
US9259515B2 (en) 2008-04-10 2016-02-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from polyurethanes with grafted radiopaque groups
WO2009134171A1 (en) * 2008-04-29 2009-11-05 St. Jude Medical Ab An implantable medical lead and a method of manufacturing of the same
TW201002781A (en) * 2008-07-08 2010-01-16 Ind Tech Res Inst Materials having shape memory properties and method for fabricating the same
US8136536B2 (en) 2008-09-24 2012-03-20 Elc Management Llc Shape memory polymer mascara brush
US9533469B2 (en) * 2008-12-23 2017-01-03 Syracuse University Self-healing product
US20100159195A1 (en) * 2008-12-24 2010-06-24 Quincy Iii Roger B High repellency materials via nanotopography and post treatment
US8633292B2 (en) * 2009-03-26 2014-01-21 Signet Armorlite Polyurethane-based photochromic optical materials
US8449903B2 (en) 2009-06-08 2013-05-28 Boston Scientific Scimed, Inc. Crosslinked bioabsorbable medical devices
US8431151B2 (en) * 2009-08-06 2013-04-30 Syracuse University Antimicrobial nanostructured hydrogel web containing silver
US7897314B1 (en) * 2009-08-31 2011-03-01 Xerox Corporation Poss melamine overcoated photoconductors
CN102781994B (en) * 2009-12-21 2014-05-07 亨茨曼国际有限公司 A method to form a polyurethane material
US8683798B2 (en) * 2010-01-15 2014-04-01 Syracuse University Stimuli-responsive product
CN102151184A (en) * 2010-02-12 2011-08-17 姜在波 Recyclable biliary stent
US9249254B2 (en) * 2010-04-22 2016-02-02 Syracuse University Polyhedral oligomeric silsesquioxane polyurethanes
US20120180802A1 (en) * 2010-06-17 2012-07-19 The Board Of Regents Of The University Of Texas System Shape memory devices and their use in controlling device-environment interactions
JP5634351B2 (en) 2010-09-07 2014-12-03 ダウ グローバル テクノロジーズ エルエルシー Coating composition
US8974217B2 (en) 2010-11-11 2015-03-10 Spirit Aerosystems, Inc. Reconfigurable shape memory polymer tooling supports
US8877114B2 (en) 2010-11-11 2014-11-04 Spirit Aerosystems, Inc. Method for removing a SMP apparatus from a cured composite part
US8815145B2 (en) 2010-11-11 2014-08-26 Spirit Aerosystems, Inc. Methods and systems for fabricating composite stiffeners with a rigid/malleable SMP apparatus
US8734703B2 (en) 2010-11-11 2014-05-27 Spirit Aerosystems, Inc. Methods and systems for fabricating composite parts using a SMP apparatus as a rigid lay-up tool and bladder
US8815054B2 (en) * 2012-10-05 2014-08-26 The Procter & Gamble Company Methods for making fibrous paper structures utilizing waterborne shape memory polymers
US9982163B2 (en) 2012-10-05 2018-05-29 Syracuse University Waterborne shape memory polymer coatings
EP2914645A4 (en) * 2012-11-02 2016-06-08 Univ Syracuse Reversible shape memory polymers exhibiting ambient actuation triggering
US9422393B2 (en) * 2012-11-13 2016-08-23 Syracuse University Water-triggered shape memory of PCL-PEG multiblock TPUs
JP2015186568A (en) 2014-03-13 2015-10-29 パナソニックIpマネジメント株式会社 massage device and massage method
CN106999637A (en) * 2014-09-23 2017-08-01 波士顿科学国际有限公司 Implantable medical device with shape-memory polymer filter layer
US9456914B2 (en) 2015-01-29 2016-10-04 Intact Vascular, Inc. Delivery device and method of delivery
US9192500B1 (en) 2015-01-29 2015-11-24 Intact Vascular, Inc. Delivery device and method of delivery
WO2016197087A1 (en) * 2015-06-05 2016-12-08 The University Of Rochester Shape-memory polymers and methods of making and use thereof
EP3312209B1 (en) 2016-10-20 2023-09-27 Samsung Electronics Co., Ltd. Self-healing composition, self-healing film, and device including the self-healing film
KR101995378B1 (en) * 2017-08-07 2019-07-03 한국생산기술연구원 Light-Curable Cohesive and Adhesive Composition
JP6850279B2 (en) 2017-11-21 2021-03-31 信越化学工業株式会社 Bioelectrode composition, bioelectrode, and method for producing bioelectrode
JP6978375B2 (en) * 2018-04-23 2021-12-08 信越化学工業株式会社 Adhesive film, method of forming adhesive film, and urethane polymer
CN110294832B (en) * 2019-07-16 2021-05-25 道勤材料技术(麻城)有限公司 Amino POSS modified polyurethane thermoplastic elastomer and preparation method thereof
CN110327783B (en) * 2019-08-15 2021-11-16 北京工商大学 Preparation method of pervaporation hybrid membrane for gasoline desulfurization
CN112759737B (en) * 2019-11-04 2022-07-12 中国石油化工股份有限公司 Triple shape memory polymer and preparation method thereof
KR102269037B1 (en) * 2020-12-17 2021-06-25 주식회사 건바이오 Mutifunctional medical polyurethane film having improved permeability by controlling fine porosity and method of manufacturing the same

Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3383336A (en) * 1966-06-27 1968-05-14 Kuyama Hiroshi Resinous insoluble reaction products
US3459725A (en) * 1964-01-17 1969-08-05 Montedison Spa High molecular weight unsaturated hydrocarbon homopolymers and process for preparing them
US3563973A (en) * 1965-03-04 1971-02-16 Radiation Applic Inc Articles with polymeric memory and method of constructing same
US4080357A (en) * 1976-06-07 1978-03-21 Shell Oil Company Multicomponent halogenated thermoplastic-block copolymer-polymer blends
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4531933A (en) * 1982-12-07 1985-07-30 C. R. Bard, Inc. Helical ureteral stent
US4612241A (en) * 1985-06-12 1986-09-16 E. I. Du Pont De Nemours And Company Impact resistant composites with elastomeric fibers
US4893623A (en) * 1986-12-09 1990-01-16 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US4969890A (en) * 1987-07-10 1990-11-13 Nippon Zeon Co., Ltd. Catheter
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US5007926A (en) * 1989-02-24 1991-04-16 The Trustees Of The University Of Pennsylvania Expandable transluminally implantable tubular prosthesis
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US5062829A (en) * 1989-03-17 1991-11-05 Carter Holt Harvey Plastic Products Group Limited Relates to devices for administering a substance such as a drug or chemical or the like
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US5145935A (en) * 1988-09-30 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Shape memory polyurethane elastomer molded article
US5147385A (en) * 1989-11-01 1992-09-15 Schneider (Europe) A.G. Stent and catheter for the introduction of the stent
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5189110A (en) * 1988-12-23 1993-02-23 Asahi Kasei Kogyo Kabushiki Kaisha Shape memory polymer resin, composition and the shape memorizing molded product thereof
US5258020A (en) * 1990-09-14 1993-11-02 Michael Froix Method of using expandable polymeric stent with memory
US5282854A (en) * 1989-10-11 1994-02-01 Daikin Industries Ltd. Fluorine-containing block copolymer and artificial lens comprising the same
US5395882A (en) * 1992-09-24 1995-03-07 Rohm Gmbh Chemische Fabrik Light-scattering polystyrene molding compounds, and molded articles produced therefrom
US5421955A (en) * 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5466242A (en) * 1994-02-02 1995-11-14 Mori; Katsushi Stent for biliary, urinary or vascular system
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5506300A (en) * 1985-01-04 1996-04-09 Thoratec Laboratories Corporation Compositions that soften at predetermined temperatures and the method of making same
US5645559A (en) * 1992-05-08 1997-07-08 Schneider (Usa) Inc Multiple layer stent
US5665822A (en) * 1991-10-07 1997-09-09 Landec Corporation Thermoplastic Elastomers
US5670161A (en) * 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US5674242A (en) * 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US5674241A (en) * 1995-02-22 1997-10-07 Menlo Care, Inc. Covered expanding mesh stent
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5755769A (en) * 1992-03-12 1998-05-26 Laboratoire Perouse Implant Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5776162A (en) * 1997-01-03 1998-07-07 Nitinol Medical Technologies, Inc. Vessel implantable shape memory appliance with superelastic hinged joint
US5800516A (en) * 1996-08-08 1998-09-01 Cordis Corporation Deployable and retrievable shape memory stent/tube and method
US5830179A (en) * 1996-04-09 1998-11-03 Endocare, Inc. Urological stent therapy system and method
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US5880240A (en) * 1996-04-03 1999-03-09 Arakawa Chemical Industries, Ltd. Alkyl-containing porous resin, process for its preparation and its use
US5889118A (en) * 1996-06-03 1999-03-30 Minnesota Mining And Manufacturing Company Thermomorphic "smart" pressure sensitive adhesives
US5908918A (en) * 1996-07-17 1999-06-01 Chronopol, Inc. Impact modified polylactide
US5910357A (en) * 1996-07-12 1999-06-08 Nitto Denko Corporation Separation membrane and method of producing the same, and shape memory polymer composition
US5955559A (en) * 1996-09-17 1999-09-21 Shell Oil Company Cast polyurethane elastomers containing low polarity amine curing agents
US5954744A (en) * 1995-06-06 1999-09-21 Quanam Medical Corporation Intravascular stent
US5964744A (en) * 1993-01-04 1999-10-12 Menlo Care, Inc. Polymeric medical device systems having shape memory
US6024764A (en) * 1997-08-19 2000-02-15 Intermedics, Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6033413A (en) * 1998-04-20 2000-03-07 Endocare, Inc. Stent delivery system
US6086204A (en) * 1999-09-20 2000-07-11 Magnante; Peter C. Methods and devices to design and fabricate surfaces on contact lenses and on corneal tissue that correct the eye's optical aberrations
US6086610A (en) * 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
US6183248B1 (en) * 1998-11-30 2001-02-06 Muhammad Chishti System and method for releasing tooth positioning appliances
US6217609B1 (en) * 1998-06-30 2001-04-17 Schneider (Usa) Inc Implantable endoprosthesis with patterned terminated ends and methods for making same
US6241691B1 (en) * 1997-12-05 2001-06-05 Micrus Corporation Coated superelastic stent
US6248129B1 (en) * 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US6283992B1 (en) * 1995-11-27 2001-09-04 Schneider (Europe) Gmbh Conical stent
US6287326B1 (en) * 1999-08-02 2001-09-11 Alsius Corporation Catheter with coiled multi-lumen heat transfer extension
US20010029398A1 (en) * 1999-06-03 2001-10-11 Jadhav Balkrishna S. Bioresorbable stent
US6315791B1 (en) * 1996-12-03 2001-11-13 Atrium Medical Corporation Self-expanding prothesis
US6323459B1 (en) * 1996-09-05 2001-11-27 Medtronic, Inc. Selectively activated shape memory device
US20020007222A1 (en) * 2000-04-11 2002-01-17 Ashvin Desai Method and apparatus for supporting a body organ
US20020015519A1 (en) * 1998-12-11 2002-02-07 Lord Corporation Fiber substrate adhesion and coatings by contact metathesis polymerization
US6348065B1 (en) * 1995-03-01 2002-02-19 Scimed Life Systems, Inc. Longitudinally flexible expandable stent
US6364904B1 (en) * 1999-07-02 2002-04-02 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US20020055787A1 (en) * 1998-10-15 2002-05-09 Charles D. Lennox Treating urinary retention
US6388043B1 (en) * 1998-02-23 2002-05-14 Mnemoscience Gmbh Shape memory polymers
US6413273B1 (en) * 1998-11-25 2002-07-02 Israel Aircraft Industries Ltd. Method and system for temporarily supporting a tubular organ
US20020137864A1 (en) * 2001-01-24 2002-09-26 Tong Tat Hung Shape memory styrene copolymer
US20020151967A1 (en) * 1996-04-09 2002-10-17 Mikus Paul W. Urological stent therapy system and method
US20020156523A1 (en) * 1994-08-31 2002-10-24 Lilip Lau Exterior supported self-expanding stent-graft
US6517569B2 (en) * 1998-09-14 2003-02-11 Endocare, Inc. Insertion device for stents and methods for use
US6517570B1 (en) * 1994-08-31 2003-02-11 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US20030040803A1 (en) * 2001-08-23 2003-02-27 Rioux Robert F. Maintaining an open passageway through a body lumen
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
US6538089B1 (en) * 1999-02-05 2003-03-25 Forskarpatent I Syd Ab Gels with a shape memory
US20030060793A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Disposable products having humidity activated materials with shape-memory
US20030060530A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Methods of making humidity activated materials having shape-memory
US6596818B1 (en) * 1996-10-08 2003-07-22 Alan M. Zamore Irradiation conversion of thermoplastic to thermoset polymers
US20030147046A1 (en) * 2002-02-06 2003-08-07 Shadduck John H. Adaptive optic lens system and method of use
US20030191276A1 (en) * 2002-02-26 2003-10-09 Mnemoscience Gmbh Polymeric networks
US6679605B2 (en) * 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20040014929A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Gmbh Polyester urethanes
US20040015187A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Corporation Biodegradable shape memory polymeric sutures
US20040015261A1 (en) * 2000-08-28 2004-01-22 Hofmann Gregory J. Shape memory polymer or alloy ophthalmic lens mold and methods of forming ophthalmic products
US20040024143A1 (en) * 2002-04-18 2004-02-05 Mnemoscience Gmbh Interpenetrating networks
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US20040116641A1 (en) * 2002-10-11 2004-06-17 Mather Patrick T. Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US6858680B2 (en) * 1999-07-20 2005-02-22 Aortech Biomaterials Pty Ltd Shape memory polyurethane or polyurethane-urea polymers
US20050216074A1 (en) * 2002-10-11 2005-09-29 Sahatjian Ronald A Implantable medical devices

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5641562A (en) * 1979-09-13 1981-04-18 Fujitsu Ltd Off-track correction system in magnetic disk unit
SE445884B (en) 1982-04-30 1986-07-28 Medinvent Sa DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION
JPS59170123A (en) * 1983-03-17 1984-09-26 Tokuyama Soda Co Ltd Polysilsesquioxane
AU5302086A (en) 1985-01-04 1986-07-29 Thoratec Laboratories Corp. Compositions that soften at predetermined temperatures and the method of making same
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
DE3817624A1 (en) 1988-05-25 1989-11-30 Bayer Ag MIXTURES MADE FROM METASTABLE AMORPHES, PARTIAL KIRSTALLINE THERMOPLASTICS
US4955377A (en) 1988-10-28 1990-09-11 Lennox Charles D Device and method for heating tissue in a patient's body
CA2002408A1 (en) 1988-11-11 1990-05-11 Shoji Suzuki Structural material and its application
EP0385443A3 (en) 1989-02-28 1990-10-10 Daikin Industries, Limited Polymer material having shape memory characteristics
US5358533A (en) * 1992-02-19 1994-10-25 Joint Medical Products Corporation Sintered coatings for implantable prostheses
JP3184328B2 (en) * 1992-08-17 2001-07-09 昭和電工株式会社 Curable resin composition and cured resin film formed from the composition
EP0674683B1 (en) 1992-12-21 1997-10-15 Raychem Corporation Polymeric blends
JPH06329752A (en) * 1993-05-26 1994-11-29 Nippon Polyurethane Ind Co Ltd Polyol composition for polyurethane
JPH07125440A (en) * 1993-11-02 1995-05-16 Japan Synthetic Rubber Co Ltd Polyurethane recording medium
JPH07124194A (en) * 1993-11-02 1995-05-16 Mitsubishi Cable Ind Ltd Eyepiece
NL9400519A (en) 1994-03-31 1995-11-01 Rijksuniversiteit Intravascular polymeric stent.
US5676685A (en) * 1995-06-22 1997-10-14 Razavi; Ali Temporary stent
DE19539449A1 (en) * 1995-10-24 1997-04-30 Biotronik Mess & Therapieg Process for the production of intraluminal stents from bioresorbable polymer material
US6060534A (en) * 1996-07-11 2000-05-09 Scimed Life Systems, Inc. Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
JPH1087834A (en) * 1996-09-10 1998-04-07 Showa Denko Kk Polyorganosilsesquioxane, its production, and resin composition containing the same compound
JPH10297110A (en) * 1997-04-25 1998-11-10 Mitsubishi Chem Corp Recording medium
US6056844A (en) 1997-06-06 2000-05-02 Triton Systems, Inc. Temperature-controlled induction heating of polymeric materials
RU2215542C2 (en) * 1998-02-23 2003-11-10 Массачусетс Инститьют Оф Текнолоджи Biodecomposing polymers able recovery of form
KR20010041801A (en) * 1998-03-11 2001-05-25 그래햄 이. 테일러 Structures and fabricated articles having shape memory made from alpha-olefin/vinyl or vinylidene aromatic and/or hindered aliphatic vinyl or vinylidene interpolymers
US6312461B1 (en) * 1998-08-21 2001-11-06 John D. Unsworth Shape memory tubular stent
DE69822470T2 (en) * 1998-11-12 2005-01-20 Takiron Co. Ltd. Biodegradable absorbable shape memory material
US6336937B1 (en) * 1998-12-09 2002-01-08 Gore Enterprise Holdings, Inc. Multi-stage expandable stent-graft
US6623823B1 (en) * 1998-12-31 2003-09-23 Ethicon, Inc. Radiopaque polymer coating
MXPA01012033A (en) 1999-05-24 2002-11-04 California Inst Of Techn Imidazolidine-based metal carbene metathesis catalysts.
AU6524400A (en) 1999-08-04 2001-03-05 Hybrid Plastics Process for the formation of polyhedral oligomeric silsesquioxanes
JP2001205689A (en) * 2000-01-26 2001-07-31 Mitsubishi Cable Ind Ltd Method for manufacturing polyurethane thermoplastic elastomer tube
WO2001056641A1 (en) * 2000-02-04 2001-08-09 C. R. Bard, Inc. Triple lumen stone balloon catheter and method
ATE275986T1 (en) 2000-05-31 2004-10-15 Mnemoscience Gmbh MEMORY THERMOPLASTIC AND POLYMER NETWORKS FOR TISSUE CONSTRUCTION
ES2257436T3 (en) * 2000-08-23 2006-08-01 Thoratec Corporation VASCULATOR IMPLANTS COVERED AND USE PROCEDURES.
JP2002069191A (en) * 2000-08-31 2002-03-08 Dow Corning Asia Ltd Method of producing hydrogenated octasilsesquioxane- hydroxyl group containing compound copolymer
US6607553B1 (en) 2000-11-17 2003-08-19 B. Braun Medical, Inc. Method for deploying a thermo-mechanically expandable stent
US6550480B2 (en) * 2001-01-31 2003-04-22 Numed/Tech Llc Lumen occluders made from thermodynamic materials
WO2002083786A1 (en) 2001-04-11 2002-10-24 Cheong Seok Hong Shape memory rubber composition
DE10152146A1 (en) 2001-10-25 2003-05-22 Ticona Gmbh Process for reducing the toughness of molded plastic parts to be machined and their use
US6866805B2 (en) * 2001-12-27 2005-03-15 Advanced Cardiovascular Systems, Inc. Hybrid intravascular stent
BR0304411A (en) 2002-04-10 2004-07-27 Mnemoscience Gmbh Process for producing impression memory effects on hair by combining impression memory polymers with cationative active substances
DE10215858A1 (en) 2002-04-10 2004-03-18 Mnemoscience Gmbh Process for hair treatment with shape memory polymers
AU2003254333A1 (en) 2002-07-10 2004-02-02 Mnemoscience Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
WO2004011525A1 (en) 2002-07-30 2004-02-05 University Of Connecticut Nonionic telechelic polymers incorporating polyhedral oligosilsesquioxane (poss) and uses thereof
EP1558671B1 (en) 2002-10-11 2011-02-16 University of Connecticut Blends of amorphous and semicrystalline polymers having shape memory properties
JP4805148B2 (en) 2003-07-18 2011-11-02 ボストン サイエンティフィック リミテッド Medical instruments
GB0401202D0 (en) 2004-01-20 2004-02-25 Ucl Biomedica Plc Polymer for use in conduits and medical devices

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459725A (en) * 1964-01-17 1969-08-05 Montedison Spa High molecular weight unsaturated hydrocarbon homopolymers and process for preparing them
US3563973A (en) * 1965-03-04 1971-02-16 Radiation Applic Inc Articles with polymeric memory and method of constructing same
US3383336A (en) * 1966-06-27 1968-05-14 Kuyama Hiroshi Resinous insoluble reaction products
US4080357A (en) * 1976-06-07 1978-03-21 Shell Oil Company Multicomponent halogenated thermoplastic-block copolymer-polymer blends
US4531933A (en) * 1982-12-07 1985-07-30 C. R. Bard, Inc. Helical ureteral stent
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US5506300A (en) * 1985-01-04 1996-04-09 Thoratec Laboratories Corporation Compositions that soften at predetermined temperatures and the method of making same
US4612241A (en) * 1985-06-12 1986-09-16 E. I. Du Pont De Nemours And Company Impact resistant composites with elastomeric fibers
US4893623A (en) * 1986-12-09 1990-01-16 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US4969890A (en) * 1987-07-10 1990-11-13 Nippon Zeon Co., Ltd. Catheter
US5089005A (en) * 1987-08-13 1992-02-18 Terumo Kabushiki Kaisha Catheter for the introduction of an expandable member
US5145935A (en) * 1988-09-30 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Shape memory polyurethane elastomer molded article
US5496311A (en) * 1988-10-28 1996-03-05 Boston Scientific Corporation Physiologic low stress angioplasty
US5189110A (en) * 1988-12-23 1993-02-23 Asahi Kasei Kogyo Kabushiki Kaisha Shape memory polymer resin, composition and the shape memorizing molded product thereof
US5007926A (en) * 1989-02-24 1991-04-16 The Trustees Of The University Of Pennsylvania Expandable transluminally implantable tubular prosthesis
US5062829A (en) * 1989-03-17 1991-11-05 Carter Holt Harvey Plastic Products Group Limited Relates to devices for administering a substance such as a drug or chemical or the like
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US5282854A (en) * 1989-10-11 1994-02-01 Daikin Industries Ltd. Fluorine-containing block copolymer and artificial lens comprising the same
US5147385A (en) * 1989-11-01 1992-09-15 Schneider (Europe) A.G. Stent and catheter for the introduction of the stent
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5163952A (en) * 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5607467A (en) * 1990-09-14 1997-03-04 Froix; Michael Expandable polymeric stent with memory and delivery apparatus and method
US6248129B1 (en) * 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5258020A (en) * 1990-09-14 1993-11-02 Michael Froix Method of using expandable polymeric stent with memory
US5769883A (en) * 1991-10-04 1998-06-23 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5665822A (en) * 1991-10-07 1997-09-09 Landec Corporation Thermoplastic Elastomers
US5421955A (en) * 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5421955B1 (en) * 1991-10-28 1998-01-20 Advanced Cardiovascular System Expandable stents and method for making same
US5755769A (en) * 1992-03-12 1998-05-26 Laboratoire Perouse Implant Expansible endoprosthesis for a human or animal tubular organ, and fitting tool for use thereof
US5645559A (en) * 1992-05-08 1997-07-08 Schneider (Usa) Inc Multiple layer stent
US5395882A (en) * 1992-09-24 1995-03-07 Rohm Gmbh Chemische Fabrik Light-scattering polystyrene molding compounds, and molded articles produced therefrom
US5964744A (en) * 1993-01-04 1999-10-12 Menlo Care, Inc. Polymeric medical device systems having shape memory
US5466242A (en) * 1994-02-02 1995-11-14 Mori; Katsushi Stent for biliary, urinary or vascular system
US5876432A (en) * 1994-04-01 1999-03-02 Gore Enterprise Holdings, Inc. Self-expandable helical intravascular stent and stent-graft
US20020156523A1 (en) * 1994-08-31 2002-10-24 Lilip Lau Exterior supported self-expanding stent-graft
US6517570B1 (en) * 1994-08-31 2003-02-11 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US5674241A (en) * 1995-02-22 1997-10-07 Menlo Care, Inc. Covered expanding mesh stent
US5968070A (en) * 1995-02-22 1999-10-19 Cordis Corporation Covered expanding mesh stent
US6348065B1 (en) * 1995-03-01 2002-02-19 Scimed Life Systems, Inc. Longitudinally flexible expandable stent
US5741333A (en) * 1995-04-12 1998-04-21 Corvita Corporation Self-expanding stent for a medical device to be introduced into a cavity of a body
US5954744A (en) * 1995-06-06 1999-09-21 Quanam Medical Corporation Intravascular stent
US5674242A (en) * 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
US6283992B1 (en) * 1995-11-27 2001-09-04 Schneider (Europe) Gmbh Conical stent
US5880240A (en) * 1996-04-03 1999-03-09 Arakawa Chemical Industries, Ltd. Alkyl-containing porous resin, process for its preparation and its use
US5928217A (en) * 1996-04-09 1999-07-27 Endocare, Inc. Urological stent therapy system and method
US6416545B1 (en) * 1996-04-09 2002-07-09 Endocare, Inc. Urological stent therapy system and method
US20020151967A1 (en) * 1996-04-09 2002-10-17 Mikus Paul W. Urological stent therapy system and method
US5830179A (en) * 1996-04-09 1998-11-03 Endocare, Inc. Urological stent therapy system and method
US6174305B1 (en) * 1996-04-09 2001-01-16 Endocare, Inc. Urological stent therapy system and method
US6139536A (en) * 1996-04-09 2000-10-31 Endocare, Inc. Urological stent therapy system and method
US5670161A (en) * 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US5889118A (en) * 1996-06-03 1999-03-30 Minnesota Mining And Manufacturing Company Thermomorphic "smart" pressure sensitive adhesives
US5910357A (en) * 1996-07-12 1999-06-08 Nitto Denko Corporation Separation membrane and method of producing the same, and shape memory polymer composition
US5908918A (en) * 1996-07-17 1999-06-01 Chronopol, Inc. Impact modified polylactide
US5800516A (en) * 1996-08-08 1998-09-01 Cordis Corporation Deployable and retrievable shape memory stent/tube and method
US6323459B1 (en) * 1996-09-05 2001-11-27 Medtronic, Inc. Selectively activated shape memory device
US5955559A (en) * 1996-09-17 1999-09-21 Shell Oil Company Cast polyurethane elastomers containing low polarity amine curing agents
US6596818B1 (en) * 1996-10-08 2003-07-22 Alan M. Zamore Irradiation conversion of thermoplastic to thermoset polymers
US6086610A (en) * 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
US6179878B1 (en) * 1996-10-22 2001-01-30 Thomas Duerig Composite self expanding stent device having a restraining element
US6315791B1 (en) * 1996-12-03 2001-11-13 Atrium Medical Corporation Self-expanding prothesis
US5776162A (en) * 1997-01-03 1998-07-07 Nitinol Medical Technologies, Inc. Vessel implantable shape memory appliance with superelastic hinged joint
US6024764A (en) * 1997-08-19 2000-02-15 Intermedics, Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6395038B1 (en) * 1997-08-19 2002-05-28 Intermedics Inc. Apparatus for imparting physician-determined shapes to implantable tubular devices
US6241691B1 (en) * 1997-12-05 2001-06-05 Micrus Corporation Coated superelastic stent
US6720402B2 (en) * 1998-02-23 2004-04-13 Mnemoscience Gmbh Shape memory polymers
US6388043B1 (en) * 1998-02-23 2002-05-14 Mnemoscience Gmbh Shape memory polymers
US6033413A (en) * 1998-04-20 2000-03-07 Endocare, Inc. Stent delivery system
US6217609B1 (en) * 1998-06-30 2001-04-17 Schneider (Usa) Inc Implantable endoprosthesis with patterned terminated ends and methods for making same
US6517569B2 (en) * 1998-09-14 2003-02-11 Endocare, Inc. Insertion device for stents and methods for use
US20020055787A1 (en) * 1998-10-15 2002-05-09 Charles D. Lennox Treating urinary retention
US6413273B1 (en) * 1998-11-25 2002-07-02 Israel Aircraft Industries Ltd. Method and system for temporarily supporting a tubular organ
US6183248B1 (en) * 1998-11-30 2001-02-06 Muhammad Chishti System and method for releasing tooth positioning appliances
US20020015519A1 (en) * 1998-12-11 2002-02-07 Lord Corporation Fiber substrate adhesion and coatings by contact metathesis polymerization
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
US6538089B1 (en) * 1999-02-05 2003-03-25 Forskarpatent I Syd Ab Gels with a shape memory
US6368346B1 (en) * 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US20010029398A1 (en) * 1999-06-03 2001-10-11 Jadhav Balkrishna S. Bioresorbable stent
US6364904B1 (en) * 1999-07-02 2002-04-02 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US6858680B2 (en) * 1999-07-20 2005-02-22 Aortech Biomaterials Pty Ltd Shape memory polyurethane or polyurethane-urea polymers
US6287326B1 (en) * 1999-08-02 2001-09-11 Alsius Corporation Catheter with coiled multi-lumen heat transfer extension
US6086204A (en) * 1999-09-20 2000-07-11 Magnante; Peter C. Methods and devices to design and fabricate surfaces on contact lenses and on corneal tissue that correct the eye's optical aberrations
US20020007222A1 (en) * 2000-04-11 2002-01-17 Ashvin Desai Method and apparatus for supporting a body organ
US6679605B2 (en) * 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20040015261A1 (en) * 2000-08-28 2004-01-22 Hofmann Gregory J. Shape memory polymer or alloy ophthalmic lens mold and methods of forming ophthalmic products
US20020137864A1 (en) * 2001-01-24 2002-09-26 Tong Tat Hung Shape memory styrene copolymer
US20030060793A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Disposable products having humidity activated materials with shape-memory
US20030060530A1 (en) * 2001-07-24 2003-03-27 Topolkaraev Vasily A. Methods of making humidity activated materials having shape-memory
US20030040803A1 (en) * 2001-08-23 2003-02-27 Rioux Robert F. Maintaining an open passageway through a body lumen
US20030147046A1 (en) * 2002-02-06 2003-08-07 Shadduck John H. Adaptive optic lens system and method of use
US20030191276A1 (en) * 2002-02-26 2003-10-09 Mnemoscience Gmbh Polymeric networks
US20040014929A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Gmbh Polyester urethanes
US20040015187A1 (en) * 2002-04-18 2004-01-22 Mnemoscience Corporation Biodegradable shape memory polymeric sutures
US20040024143A1 (en) * 2002-04-18 2004-02-05 Mnemoscience Gmbh Interpenetrating networks
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US20040116641A1 (en) * 2002-10-11 2004-06-17 Mather Patrick T. Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US20050216074A1 (en) * 2002-10-11 2005-09-29 Sahatjian Ronald A Implantable medical devices

Cited By (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222677A1 (en) * 1995-06-07 2005-10-06 Bates Brian L Coated implantable medical device
US20090285975A1 (en) * 1995-06-07 2009-11-19 Bates Brian L Methods for making implantable medical devices
US20060195176A1 (en) * 1995-06-07 2006-08-31 Cook Incorporated Coated implantable medical device
US20070150047A1 (en) * 1995-06-07 2007-06-28 Med Institute, Inc. Implantable medical device with bioabsorbable coating
US20080145398A1 (en) * 1995-06-07 2008-06-19 Bates Brian L Coated implantable medical device
US20080215138A1 (en) * 1995-06-07 2008-09-04 Bates Brian L Coated implantable medical device
US8556962B2 (en) 1995-06-07 2013-10-15 Cook Medical Technologies Llc Coated implantable medical device
US20080147166A1 (en) * 1995-06-07 2008-06-19 Bates Brian L Coated implantable medical device
US8945206B2 (en) 1995-06-07 2015-02-03 Cook Medical Technologies Llc Methods for making implantable medical devices
US8758428B2 (en) 1995-06-07 2014-06-24 Cook Medical Technologies Llc Coated implantable medical device
US20080145399A1 (en) * 1995-06-07 2008-06-19 Bates Brian L Coated implantable medical device
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7901453B2 (en) * 1995-06-07 2011-03-08 Cook Incorporated Coated implantable medical device
US8469943B2 (en) 1995-06-07 2013-06-25 Cook Medical Technologies Llc Coated implantable medical device
US8313521B2 (en) 1995-06-07 2012-11-20 Cook Medical Technologies Llc Method of delivering an implantable medical device with a bioabsorbable coating
US20110046723A1 (en) * 1995-06-07 2011-02-24 Bates Brian L Coated implantable medical device
US8257433B2 (en) 1995-06-07 2012-09-04 Cook Medical Technologies Llc Coated implantable medical device
US8540663B2 (en) 1998-02-24 2013-09-24 Navilyst Medical, Inc. High flow rate dialysis catheters and related methods
US20090012481A1 (en) * 1998-02-24 2009-01-08 Davey Christopher T High Flow Rate Dialysis Catheters and Related Methods
US8066763B2 (en) 1998-04-11 2011-11-29 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US20100286763A1 (en) * 1998-04-11 2010-11-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US8303643B2 (en) 2001-06-27 2012-11-06 Remon Medical Technologies Ltd. Method and device for electrochemical formation of therapeutic species in vivo
US20040030062A1 (en) * 2002-05-02 2004-02-12 Mather Patrick T. Castable shape memory polymers
US20060041089A1 (en) * 2002-05-02 2006-02-23 Mather Patrick T Castable shape memory polymers
US7173096B2 (en) 2002-10-11 2007-02-06 University Of Connecticut Crosslinked polycyclooctene
US7524914B2 (en) 2002-10-11 2009-04-28 The University Of Connecticut Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20070135578A1 (en) * 2002-10-11 2007-06-14 Mather Patrick T Blends of amorphous and semicrystalline polymers having shape memory properties
US7208550B2 (en) * 2002-10-11 2007-04-24 The University Of Connecticut Blends of amorphous and semicrystalline polymers having shape memory properties
US20070142562A1 (en) * 2002-10-11 2007-06-21 Mather Patrick T Crosslinked polycyclooctene
US20040122184A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Crosslinked polycyclooctene
US20110054591A1 (en) * 2002-10-11 2011-03-03 Boston Scientific Scimed, Inc., a Delaware corporation Implantable medical devices
US8784465B2 (en) 2002-10-11 2014-07-22 Boston Scientific Scimed, Inc. Implantable medical devices
US7906573B2 (en) 2002-10-11 2011-03-15 University Of Connecticut Crosslinked polycyclooctene
US7976936B2 (en) 2002-10-11 2011-07-12 University Of Connecticut Endoprostheses
US20100331954A1 (en) * 2002-10-11 2010-12-30 Scimed Life Systems, Inc. A Minnesota Corporation Implantable medical devices
US7563848B2 (en) 2002-10-11 2009-07-21 University Of Connecticut Crosslinked polycyclooctene
US20090253842A1 (en) * 2002-10-11 2009-10-08 Mather Patrick T Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20100160522A1 (en) * 2002-10-11 2010-06-24 Mather Patrick T Crosslinked polycyclooctene
US20050216074A1 (en) * 2002-10-11 2005-09-29 Sahatjian Ronald A Implantable medical devices
US20050245719A1 (en) * 2002-10-11 2005-11-03 Mather Patrick T Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments
US20040122174A1 (en) * 2002-10-11 2004-06-24 Mather Patrick T. Blends of amorphous and semicrystalline polymers having shape memory properties
US20050251249A1 (en) * 2002-10-11 2005-11-10 Sahatjian Ronald A Endoprostheses
US20090275704A1 (en) * 2002-10-11 2009-11-05 Mather Patrick T Crosslinked polycyclooctene
US9115245B2 (en) 2002-10-11 2015-08-25 Boston Scientific Scimed, Inc. Implantable medical devices
US7371799B2 (en) 2002-10-11 2008-05-13 University Of Connecticut Blends of amorphous and semicrystalline polymers having shape memory properties
US7795350B2 (en) 2002-10-11 2010-09-14 Connecticut, University Of Blends of amorphous and semicrystalline polymers having shape memory properties
US7794494B2 (en) 2002-10-11 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices
US20080249245A1 (en) * 2002-10-11 2008-10-09 Mather Patrick T Blends of amorphous and semicrystalline polymers having shape memory properties
US7705098B2 (en) 2002-10-11 2010-04-27 University Of Connecticut Crosslinked polycyclooctene
US20050021131A1 (en) * 2003-06-16 2005-01-27 Subramanian Venkatraman Polymeric stent and method of manufacture
US20080208321A1 (en) * 2003-06-16 2008-08-28 Nanyang Technological University Polymeric stent and method of manufacture
US20110172753A1 (en) * 2003-07-18 2011-07-14 University of Connecticut, a Connecticut public institution of higher education Endoprostheses
US7452956B2 (en) * 2003-10-10 2008-11-18 Dow Corning Corporation Urethane compositions containing carbinol-functional silicone resins
US20070093618A1 (en) * 2003-10-10 2007-04-26 Tammy Cheng Urethane compositions containing carbinol-functional silicone resins
US7820769B2 (en) * 2004-01-20 2010-10-26 Ucl Biomedica Plc Polymer for use in conduits, medical devices and biomedical surface modification
US20080233164A1 (en) * 2004-01-20 2008-09-25 Ucl Biomedical Plc Polymer for Use in Conduits, Medical Devices and Biomedical Surface Modification
US8998973B2 (en) 2004-03-02 2015-04-07 Boston Scientific Scimed, Inc. Medical devices including metallic films
US20050197689A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US20050197687A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US20050197690A1 (en) * 2004-03-02 2005-09-08 Masoud Molaei Medical devices including metallic films and methods for making same
US8591568B2 (en) 2004-03-02 2013-11-26 Boston Scientific Scimed, Inc. Medical devices including metallic films and methods for making same
US20100204778A1 (en) * 2004-04-02 2010-08-12 Arterial Remodelling Technologies, Inc. Polymer-based stent assembly
US9283094B2 (en) * 2004-04-02 2016-03-15 Arterial Remodelling Technologies, Inc. Polymer-based stent assembly
US8999364B2 (en) 2004-06-15 2015-04-07 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US20080039921A1 (en) * 2004-06-30 2008-02-14 Wallsten Medical S.A. Balloon Catheter
US20100280612A1 (en) * 2004-12-09 2010-11-04 Boston Scientific Scimed, Inc. Medical Devices Having Vapor Deposited Nanoporous Coatings For Controlled Therapeutic Agent Delivery
US20060129232A1 (en) * 2004-12-10 2006-06-15 Dicarlo Paul Implantable medical devices, and methods of delivering the same
US8043361B2 (en) 2004-12-10 2011-10-25 Boston Scientific Scimed, Inc. Implantable medical devices, and methods of delivering the same
US8992592B2 (en) 2004-12-29 2015-03-31 Boston Scientific Scimed, Inc. Medical devices including metallic films
US20110144740A1 (en) * 2004-12-29 2011-06-16 Boston Scientific Scimed, Inc. Medical Devices Including Metallic Film and at Least One Filament
US20060142845A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for making same
US20060142842A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for making same
US7901447B2 (en) 2004-12-29 2011-03-08 Boston Scientific Scimed, Inc. Medical devices including a metallic film and at least one filament
US8632580B2 (en) 2004-12-29 2014-01-21 Boston Scientific Scimed, Inc. Flexible medical devices including metallic films
US20060142838A1 (en) * 2004-12-29 2006-06-29 Masoud Molaei Medical devices including metallic films and methods for loading and deploying same
US8864815B2 (en) 2004-12-29 2014-10-21 Boston Scientific Scimed, Inc. Medical devices including metallic film and at least one filament
US20060171981A1 (en) * 2005-02-01 2006-08-03 Richard Robert E Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
US8075906B2 (en) 2005-02-01 2011-12-13 Boston Scientific Scimed, Inc. Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
US8992512B2 (en) 2005-02-01 2015-03-31 Boston Scientific Scimed, Inc. Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species
US20100318183A1 (en) * 2005-02-28 2010-12-16 Keraenen Olli System For Improving The Function Of A Heart Valve
US9526614B2 (en) * 2005-02-28 2016-12-27 Medtentia International Ltd. Oy System for improving the function of a heart valve
US20060259051A1 (en) * 2005-04-08 2006-11-16 Alveolus, Inc. Duodenum stent and associated method
US8323350B2 (en) 2005-04-08 2012-12-04 Merit Medical Systems, Inc. Duodenum stent and associated method
US20060259113A1 (en) * 2005-04-26 2006-11-16 Alveolus, Inc. Esophageal stent and associated method
US8834558B2 (en) 2005-04-26 2014-09-16 Merit Medical Systems, Inc. Esophageal stent and associated method
US20100204784A1 (en) * 2005-05-16 2010-08-12 Boston Scientific Scimed, Inc. Medical devices including metallic films
US20060259131A1 (en) * 2005-05-16 2006-11-16 Masoud Molaei Medical devices including metallic films and methods for making same
US7854760B2 (en) * 2005-05-16 2010-12-21 Boston Scientific Scimed, Inc. Medical devices including metallic films
US8152841B2 (en) 2005-05-16 2012-04-10 Boston Scientific Scimed, Inc. Medical devices including metallic films
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
US20070038176A1 (en) * 2005-07-05 2007-02-15 Jan Weber Medical devices with machined layers for controlled communications with underlying regions
US8758429B2 (en) * 2005-07-15 2014-06-24 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US20090123515A1 (en) * 2005-07-15 2009-05-14 Doug Taylor Polymer coatings containing drug powder of controlled morphology
US9827117B2 (en) 2005-07-15 2017-11-28 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10898353B2 (en) 2005-07-15 2021-01-26 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US10835396B2 (en) 2005-07-15 2020-11-17 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US11911301B2 (en) 2005-07-15 2024-02-27 Micell Medtech Inc. Polymer coatings containing drug powder of controlled morphology
US10195029B2 (en) 2005-09-07 2019-02-05 Medtentia Internatinal Ltd Oy Device and method for improving the function of a heart valve
US11241314B2 (en) 2005-09-07 2022-02-08 Medtentia International Ltd Oy Device and method for improving the function of a heart valve
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
US20070135751A1 (en) * 2005-12-09 2007-06-14 Dicarlo Paul D Medical devices
US20070156231A1 (en) * 2006-01-05 2007-07-05 Jan Weber Bioerodible endoprostheses and methods of making the same
US8840660B2 (en) 2006-01-05 2014-09-23 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8277498B2 (en) 2006-01-06 2012-10-02 Advanced Cardiovascular Systems, Inc. System for delivery of a stent at an elevated temperature
US20090026650A1 (en) * 2006-01-06 2009-01-29 Vipul Bhupendra Dave Method of forming a bioabsorbable drug delivery devices
US20110196471A1 (en) * 2006-01-06 2011-08-11 Advanced Cardiovascular Systems, Inc. Delivery of a Stent at an Elevated Temperature
US7951185B1 (en) * 2006-01-06 2011-05-31 Advanced Cardiovascular Systems, Inc. Delivery of a stent at an elevated temperature
US7927529B2 (en) * 2006-01-06 2011-04-19 Cordis Corporation Method of forming bioabsorbable drug delivery devices
US8089029B2 (en) 2006-02-01 2012-01-03 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US20070178129A1 (en) * 2006-02-01 2007-08-02 Boston Scientific Scimed, Inc. Bioabsorbable metal medical device and method of manufacture
US9526814B2 (en) 2006-02-16 2016-12-27 Boston Scientific Scimed, Inc. Medical balloons and methods of making the same
US20070191931A1 (en) * 2006-02-16 2007-08-16 Jan Weber Bioerodible endoprostheses and methods of making the same
US20070191923A1 (en) * 2006-02-16 2007-08-16 Jan Weber Medical balloons and methods of making the same
US20070224244A1 (en) * 2006-03-22 2007-09-27 Jan Weber Corrosion resistant coatings for biodegradable metallic implants
US8574615B2 (en) 2006-03-24 2013-11-05 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US20100233238A1 (en) * 2006-03-24 2010-09-16 Boston Scientific Scimed, Inc. Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US20070224116A1 (en) * 2006-03-27 2007-09-27 Chandru Chandrasekaran Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8048150B2 (en) 2006-04-12 2011-11-01 Boston Scientific Scimed, Inc. Endoprosthesis having a fiber meshwork disposed thereon
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US11007307B2 (en) 2006-04-26 2021-05-18 Micell Technologies, Inc. Coatings containing multiple drugs
US20090186069A1 (en) * 2006-04-26 2009-07-23 Micell Technologies, Inc. Coatings Containing Multiple Drugs
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9737645B2 (en) 2006-04-26 2017-08-22 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US20110189377A1 (en) * 2006-05-12 2011-08-04 Boston Scientific Scimed, Inc. Coating for Medical Devices Comprising An Inorganic or Ceramic Oxide and a Therapeutic Agent
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
US10849770B2 (en) 2006-05-17 2020-12-01 C. R. Bard, Inc. Bend-capable tubular prosthesis
US20070271763A1 (en) * 2006-05-25 2007-11-29 Bin Huang Method of crimping a polymeric stent
US7966708B2 (en) 2006-05-25 2011-06-28 Advanced Cardiovascular Systems, Inc. Method of crimping a polymeric stent
US7761968B2 (en) * 2006-05-25 2010-07-27 Advanced Cardiovascular Systems, Inc. Method of crimping a polymeric stent
US20100242254A1 (en) * 2006-05-25 2010-09-30 Bin Huang Method Of Crimping A Polymeric Stent
US7951194B2 (en) 2006-05-26 2011-05-31 Abbott Cardiovascular Sysetms Inc. Bioabsorbable stent with radiopaque coating
US20080097620A1 (en) * 2006-05-26 2008-04-24 Nanyang Technological University Implantable article, method of forming same and method for reducing thrombogenicity
US20080009939A1 (en) * 2006-05-26 2008-01-10 Gueriguian Vincent J Bioabsorbable stent with radiopaque coating
US20080161900A1 (en) * 2006-06-20 2008-07-03 Boston Scientific Scimed, Inc. Medical devices including composites
US9011516B2 (en) 2006-06-20 2015-04-21 Boston Scientific Scimed, Inc. Medical devices including composites
US20110169197A1 (en) * 2006-06-28 2011-07-14 Bin Huang Fabricating Polymer Stents with Injection Molding
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
US20080004691A1 (en) * 2006-06-29 2008-01-03 Boston Scientific Scimed, Inc. Medical devices with selective coating
US8771343B2 (en) 2006-06-29 2014-07-08 Boston Scientific Scimed, Inc. Medical devices with selective titanium oxide coatings
US9265866B2 (en) 2006-08-01 2016-02-23 Abbott Cardiovascular Systems Inc. Composite polymeric and metallic stent with radiopacity
US20080058919A1 (en) * 2006-08-01 2008-03-06 Kramer-Brown Pamela A Composite polymeric and metallic stent with radiopacity
US8052743B2 (en) 2006-08-02 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis with three-dimensional disintegration control
US20080131479A1 (en) * 2006-08-02 2008-06-05 Jan Weber Endoprosthesis with three-dimensional disintegration control
US20080051759A1 (en) * 2006-08-24 2008-02-28 Boston Scientific Scimed, Inc. Polycarbonate polyurethane venous access devices
US8353949B2 (en) 2006-09-14 2013-01-15 Boston Scientific Scimed, Inc. Medical devices with drug-eluting coating
EP2399616A1 (en) 2006-09-15 2011-12-28 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8057534B2 (en) 2006-09-15 2011-11-15 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US7955382B2 (en) 2006-09-15 2011-06-07 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
US20080086201A1 (en) * 2006-09-15 2008-04-10 Boston Scientific Scimed, Inc. Magnetized bioerodible endoprosthesis
US8052744B2 (en) 2006-09-15 2011-11-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20080071351A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis with adjustable surface features
US20080082162A1 (en) * 2006-09-15 2008-04-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8808726B2 (en) 2006-09-15 2014-08-19 Boston Scientific Scimed. Inc. Bioerodible endoprostheses and methods of making the same
US8128689B2 (en) 2006-09-15 2012-03-06 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US20080109072A1 (en) * 2006-09-15 2008-05-08 Boston Scientific Scimed, Inc. Medical devices and methods of making the same
US20080071353A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Endoprosthesis containing magnetic induction particles
US20080071352A1 (en) * 2006-09-15 2008-03-20 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis with biostable inorganic layers
US8002821B2 (en) 2006-09-18 2011-08-23 Boston Scientific Scimed, Inc. Bioerodible metallic ENDOPROSTHESES
US7963942B2 (en) 2006-09-20 2011-06-21 Boston Scientific Scimed, Inc. Medical balloons with modified surfaces
US20080097302A1 (en) * 2006-09-20 2008-04-24 Boston Scientific Scimed, Inc. Medical balloons with modified surfaces
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US20080086195A1 (en) * 2006-10-05 2008-04-10 Boston Scientific Scimed, Inc. Polymer-Free Coatings For Medical Devices Formed By Plasma Electrolytic Deposition
US20080097577A1 (en) * 2006-10-20 2008-04-24 Boston Scientific Scimed, Inc. Medical device hydrogen surface treatment by electrochemical reduction
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080095919A1 (en) * 2006-10-23 2008-04-24 Mcclain James B Holder For Electrically Charging A Substrate During Coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US10500075B2 (en) 2006-11-10 2019-12-10 C. R. Bard, Inc. Stent
US20100249903A1 (en) * 2006-11-10 2010-09-30 C. R. Bard, Inc. Stent
US8551156B2 (en) * 2006-11-10 2013-10-08 C. R. Bard, Inc. Stent
US20080132988A1 (en) * 2006-12-01 2008-06-05 Scimed Life Systems, Inc. Balloon geometry for delivery and deployment of shape memory polymer stent with flares
US8080055B2 (en) 2006-12-28 2011-12-20 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US8715339B2 (en) 2006-12-28 2014-05-06 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20080161906A1 (en) * 2006-12-28 2008-07-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
WO2008086369A1 (en) * 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
US9737642B2 (en) 2007-01-08 2017-08-22 Micell Technologies, Inc. Stents having biodegradable layers
US10617795B2 (en) 2007-01-08 2020-04-14 Micell Technologies, Inc. Stents having biodegradable layers
US20080199646A1 (en) * 2007-02-15 2008-08-21 Medtronic Vascular, Inc. Inline Particle Deposition Extrusion
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US9486338B2 (en) 2007-04-17 2016-11-08 Micell Technologies, Inc. Stents having controlled elution
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9775729B2 (en) 2007-04-17 2017-10-03 Micell Technologies, Inc. Stents having controlled elution
US20100272778A1 (en) * 2007-04-17 2010-10-28 Micell Technologies, Inc. Stents having controlled elution
US20100211164A1 (en) * 2007-04-17 2010-08-19 Mcclain James B Stents having biodegradable layers
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US20080294246A1 (en) * 2007-05-23 2008-11-27 Boston Scientific Scimed, Inc. Endoprosthesis with Select Ceramic Morphology
US20100228348A1 (en) * 2007-05-25 2010-09-09 Micell Technologies, Inc. Polymer Films for Medical Device Coating
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US20080303194A1 (en) * 2007-06-08 2008-12-11 Sabic Innovative Plastics Ip B.V. Mold apparatus for forming polymer and method
US8840386B2 (en) 2007-06-08 2014-09-23 Sabic Innovative Plastics Ip B.V. Mold apparatus for forming polymer and method
US8021135B2 (en) 2007-06-08 2011-09-20 Sabic Innovative Plastics Ip B.V. Mold apparatus for forming polymer and method
US8435283B2 (en) 2007-06-13 2013-05-07 Boston Scientific Scimed, Inc. Anti-migration features and geometry for a shape memory polymer stent
US10117759B2 (en) 2007-06-13 2018-11-06 Boston Scientific Scimed, Inc. Anti-migration features and geometry for a shape memory polymer stent
US20080319540A1 (en) * 2007-06-13 2008-12-25 Boston Scientific Scimed, Inc. Anti-migration features and geometry for a shape memory polymer stent
US20090018639A1 (en) * 2007-07-11 2009-01-15 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US20090029077A1 (en) * 2007-07-27 2009-01-29 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US20100137977A1 (en) * 2007-08-03 2010-06-03 Boston Scientific Scimed, Inc. Coating for Medical Device Having Increased Surface Area
US20090076588A1 (en) * 2007-09-13 2009-03-19 Jan Weber Endoprosthesis
US8052745B2 (en) 2007-09-13 2011-11-08 Boston Scientific Scimed, Inc. Endoprosthesis
US20090187141A1 (en) * 2007-10-19 2009-07-23 Raymond Lareau Recirculation minimizing catheter
US8337451B2 (en) 2007-10-19 2012-12-25 Angio Dynamics, Inc. Recirculation minimizing catheter
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
US9096009B2 (en) 2007-10-26 2015-08-04 Sabic Global Technologies B.V. Method for forming a polymer part
US20090115104A1 (en) * 2007-10-26 2009-05-07 Sabic Innovative Plastics Ip B.V. System and Method for Forming Polymer
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US20090118822A1 (en) * 2007-11-02 2009-05-07 Holman Thomas J Stent with embedded material
US20090118809A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Endoprosthesis with porous reservoir and non-polymer diffusion layer
US20090118813A1 (en) * 2007-11-02 2009-05-07 Torsten Scheuermann Nano-patterned implant surfaces
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US20090143855A1 (en) * 2007-11-29 2009-06-04 Boston Scientific Scimed, Inc. Medical Device Including Drug-Loaded Fibers
US9282968B2 (en) 2007-11-30 2016-03-15 Treus Medical, Inc. Applicator for endoscopic treatment of biliary disease
US20090143713A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Biliary Shunts, Delivery Systems, Methods of Using the Same and Kits Therefor
US9486219B2 (en) 2007-11-30 2016-11-08 Treus Medical, Inc. Biliary shunts, delivery systems, methods of using the same and kits therefor
US20090143759A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Cystic Duct
US20110071350A1 (en) * 2007-11-30 2011-03-24 Jacques Van Dam Applicator for endoscopic treatment of biliary disease
US20090143760A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder
US9545322B2 (en) 2007-12-12 2017-01-17 Intact Vascular, Inc. Device and method for tacking plaque to blood vessel wall
US10799374B2 (en) 2007-12-12 2020-10-13 Intact Vascular, Inc. Device and method for tacking plaque to blood vessel wall
US10278839B2 (en) 2007-12-12 2019-05-07 Intact Vascular, Inc. Endovascular impant
US10299945B2 (en) 2007-12-12 2019-05-28 Intact Vascular, Inc. Method of treating atherosclerotic occlusive disease
US20110152992A1 (en) * 2007-12-12 2011-06-23 Peter Schneider Device and method for tacking plaque to blood vessel wall using wire mesh annular band
US9603730B2 (en) 2007-12-12 2017-03-28 Intact Vascular, Inc. Endoluminal device and method
US10660771B2 (en) 2007-12-12 2020-05-26 Intact Vacsular, Inc. Deployment device for placement of multiple intraluminal surgical staples
US20100262225A1 (en) * 2007-12-12 2010-10-14 Peter Schneider Device and method for tacking plaque to a blood vessel wall
US9974670B2 (en) 2007-12-12 2018-05-22 Intact Vascular, Inc. Method of treating atherosclerotic occlusive disease
US8128677B2 (en) 2007-12-12 2012-03-06 Intact Vascular LLC Device and method for tacking plaque to a blood vessel wall
US10835395B2 (en) 2007-12-12 2020-11-17 Intact Vascular, Inc. Method of treating atherosclerotic occlusive disease
US10188533B2 (en) 2007-12-12 2019-01-29 Intact Vascular, Inc. Minimal surface area contact device for holding plaque to blood vessel wall
US9730818B2 (en) 2007-12-12 2017-08-15 Intact Vascular, Inc. Endoluminal device and method
US10166127B2 (en) 2007-12-12 2019-01-01 Intact Vascular, Inc. Endoluminal device and method
US9375327B2 (en) 2007-12-12 2016-06-28 Intact Vascular, Inc. Endovascular implant
US10117762B2 (en) 2007-12-12 2018-11-06 Intact Vascular, Inc. Endoluminal device and method
US10022250B2 (en) 2007-12-12 2018-07-17 Intact Vascular, Inc. Deployment device for placement of multiple intraluminal surgical staples
US20100008970A1 (en) * 2007-12-14 2010-01-14 Boston Scientific Scimed, Inc. Drug-Eluting Endoprosthesis
US10350333B2 (en) 2008-04-17 2019-07-16 Micell Technologies, Inc. Stents having bioabsorable layers
US9789233B2 (en) 2008-04-17 2017-10-17 Micell Technologies, Inc. Stents having bioabsorbable layers
US20090292351A1 (en) * 2008-04-17 2009-11-26 Micell Technologies, Inc. Stents having bioabsorbable layers
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US7998192B2 (en) 2008-05-09 2011-08-16 Boston Scientific Scimed, Inc. Endoprostheses
US20090281613A1 (en) * 2008-05-09 2009-11-12 Boston Scientific Scimed, Inc. Endoprostheses
US8236046B2 (en) 2008-06-10 2012-08-07 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20090306765A1 (en) * 2008-06-10 2009-12-10 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
US10893960B2 (en) 2008-06-20 2021-01-19 Razmodics Llc Stent fabrication via tubular casting processes
US9908143B2 (en) 2008-06-20 2018-03-06 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US10646359B2 (en) 2008-06-20 2020-05-12 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9981071B2 (en) 2008-07-17 2018-05-29 Micell Technologies, Inc. Drug delivery medical device
US20100015200A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug Delivery Medical Device
US10350391B2 (en) 2008-07-17 2019-07-16 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US20100030326A1 (en) * 2008-07-30 2010-02-04 Boston Scientific Scimed, Inc. Bioerodible Endoprosthesis
US7985252B2 (en) 2008-07-30 2011-07-26 Boston Scientific Scimed, Inc. Bioerodible endoprosthesis
US20100049296A1 (en) * 2008-08-22 2010-02-25 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20100087910A1 (en) * 2008-10-03 2010-04-08 Jan Weber Medical implant
US8382824B2 (en) 2008-10-03 2013-02-26 Boston Scientific Scimed, Inc. Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US9980806B2 (en) 2008-10-22 2018-05-29 Boston Scientific Scimed, Inc. Shape memory tubular stent with grooves
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US20100137978A1 (en) * 2008-12-03 2010-06-03 Boston Scientific Scimed, Inc. Medical Implants Including Iridium Oxide
US20110159069A1 (en) * 2008-12-26 2011-06-30 Shaw Wendy J Medical Implants and Methods of Making Medical Implants
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US20100222873A1 (en) * 2009-03-02 2010-09-02 Boston Scientific Scimed, Inc. Self-Buffering Medical Implants
US8267992B2 (en) 2009-03-02 2012-09-18 Boston Scientific Scimed, Inc. Self-buffering medical implants
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US20100228341A1 (en) * 2009-03-04 2010-09-09 Boston Scientific Scimed, Inc. Endoprostheses
US20100239635A1 (en) * 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US20100241220A1 (en) * 2009-03-23 2010-09-23 Mcclain James B Peripheral Stents Having Layers
US10653820B2 (en) 2009-04-01 2020-05-19 Micell Technologies, Inc. Coated stents
US20100256748A1 (en) * 2009-04-01 2010-10-07 Micell Technologies, Inc. Coated stents
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
US20100256546A1 (en) * 2009-04-03 2010-10-07 Davis Scott A Polycarbonate Polyurethane Venous Access Devices Having Enhanced Strength
US20100272882A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Endoprosthese
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
US20100274352A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scrimed, Inc. Endoprosthesis with Selective Drug Coatings
US9901347B2 (en) 2009-05-29 2018-02-27 Terus Medical, Inc. Biliary shunts, delivery systems, and methods of using the same
US20110054381A1 (en) * 2009-05-29 2011-03-03 Jacques Van Dam Biliary shunts, delivery systems, and methods of using the same
US10888443B2 (en) 2009-06-11 2021-01-12 Intact Vascular, Inc. Device for holding plaque to blood vessel wall
AU2010259907B2 (en) * 2009-06-11 2015-04-30 Intact Vascular, Inc. Minimal surface area contact device for holding plaque to blood vessel wall
US20110230954A1 (en) * 2009-06-11 2011-09-22 Peter Schneider Stent device having focal elevating elements for minimal surface area contact with lumen walls
WO2010144845A3 (en) * 2009-06-11 2011-04-28 Innovasc Llc Minimal surface area contact device for holding plaque to blood vessel wall
US10779971B2 (en) 2009-06-11 2020-09-22 Intact Vascular, Inc. Endovascular implant
US20110022158A1 (en) * 2009-07-22 2011-01-27 Boston Scientific Scimed, Inc. Bioerodible Medical Implants
US20110071500A1 (en) * 2009-09-21 2011-03-24 Navilyst Medical, Inc. Branched catheter tip
US20110172642A1 (en) * 2010-01-11 2011-07-14 Navilyst Medical Occlusion Resistant Catheter
US8328760B2 (en) 2010-01-11 2012-12-11 Angiodynamics, Inc. Occlusion resistant catheter
US20110190864A1 (en) * 2010-02-02 2011-08-04 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8668732B2 (en) 2010-03-23 2014-03-11 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110238151A1 (en) * 2010-03-23 2011-09-29 Boston Scientific Scimed, Inc. Surface treated bioerodible metal endoprostheses
US20110238161A1 (en) * 2010-03-26 2011-09-29 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US9687864B2 (en) 2010-03-26 2017-06-27 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US20120003410A1 (en) * 2010-04-15 2012-01-05 Tatarka Paul D Partially crystalline cycloolefin elastomer medical tubing
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US10137013B2 (en) 2010-05-29 2018-11-27 Intact Vascular, Inc. Endoluminal device and method
US10779968B2 (en) 2010-05-29 2020-09-22 Intact Vascular, Inc. Endoluminal device and method
US11904118B2 (en) 2010-07-16 2024-02-20 Micell Medtech Inc. Drug delivery medical device
US9636309B2 (en) 2010-09-09 2017-05-02 Micell Technologies, Inc. Macrolide dosage forms
US10293050B2 (en) 2010-09-09 2019-05-21 Micell Technologies, Inc. Macrolide dosage forms
US10729881B2 (en) 2011-03-22 2020-08-04 Angiodynamics, Inc. High flow catheters
US9050435B2 (en) 2011-03-22 2015-06-09 Angiodynamics, Inc. High flow catheters
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10271973B2 (en) 2011-06-03 2019-04-30 Intact Vascular, Inc. Endovascular implant
US10285831B2 (en) 2011-06-03 2019-05-14 Intact Vascular, Inc. Endovascular implant
US10779969B2 (en) 2011-06-03 2020-09-22 Intact Vascular, Inc. Endovascular implant and deployment devices
US10390977B2 (en) 2011-06-03 2019-08-27 Intact Vascular, Inc. Endovascular implant
US20130006141A1 (en) * 2011-06-29 2013-01-03 Cook Medical Technologies Llc Expandable Device for Full Thickness Biopsy
US8758264B2 (en) * 2011-06-29 2014-06-24 Cook Medical Technologies Llc Expandable device for full thickness biopsy
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10729819B2 (en) 2011-07-15 2020-08-04 Micell Technologies, Inc. Drug delivery medical device
US9180228B2 (en) * 2011-10-03 2015-11-10 Abbott Cardiovascular Systems Inc. Rubber toughened bioresorbable polymer peripheral scaffolds
US20130085563A1 (en) * 2011-10-03 2013-04-04 Abbott Cardiovascular Systems Inc. Rubber toughened bioresorbable polymer peripheral scaffolds
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9707339B2 (en) 2012-03-28 2017-07-18 Angiodynamics, Inc. High flow rate dual reservoir port system
US9713704B2 (en) 2012-03-29 2017-07-25 Bradley D. Chartrand Port reservoir cleaning system and method
US20170079764A1 (en) * 2012-05-10 2017-03-23 Hoon Bum Lee Filler for removing wrinkles
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20180249987A1 (en) * 2013-11-20 2018-09-06 Covidien Lp Devices, systems, and methods for navigating a biopsy tool to a target location and obtaining a tissue sample using the same
US11160539B2 (en) * 2013-11-20 2021-11-02 Covidien Lp Devices, systems, and methods for navigating a biopsy tool to a target location and obtaining a tissue sample using the same
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
US9913649B2 (en) 2014-05-28 2018-03-13 Boston Scientific Scimed, Inc. Catheter with radiofrequency cutting tip and heated balloon
US10427329B2 (en) 2014-06-27 2019-10-01 Sabic Global Technologies B.V. Induction heated mold apparatus with multimaterial core and method of using the same
US20180126129A1 (en) * 2014-07-21 2018-05-10 Stentorium Ltd Implantable Stent
US11304836B2 (en) 2015-01-29 2022-04-19 Intact Vascular, Inc. Delivery device and method of delivery
US10898356B2 (en) 2015-01-29 2021-01-26 Intact Vascular, Inc. Delivery device and method of delivery
US10245167B2 (en) 2015-01-29 2019-04-02 Intact Vascular, Inc. Delivery device and method of delivery
US9840593B2 (en) * 2015-02-24 2017-12-12 Albert-Ludwigs-Universität Freiburg Phase segregated block copolymers with tunable properties
US20160244570A1 (en) * 2015-02-24 2016-08-25 Albert-Ludwigs-Universität Freiburg Phase segregated block copolymers with tunable properties
US11497888B2 (en) * 2015-05-29 2022-11-15 Biosensors International Group, Ltd. Bi-lumenal tube catheter support system
US10258487B2 (en) 2015-10-12 2019-04-16 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
US11253379B2 (en) 2015-10-12 2022-02-22 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
US10172729B2 (en) 2015-10-12 2019-01-08 Reflow Medical, Inc. Stents having protruding drug-delivery features and associated systems and methods
US10993824B2 (en) 2016-01-01 2021-05-04 Intact Vascular, Inc. Delivery device and method of delivery
US20180160216A1 (en) * 2016-12-06 2018-06-07 Bose Corporation Earpieces employing viscoelastic materials
US10623846B2 (en) * 2016-12-06 2020-04-14 Bose Corporation Earpieces employing viscoelastic materials
US11903859B1 (en) 2016-12-09 2024-02-20 Zenflow, Inc. Methods for deployment of an implant
US11096774B2 (en) 2016-12-09 2021-08-24 Zenflow, Inc. Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra
US11660218B2 (en) 2017-07-26 2023-05-30 Intact Vascular, Inc. Delivery device and method of delivery
US11491038B2 (en) 2018-07-26 2022-11-08 Endobetes Inc. Lumen reinforcement and anchoring system
US10743857B2 (en) * 2018-07-26 2020-08-18 Endobetes, Inc. Lumen reinforcement and anchoring system
CN109265972A (en) * 2018-09-07 2019-01-25 浙江华峰热塑性聚氨酯有限公司 The Matte thermoplastic polyurethane elastomer and preparation method thereof of easy processing high-modulus
CN110960734A (en) * 2019-10-30 2020-04-07 上海七木医疗器械有限公司 Preparation method of degradable spiral stent
US11890213B2 (en) 2019-11-19 2024-02-06 Zenflow, Inc. Systems, devices, and methods for the accurate deployment and imaging of an implant in the prostatic urethra
US11931484B2 (en) 2021-01-15 2024-03-19 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof

Also Published As

Publication number Publication date
EP2260882A3 (en) 2014-05-21
EP1554328A2 (en) 2005-07-20
JP2006503170A (en) 2006-01-26
JP4960631B2 (en) 2012-06-27
JP2011099121A (en) 2011-05-19
EP1560612B1 (en) 2019-09-04
WO2004033515A3 (en) 2004-06-03
EP2260882B1 (en) 2020-03-04
DE60336158D1 (en) 2011-04-07
AU2010246481A1 (en) 2010-12-23
EP2311902A2 (en) 2011-04-20
EP2260881A3 (en) 2014-05-07
EP2260882A2 (en) 2010-12-15
WO2004033515A2 (en) 2004-04-22
EP2260881B1 (en) 2020-03-25
AU2010200568B2 (en) 2012-02-02
EP1560612A2 (en) 2005-08-10
AU2010246481B2 (en) 2012-08-16
WO2004032799A3 (en) 2004-07-29
CA2501617C (en) 2012-04-24
CA2501617A1 (en) 2004-04-22
WO2004032799A2 (en) 2004-04-22
EP2260881A2 (en) 2010-12-15
US7091297B2 (en) 2006-08-15
AU2003277332A1 (en) 2004-05-04
CA2501643A1 (en) 2004-04-22
EP2311902A3 (en) 2014-01-01
ATE499396T1 (en) 2011-03-15
AU2003284088A1 (en) 2004-05-04
AU2003277332B2 (en) 2009-03-12
US20040116641A1 (en) 2004-06-17
EP1554328B1 (en) 2011-02-23
AU2010200568A1 (en) 2010-03-11
CA2501643C (en) 2013-12-31

Similar Documents

Publication Publication Date Title
EP1560612B1 (en) Implantable medical devices
US9115245B2 (en) Implantable medical devices
US5670161A (en) Biodegradable stent
KR101098267B1 (en) Polymer-based stent assembly
Zilberman et al. Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiber‐based stents
AU2004292439B2 (en) Highly convertible endolumenal prostheses and methods of manufacture
EP1633410B1 (en) Biodegradable stents
JP5309306B2 (en) Tubular tissue support removal
EP1587453B1 (en) Absorbable / biodegradable tubular stent and methods of making the same
US9682178B2 (en) Implantable medical devices fabricated from polymers with radiopaque groups
US7297758B2 (en) Method for extending shelf-life of constructs of semi-crystallizable polymers
JP2009507528A (en) Fiber-reinforced composite stent
JP2010540101A (en) Implantable medical devices made from block copolymers
JP2009529349A (en) Compressible tubular tissue support
WO2010068381A2 (en) Implantable medical devices having multiblock copolymers
US20150252144A1 (en) Biodegradable Cross-Linked Polymer, Vascular Stent and Manufacturing Methods Therefor
US9259515B2 (en) Implantable medical devices fabricated from polyurethanes with grafted radiopaque groups
US20090326642A1 (en) Implantable Medical Devices Fabricated From Radiopaque Polymers With High Fracture Toughness

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHANGDENG LIU, CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOCKWOOD, KURT;REEL/FRAME:016518/0722

Effective date: 20041007

Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAHATJIAN, RONALD A.;TAN, FRANCISCA;MATHER, PATRICK T.;AND OTHERS;REEL/FRAME:016518/0743;SIGNING DATES FROM 20040726 TO 20040811

Owner name: PATRICK T. MATHER, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOCKWOOD, KURT;REEL/FRAME:016518/0722

Effective date: 20041007

Owner name: CONNECTICUT, UNIVERSITY OF, CONNECTICUT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATHER, PATRICK T.;LIU, CHANGDENG;CAMPO, CHERYL J.;REEL/FRAME:016518/0710;SIGNING DATES FROM 20041206 TO 20050603

AS Assignment

Owner name: MATHER, PATRICK T., OHIO

Free format text: RE-RECORD TO CORRECT THE NAME OF THE ASSIGNOR, PREVIOUSLY RECORDED ON REEL 016518 FRAME 0722.;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018719/0447

Effective date: 20041007

Owner name: LIU, CHANGDENG, CONNECTICUT

Free format text: RE-RECORD TO CORRECT THE NAME OF THE ASSIGNOR, PREVIOUSLY RECORDED ON REEL 016518 FRAME 0722.;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018719/0447

Effective date: 20041007

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION